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Abstract 
 
Telomere repeat binding factor 2 (TRF2) is reported to be a key component of 
shelterin, a multi-protein complex that binds telomeric deoxyribonucleic acid (DNA) 
to protect chromosome ends and maintain genome stability. However, in recent 
years, TRF2 has been found to also bind non-telomeric regions and to act as a protein 
hub, interacting with a wide range of non-telomeric proteins and thus raising the 
possibility that it may serve functions independent of telomere maintenance. Despite 
the importance of TRF2, there is little information about how TRF2 is expressed 
during development and whether it could have an extratelomeric role in this process. 
Human embryonic stem cells (hESCs) derived from pre-implantation embryos are 
able to differentiate into most, if not all, tissues of the adult body, thereby provide a 
good cell model to tackle the problem. Given the abundance of TRF2 in the human 
brain and its potential for extratelomeric roles, this study focused on neural 
differentiation. TRF2 protein levels were found dramatically increased upon 
differentiation of hESCs to neural progenitor cells (NPCs) and these high levels, 
similarly to what is observed in vivo, were specific to the neural lineage. Gain and 
loss of function approaches revealed that exogenous expression of TRF2 in hESCs 
induced neural differentiation while, in contrast, TRF2 knockdown in NPCs 
drastically hindered their ability to terminally differentiate into neurons and glia. 
This enhancing neural function of TRF2 is achieved through the ability of TRF2 to 
inhibit the proteasomal degradation of REST4, an alternative splice variant of RE1-
Silencing Transcription factor (REST), which alleviates REST repression over neural 
genes, hence consolidating neural progenitor identity and potency.  This study 
identifies TRF2 as a novel component of neural differentiation, suggesting its 
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importance in central nervous system development as well as in neurological 
disorders. 
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Chapter 1  General introduction 
1.1 Telomeres and telomerase 
1.1.1 Telomere structure and function 
 
Eukaryotic telomeres are regions located at the ends of chromosomes composed of 
non-coding repetitive DNA and its associated protein complex, shelterin (Blackburn, 
1991). In mammals, telomeric DNA is composed of conserved double stranded 
TTAGGG repeats which end as a single-strand 3′-overhang, which can vary greatly 
in length between species (Figure 1.1 A). For instance, telomeres in humans may 
only be a few kilobases (kb) long whereas in mice and rats may be as long as 100 kb 
(Meyne et al., 1989; de Lange et al., 1990; Kipling and Cooke, 1990). These DNA 
repeats are packaged with histones to form constitutive heterochromatin and have 
been shown to have transcriptional activity (Azzalin et al., 2007; Blasco, 2007; 
Schoeftner and Blasco, 2008).  
 
In 1999 Griffith et al used electron microscopy to show that human and mouse 
telomeres end in a large organised duplex loop, known as the t-loop (Figure 1.1 B), 
rather than in a double stranded linear form as previously thought (Figure 1.1 A). 
The mechanism by which these t-loops are formed is still not fully understood, but 
the most accepted hypothesis is that these are formed through invasion of the single-
strand guanine-rich (G-strand) 3′-overhang into the double stranded DNA.  The 
guanine-rich overhang then complementary base-pairs with the 5′-end of cytosine-
rich strand (C-strand), displacing the G-strand into a displacement loop (d-loop) 
(Figure 1.1 B). The formation of this t-loop structure is regarded as a capping 
mechanism that prevents telomeric DNA ends from being detected as double strand 
breaks (DSB) by the DNA damage response (DDR) mechanism, protecting 
chromosomes against end-to-end fusions and ultimately cell senescence and genomic 
instability (Smogorzewska and de Lange, 2002; Takai et al., 2003; Karlseder et al., 
2004; Bae and Baumann, 2007; Denchi and de Lange, 2007). 
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Figure 1.1 Schematic representation of telomeres and t-loops structure. 
(A) Human telomeres are composed of double stranded TTAGGG DNA repeats of up to 15 Kb in 
length with a 3′-end G-rich overhang of approximately 50-500 nucleotides. The 5′ C-rich strand 
features the sequence ATC. (B) Schematic of the t-loop formation. 3′-end overhang invades the 
double stranded DNA, forming the d-loop. Image adapted from Palm and de Lange, 2008. 
 
 
Telomere length also plays an important role in genome maintenance. Given that the 
DNA replication mechanism is unable to replicate DNA fully to the end of the 
chromosomes (Olovnikov, 1971; Ohki et al., 2001), each cell division results in a 
progressive shortening of the genomic DNA, a phenomenon known as the end 
replication problem. Thus to prevent the erosion of our coding DNA, telomeres act as 
a buffer for the gradual loss of chromosome ends. Shortening of one or more 
telomeres to a critical limit activates p53 and p16 DNA-damage signalling pathways 
resulting in induction of senescence (Kipling et al., 1999; Espejel and Blasco, 2002), 
a permanent state of cell cycle arrest but continued viability. This process is referred 
to as replicative senescence and explains why primary cells can only divide in culture 
a certain number of times, referred to as the Hayflick limit (Hayflick and Moorhead, 
1961). Therefore telomeres are thought to act as a biological clock, where replicative 
senescence is a mechanism of ageing and tumour-suppression (Hiyama et al., 1995). 
This view is partly supported by some studies that have reported a direct correlation 
between an organism age and telomere length (Hastie et al., 1990; Beneto et al., 
2001) and by recent suggestions that an active lifestyle may actually increase 
telomere length by increasing telomerase activity (Ornish et al., 2013) and therefore 
may result in an increased lifespan. However, other studies have found no evidence 
of a relationship between telomere length and normal ageing (Harris et al., 2012). 
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The precise mechanism by which replicative senescence is triggered is still unclear. 
Critically short telomeres, known as dysfunctional telomeres, accumulate DDR 
factors commonly found in DSB such as phosphorylated histone 2A.X (γH2AX), 
p53-binding protein (53BP1) and ataxia telangiectasia mutated (ATM). Short 
telomeres that have accumulated DDR factors are termed telomere-induced foci. 
These are thought to occur because telomeres are too short to form the t-loop 
structure (Griffith et al., 1999), resulting in exposure of the telomere ends and 
activation of ATM, which leads to activation of p53 via Chk2 (Gire et al., 2004; Guo 
et al., 2007). Activation of p53 leads to transcription activation of Cip/WAF CDK 
inhibitor p21 which prevents entry into S-phase and induces senescence. 
Interestingly it has been shown that these events can be recapitulated by inducing 
overexpression of dominant negative mutant TRF2, which strips endogenous TRF2 
from telomeres (Smogorzewska and de Lange, 2002).  
 
While most cell types are subjected to telomere shortening and replicative 
senescence, cells in the early embryo, germ cells, certain stem cell populations and 
cancer cells are not (Hiyama et al., 1995; Wright et al., 1996; Soder et al., 1997; 
Betts and Kind, 1999). This is because telomeric shortening in these cells is 
counteracted by the action of telomerase, an enzyme that replenishes the TTAGGG 
DNA repeats at the end of the telomere, allowing self-renewal (Greider and 
Blackburn, 1985; Lingner et al., 1997).  
 
1.1.2 Telomerase components and function 
 
Telomerase was first discovered and characterised in the ciliate Tetrahymena by 
Nobel Prize winners Elizabeth Blackburn, Carol Greider and Jack Szostak in 1985 
(Greider and Blackburn, 1985). Human telomerase is a ribonucleoprotein complex 
consisting of three main components: a reverse transcriptase catalytic subunit 
(hTERT) (Lingner et al., 1997; Nakamura et al., 1997), a telomerase RNA 
component (hTERC also known as hTR) (Feng et al., 1995) and accessory factors 
Dyskerin and Est1A/B. Dyskerin, a small nucleolar ribonucleoprotein, stabilises the 
telomerase complex (Mitchell et al., 1999; Cohen et al., 2007) while Est1A/B are 
known to bind hTERT but their function remains unknown (Reichenbach et al., 
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2003; Snow et al., 2003; Sealey et al., 2011). hTERC contains the sequence 
CUAACCCUAAC, which is complementary to the telomere repeat unit TTAGGG 
(Figure 1.2) and acts as a template for the addition of TTAGGG repeats to the 3′-
overhang by hTERT. The extended 3′-overhang allows DNA polymerase to function 
in conventional DNA replication, preventing telomere shortening and replicative 
senescence. Both hTERT and hTERC elements are required and sufficient for 
maintenance and elongation of telomeres (Linger et al., 1997). 
 
 
 
 
Figure 1.2 Telomerase binding to telomere 3′ end overhang 
Schematic representation of human telomerase, composed of hTERT, hTERC, Dyskerin and 
EST1A/B, binding to the 3′ end of a telomere. Image adapted from Smogorzewska and de Lange, 
2004.  
 
 
While telomerase activity and hTERT expression in the adult organism is restricted 
to germ cells, T-lymphocytes, and stem cell population, almost 90% of cancers 
express hTERT and have telomerase activity (Blasco and Hahn, 2003). hTERC is 
found to be ubiquitously expressed in all cells but is also upregulated in cancer 
(Soder et al., 1997). Mouse TERT or TERC knockout models are viable but begin to 
display defects such as infertility, reduced lymphocyte proliferation, reduced wound 
healing and premature ageing after 3-7 generations (Blasco, 2005; Sahin and 
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DePinho, 2010). Some of these phenotypes are associated with the loss of stem cell 
function and mimic human premature ageing conditions; supporting the notion that 
telomere function is related to ageing. Furthermore, several of human premature 
ageing diseases are also found to be caused by mutations in telomerase components. 
For example in Dyskeratosis congenita, a disease that causes bone marrow failure 
and skin abnormalities, involves a mutation in dyskerin or hTERC (Vulliamy et al., 
2001).  
 
Overexpression of hTERT in somatic cells counteracts telomere shortening and 
prevents replicative senescence without necessarily inducing cell transformation 
(Bodnar et al., 1998). Thus, hTERT overexpression has become a useful tool to 
“immortalise” primary cell lines so they can be studied over long periods of time. 
The immortalisation of primary cell lines by hTERT automatically hinted to whether 
this could be used to artificially increase the lifespan of whole organisms. This was 
attempted in different labs with very interesting results. Initially, overexpression of 
TERT in mice resulted in increased incidences of cancer (Gonzalez-Suarez et al., 
2001; Blasco, 2003). However, when these mice were crossed with mice 
overexpressing tumour suppressor genes, the resulting progeny revealed an increased 
lifespan, providing evidence that expression of TERT is important in mammalian 
ageing (Tomas-Loba et al., 2008). Furthermore, reactivation of TERT expression in 
telomerase knockout mice has been shown to result in increased telomere length, 
attenuation of DDR activation and restoration of stem cell functionality, ultimately 
reversing the ageing phenotype and increasing lifespan (Jaskelioff et al., 2011).  
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1.2 The shelterin complex 
1.2.1 Components and functions of the shelterin complex 
 
Telomere TTAGGG repeats provide a platform for specific binding of a complex of 
proteins called shelterin. Shelterin is a 6-protein complex, consisting of TRF1 
(telomere repeat binding factor 1) (Chang et al., 1995), TRF2 (Broccoli et al., 1997), 
TIN2 (TRF1-interacting nuclear protein 2) (Kim et al., 1999), Rap1 
(repressor/activator protein 1) (Li et al., 2000), POT1 (protection of telomere 1) 
(Baumann and Cech, 2001) and TPP1 (formerly known as TINT1, PTOP or PIP1) 
(Houghtaling et al., 2004; Liu et al., 2004; Ye et al., 2004c). 
 
Each of the 6 proteins interacts with telomere directly or indirectly. Telomere 
binding proteins TRF1 and TRF2 bind to double stranded TTAGGG repeats while 
POT1 only binds to single stranded 3′-overhang (Figure 1.3). TRF1, TRF2 and POT1 
do not interact with each other directly, rather they are held in place by TIN2, which 
occupies a central position in the shelterin complex, binding to TRF1 and TRF2 
directly, and to POT1 via TPP1, thus providing a link between double-stranded DNA 
and single-stranded DNA binding proteins (Figure 1.3) (Kim et al., 1999; Kim et al., 
2004; Ye et al., 2004a; Ye et al., 2004b). Rap1 binds to TRF2 and is dependent on 
TRF2 for its telomeric localisation and stability while TPP1 binds POT1 and is 
dependent on its interaction with TIN2 and POT1 for its localisation at the 3′-
overhang (Figure 1.3) (Li et al., 2000; Celli and de Lange, 2005; Denchi and de 
Lange, 2007; Hockemeyer et al., 2007). The shelterin complex has been shown to 
play an important role in maintaining and protecting telomere structure and 
functionality (de Lange, 2005). It controls the accessibility of telomerase to telomere 
ends and regulates telomere elongation. It is also heavily involved in inhibiting DDR 
activation at telomeres (Denchi and de Lange, 2007).  
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Figure 1.3 Schematic structure of the shelterin complex and telomeric DNA. 
(A) Telomere binding proteins TRF1 and TRF2 bind to double stranded TTAGGG repeats while 
POT1 binds single stranded only. Rap1 is loaded onto the double stranded DNA by TRF2 and TPP1 is 
loaded onto the single stranded DNA by POT1. TIN2 occupies a central position and binds to TRF1, 
TRF2 and TPP1, stabilising the complex. (B) Representation of what the t-loop structure might look 
like with the shelterin complex bound to it. Images adapted from Palm et al., 2008.  
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1.2.2 Regulation of telomeres by TRF1 and TRF2 
 
TRF1 and TRF2, the first two telomere binding proteins identified, have similar 
protein structures and both bind to double stranded telomeric DNA. They share a 
TRF homology (TRFH) domain and a C-terminus SANT/Myb DNA-binding domain 
connected through a hinge domain (Figure 1.4) (Hanoaka et al., 2005). However, 
they differ in their N-terminus regions, where TRF1 has an acidic N-terminus while 
TRF2 bears a basic Gly/Arg rich domain (Figure 1.4). Both proteins bind to the DNA 
as homodimers, formed through interactions between their TRFH domain (Broccoli 
et al., 1997).  
 
 
 
Figure 1.4 Schematic representations of the domains of TRF1 and TRF2. 
TRF1 and TRF2 share a TRFH, Hinge and Myb DNA binding domain but differ in their N-terminus 
regions, where TRF1 has an acidic domain (red) and TRF2 bears a basic domain (purple). The 
sequence identity between the TRFH (yellow), Hinge (blue) and Myb domains (green) of TRF1 and 
TRF2 appears indicated as percentages.   
 
 
TRF1 has been shown to negatively regulate telomerase-dependent telomere 
elongation (van Steensel and de Lange, 1997; Smogorzewska et al., 2000). 
Overexpression of TRF1 in telomerase-positive tumour cell lines results in telomere 
shortening, whereas ectopic expression of a dominant negative TRF1 in these cells 
leads to telomere elongation. In addition, TRF1 also regulates the binding stability of 
TIN2 and TRF2 to telomeres, which subsequently affects functional telomere 
structure and chromosomal stability (Iwano et al., 2004). Depletion of TRF1 has also 
been shown to lead to destabilisation of POT1, leading to activation of ATM and 
Rad3 related (ATR) DDR (Okamoto et al., 2008).  
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Similarly to TRF1, TRF2 was also found to be a negative regulator of telomerase-
dependent telomere length (Smogorzewska et al., 2000). However, when TRF2 was 
overexpressed in TRF1-null mouse ES cells, instead of shortening, as previously 
reported in TRF1-wild type cells (van Steensel et al., 1997; Smogorzewska et al., 
2000), the telomeres elongated (Okamoto et al., 2008). Thus, suggesting that TRF2 
telomere length regulation may be also dependent on TRF1 expression. In addition to 
telomere length regulation, TRF2 has been shown to have the property to aid 
telomere repeats to form and maintain t-loop structures in vitro (Griffith et al., 1999; 
Stansel et al., 2001). These structures have been proposed to be the means by which 
telomere ends inhibit DDR activation and non-homologous end joining (NHEJ) of 
chromosome ends (Smogorzewska and de Lange, 2002; Takai et al., 2003; Karlseder 
et al., 2004; Bae and Baumann, 2007; Denchi and de Lange, 2007). However, little is 
known about the molecular mechanisms behind these properties of TRF2. It has been 
proposed that TRF2 may carry these functions through its ability to inhibit Holliday 
junction resolution (Poulet et al., 2009), which are thought to occur during d-loop 
formation (Stansel et al., 2001), and stimulating d-loop formation (Amiard et al., 
2007). These functions have been proposed to be a consequence of change in 
topology generated by the N-terminal domain of TRF2 (Poulet et al., 2012).  
 
1.2.3 TRF1 and TRF2 protect telomeres from DNA damage response 
 
TRF1 and TRF2 protect telomeres from DNA damage response not only through 
binding to telomeres themselves but also via recruitment of other proteins.  
Recruitment of these non-telomeric proteins is carried out predominantly by the 
TRFH domains of TRF1 and TRF2 (Chen et al., 2008) and the hinge region of TRF2 
(Okamoto et al., 2013) (Figure 1.4). Crystal structure studies of TRF1 and TRF2 
identified the conserved peptide docking sites F141 and F120 located in the TRFH 
domains of TRF1 and TRF2, respectively, which recognise the binding motifs FxLxP 
and YxLxP. Although both proteins have similar docking sites, their significant 
sequence differences (Hanoaka et al., 2005) result in different protein structures 
surrounding the docking sites, making TRF1 bind more efficiently to FxLxP and 
TRF2 bind more efficiently to YxLxP (Chen et al., 2008). Proteomic studies further 
confirmed that the core motif to achieve TRF2 binding is [Y/F]xL (Kim et al., 2009).  
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Most of the proteins that bind to TRF1 and TRF2, particularly TRF2, are involved in 
DNA damage signalling and repair, especially DSB signalling and repair, such as 
ATM, Ku70/80, XPF/ERCC1, Apollo, MRN complex, RAD51D, PARP1, PARP2, 
RecQ helicases (Hsu et al., 2000; Zhu et al., 2000; Tarsounas et al., 2004; Francia et 
al., 2006; Hsiao et al., 2006; Lenain et al., 2006; Deng et al., 2007). The primary 
mechanisms for DNA DSB repair in human cells are homologous recombination 
(HR) and NHEJ. Detection of DSB leads to activation of ATM (Bakkenist and 
Kastan, 2003). ATM activation results in phosphorylation of downstream effectors of 
the DDR, such as γH2AX, MDC1, 53BP1 and p53 (Dimitrova and de Lange, 2006), 
consequently leading to HR or NHEJ DNA DSB repair. NHEJ is an error-prone 
DNA damage repair mechanism and can often lead to the introduction of mutations 
(van Gent and van der Burg, 2007), which in the case of the telomere ends can lead 
to incorrect telomere structure, telomere bridging, cell senescence and apoptosis 
(Karlseder et al., 1999; Denchi and de Lange, 2007).  
 
TRF2 interaction with ATM on telomeres can prevent ATM-dependent DDR 
activation and inhibit NHEJ of chromosome ends; however the precise molecular 
mechanism has yet to be elucidated. TRF2 binds to a region of ATM containing 
residue serine 1981 (S1981), which is activated by autophosphorylation in response 
to DNA damage. Therefore, TRF2 could act as a specific inhibitor of ATM at the 
telomeres (Karlseder et al., 2004; Bakkenist and Kastan, 2003).  It has been shown 
that TRF2 overexpression in cells with very short telomeres inhibited S1981 
phosphorylation which otherwise would have been activated (Karlseder et al., 2004). 
However, it is still unknown if this effect is due to the formation of t-loops upon 
overexpression of TRF2 or as a direct repression of ATM autophosphorylation. 
Deletion of TRF2 usually results in loss of the t-loop structure, resulting in the 
recognition of the telomere ends as DSB, therefore leading to ATM activation and 
resulting in NHEJ initiation. Recent reports have revealed that TRF2 inhibits DDR in 
a two step-mechanism where TRF2 blocks DDR by, first, dimerization of its TRFH 
domains which inhibits ATM activation, and secondly, by inhibiting 53BP1 
localization to the telomeres through suppression of chromatin ubiquitination by 
RNF168, an E3 ubiquitin ligase (Okamoto et al., 2013). Furthermore, it has been 
suggested that very small amounts of TRF2 at the telomeres are sufficient to inhibit 
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end joining of chromosome ends (Cesare et al., 2013). In addition, in 2005 Tanaka et 
al showed that TRF2 was rapidly phosphorylated upon X-ray irradiation, most likely 
through binding partner ATM, and that this phosphorylated form did not bind to the 
telomeres but to the sites of DNA damage. This indicates a possible extra-telomeric 
role of TRF2 in DNA damage response.  It is possible that TRF2 is not only required 
for telomere capping, as suggested by deletion and overexpression experiments, but 
also for non-telomeric functions related to DNA damage response which may be 
masked upon de-capping of the telomere by TRF2 deletion. 
 
1.2.4 TRF2 potential for extra-telomeric roles 
 
Despite the importance of TRF2 in genomic stability, little is known about the 
expression and involvement during embryonic development and adult tissue 
homeostasis. This is because the majority of studies were performed in either tumour 
cell lines or primary/immortalized fibroblasts which may not be adequate 
representatives of normal tissue development. Furthermore TRF2 knockout mice 
exhibited embryonic lethality, restricting further interrogation of TRF2 functions 
during development (Celli and de Lange, 2005). However, TRF2 has recently been 
found to bind to other non-telomeric regions in chromosomes (Bradshaw et al., 2005: 
Simonet et al., 2011; Yang et al., 2011) and to interact with many non-telomeric 
proteins (Chen et al., 2008; Zhang et al., 2008; Kim et al., 2009; Giannone et al., 
2010; Okamoto et al., 2013), raising the possibility of TRF2 having alternative 
functions independent of telomere maintenance. 
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1.2.5 TRF2 role in neurogenesis 
 
Two research groups have proposed that TRF2 has a role in neurogenesis. Zhang and 
colleagues in their first study showed that in rat non-dividing cells TRF2 inhibition 
enhanced the morphological, molecular and biophysical differentiation of already 
differentiated neurons while in dividing human and rat cells, SH-SY5Y and 
astrocytes respectively, it induced cell senescence (Zhang et al., 2006). According to 
their study this indicated that TRF2 in addition to protecting cells from DNA damage 
responses it also had a role in neural differentiation. In their second study they 
proposed a mechanism whereby TRF2 regulates neurogenesis. They showed that 
TRF2 inhibition in SH-SY5Y and NTera2 dividing cells induced neural 
differentiation and proposed that this was due TRF2 stabilising the neural master 
repressor REST. Inihibition of TRF2 resulted in degradation of REST protein and 
derepression of its neural lineage target genes, ultimately leading to acquisition of a 
neuronal phenotype (Zhang et al., 2008). In their latest study, Zhang et al propose 
that in nondividing neural cells TRF2 switches its full length expression to a unique 
short nontelomeric isoform (TRF2-S) that sequesters REST from the nuclei to the 
cytoplasm so neural gene expression can be maintained in mature neurons (Zhang et 
al., 2011).  Their studies propose that TRF2 and TRF2-S have opposing effects on 
REST. Their model proposes that in neural progenitors expression of full length 
TRF2 mantains REST protein levels and therefore limits neural differentiation while 
upon differentiation into mature neurons TRF2-S expression occurs and results in 
REST sequestral to the cytoplasm allowing neural gene expression in the mature 
neurons to continue (Figure 1.5). 
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Figure 1.5 Zhang and colleagues TRF2 model of neural differentiation 
regulation. 
Full length TRF2 and TRF2-s can both bind to REST but have opposing effects. TRF2 stabilizes 
REST in proliferating neural stem cells to inhibit neural gene expression (e.g. L1cam) and maintain 
the pluripotent state, while TRF2-s sequesters REST from the nuclei of mature neurons to allow 
neural gene expression in mature neurons.  
 
 
While Zhang and collegues suggested that TRF2 regulates neurogenesis through 
protein-protein interactions, a second research group suggested that TRF2 could 
regulate neurogenesis through protein-DNA interactions. Through ChIP-Seq 
experiments Simonet and collegues found that in the tumor cel line BJ-HELTRa, 
TRF2 binds near the genic regions of neural lineage genes that are regulated by 
REST. In fact TRF2 was found bound near the REST binding sites of these genes. 
Therefore this second group proposed that perhaps TRF2 could be regulating neural 
gene expression through a TRF2-mediated synergistic interaction between the TRF2 
and the REST binding sites (Simonet et al., 2011).  
 
While these studies where carried out in cancer cell lines which may not reflect the 
normal situation in vivo, they revealed a potential extra-telomeric role of TRF2 in 
neurogenesis. Since TRF2 expression has been found to be very abundant in human 
brain tissue (Jung et al., 2004), it is plausible to think that TRF2 may have a role in 
human neurogenesis.  
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1.3 Neural induction and adult neurogenesis of the central nervous 
system 
 
1.3.1 Neural induction 
 
Development of the vertebrate central nervous system (CNS) is one of the earliest 
events in embryonic germ layer induction and a multi-step process that has long been 
thought to follow formation of the embryonic ectoderm, one of the three primary 
germ cell layers (i.e. endoderm, mesoderm and ectoderm) (Hamburger, 1988). The 
CNS is a complex tissue both in terms of cell type and number of cells. Furthermore, 
billions of neurons have to interact in a very precise manner in order to form 
functional neuronal networks. Development and maintenance of such a complex 
dynamic structure involves highly controlled gene expression and signalling 
pathways. CNS development in vertebrate embryos starts with the formation of the 
neuroepithelium from the neuronal ectoderm and finishes with the formation of 
different brain regions responsible for different cognitive functions (Waddington, 
1939; Morange, 2001; Stiles, 2008). 
 
The first insights into the mechanism of neural induction were obtained from studies 
carried out in amphibian embryos. Two major findings were obtained: the discovery 
of the organizer and its role in neural induction (Spemann and Mangold, 1924), and 
the discovery of the mechanisms that lead to neural induction (Sasai and De 
Robertis, 1997). Spemann and Mangold, discovered that when they transplanted a 
dorsal blastopore lip from one donor embryo to the ventral side of a host embryo this 
caused the initiation of a second neural induction site. Therefore, the dorsal 
blastopore lip was proposed as the region that induces and organises the CNS, and 
was named “Spemann’s organizer” (Spemann and Mangold, 1924). They proposed 
that the organization of the vertebrate embryo results from a succession of cell-cell 
inductions rising from the organizer, which organizes neighbouring cells and 
instructs their positional fate (anteroposterior and dorsoventral) and differentiation 
(neural tissue, notochord, somites). Following this study an “organizer” was found in 
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other embryos such as fish, birds and mammals (Waddington, 1934; Oppenheimer, 
1936; Beddington, 1994). 
 
The discovery of the organizer in the various species prompted investigation in the 
signalling mechanisms that give rise to this neural-inducing region. Experiments in 
Xenopus laevis provided insights into the mechanisms that underlie the phenomenon 
of neural induction in vertebrates. Noggin, found to be excreted by the organizer, 
was the first isolated factor shown to induce neural tissue formation (Smith and 
Harland, 1992; Lamb et al., 1993).  Similarly to noggin, follistatin (Hemmati-
Brivanlou and Melton, 1994) and chordin (Sasai et al., 1994) were also identified to 
induce neural tissue formation. Throughout studies of chordin, it was found that its 
sequence showed considerably homology to the Drosophila melanogaster gene short 
gastrulation, which had been previously reported to act as an antagonist to the gene 
decapentaplegic, which is a homologous of vertebrate genes bone morphogenetic 
protein (BMP) 2 and 4 (Holley et al., 1995).  BMP2 and 4, expressed in the ventral 
part of the embryo (Dale et al., 1992; Jones et al., 1992), are members of the 
transforming growth factor (TGF) superfamily and have been shown to inhibit neural 
induction and promote epithelial growth. When BMP4 was added to dissociated 
animal cap (roof region of the embryo that gives rise to ectodermal derivatives) cells, 
neural induction was inhibited (Wilson and Hemmati-Brivanlou, 1995). Furthermore, 
during Xenopus laevis embryo development BMPs messenger RNA (mRNA) 
expression, which is ubiquitously expressed at first, is cleared from the neural plate 
as the organizer begins to form (Fainsod et al., 1994). Therefore, since BMPs are 
found to normally prevent embryonic ectoderm development, these data indicated 
that chordin may induce neural development by inhibiting BMP signalling pathway. 
In fact, in addition to chordin, follistatin and noggin were also found to bind and 
inhibit the activity of BMP-4 and BMP-2 (Piccolo et al., 1996; Zimmerman et al., 
1996; Iemura et al., 1998; Sasai et al, 1995). Noggin and chordin have high affinity 
to bind to BMP ligands and to prevent their binding to BMP receptors, whereas 
follistatin mainly binds to activin and its antagonizing effects on BMPs may be 
through a different mechanism (Zimmerman et al. 1996; Sasai et al. 1995). These 
BMP inhibitors are expressed in the organizer region of Xenopus embryos and can 
induce neural markers in blastula stage animal cap cells (Hemmati-Brivanlou and 
Melton, 1994). Furthermore, dominant negative forms of the BMPs introduced into 
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early Xenopus embryos also promote neurogenesis (Hawley et al., 1995). Taken 
together, it is implied that the suppression of BMP signalling by BMP antagonists 
secreted from the organizer is sufficient to induce neural differentiation and that this 
double gradient that emanates from opposite poles of the embryo aids dorsal-ventral 
formation.  
 
While neural induction in amphibians is largely considered to be dependent on BMP 
signalling and secretion of BMP antagonists, further experiments in chick and 
Xenopus embryos have questioned this hypothesis and have led to the proposal that 
BMP inhibition is not sufficient for neural induction, suggesting that fibroblast 
growth factors (FGFs) may be involved in embryo neurogenesis (Lamb and Harland, 
1995; Launay et al., 1996; McGrew et al., 1997). 
 
FGFs are a large class of secreted diffusible glycoproteins that bind to four classes of 
extracellular receptors (called FGFR1-4) to mediate their effects (Launay et al., 
1996). In Xenopus it has been shown that overexpression of dominant negative forms 
of FGF receptors in animal cap cells blocks the ability of noggin or chordin to induce 
neuralization (Lamb and Harland, 1995; Launay et al., 1996), indicating the 
requirement of FGF for neural induction. Furthermore, it has been shown that 
blocking BMP signals at the gastrula stage does not result in neural induction; neural 
induction was only observed when BMP was inhibited prior gastrula stage 
(Wawersik, 2006). However, when FGF activation was accompanied by BMP 
inhibition at the gastrula stage neural induction occurred (Wawersik, 2006). This 
suggested that FGF signalling occurred prior to BMP signalling and therefore is also 
important for neural induction. In fact, FGF has been shown to be required for neural 
induction independently of BMP expression (Linker and Stern, 2004; Delaune et al., 
2005). Studies in chick have shown that FGF signalling can repress expression of 
BMP mRNA (Wilson et al., 2000; Streit et al., 2000) and downregulate BMP 
signalling (Pera et al., 2003). In addition, in zebrafish, it has been proposed that both 
BMP inhibition and FGF signalling can act as neural inducers, with BMP antagonism 
inducing anterior and FGFs inducing posterior neural fates (Kudoh et al., 2004). In 
contrast with these studies, how is neural induction regulated in the mouse embryo is 
less clear. Double mutants for the BMP antagonists chordin and noggin are still able 
to form a neural plate but fail to maintain forebrain markers at later stages (Bachiller 
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et al., 2000), raising the question of what is relieving BMP inhibition in the mouse 
embryo. Given that inhibition of FGF signalling has been shown by several reports to 
result in neural tissue formation in mice and that presence of FGF leads to inhibition 
of neural fate (Sun et al., 1999; Ciruna et al., 1997; Burdsal et al., 1998; Di-Gregorio 
et al., 2007), it is possible that FGF does not act as a neural inducer in mice. While in 
Xenopus, chick, and zebrafish embryos, FGFs and BMP antagonists may play a role 
in neural induction, in mice the mechanism of neural induction appears to be 
different.   
 
Overall, the current evidence indicates that FGFs can play a role in promoting 
acquisition of neural fate. Although the mechanisms might vary between species, the 
abrogation of BMP signalling remains the central event that precedes this 
acquisition. 
 
1.3.2 Establishment of the anterior-posterior axis 
Primary Neurulation 
 
Formation of the CNS in vertebrate embryos starts with the allocation of a group of 
ectodermal precursor cells that will give rise to the entire CNS (Hemmati-Brivanlou 
and Melton, 1997). The discovery of the organizer in amphibian by Spemann and 
Mangold in the 1920’s initiated the search for a homologous structure in vertebrates. 
Therefore, soon after the equivalent region was discovered in most vertebrate 
species. In birds and mammals the organizer was named “Hanns node” and “the 
node” respectively (Waddington, 1933; Waddington, 1936). Recent studies in the 
chick embryo have shown that neural induction starts before formation of the 
organizer, likely by the FGF signalling pathway. The neural plate area is established 
by FGF8 activity coming from the primary endoderm and the suppression of BMP 
signalling stabilises neural differentiation rather than initiates (Linker et al. 2009). 
During gastrulation, these molecular interactions together with the activity of Hox 
genes leads to the formation of the anterior-posterior and dorso-verntral axes of the 
embryo including the generation of the three germ layers: ectoderm, mesoderm and 
endoderm. During this process, the neural plate forms along the anterior-posterior 
axis of the embryo in the medial region of the embryo as a result of planar and 
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vertical signalling (Figure 1.6 A). The neural plate which starts as a single layer of 
neuroepithelial cells goes through a process of thickening known as apicobasal 
thickening and pseudostratification, where cells become thicker while maintaining a 
single layer of cells (Smith and Schoenwolf, 1989; Keller et al., 1992). This 
thickening of the ectoderm plate has been shown to be an intrinsic property that 
occurs when neuroepithelial cells have been induced to become neural and is a result 
of the “interkinetic movement” of the nuclei of these cells which migrate up and 
down the anterior-posterior axis during cell cycles (Shoenwolf, 1988; McConnell, 
1995). Following formation of the neural plate, the neuroepithelial cells change in 
shape and rearrange to form neural folds which establish a through like space called 
the neural groove (Figure 1.6 B). The neural plate becomes narrower along the 
anterior-posterior axis so the neural folds can bend enough to be brought together at 
the dorsal midline (Figure 1.6 C) to finally form the neural tube (Figure 1.6 D) 
(Voiculescu et al., 2007).  
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Figure 1.6 The process of neural induction. 
Left side of the figure is a schematic representation of chick neural tube development shown on the 
right hand side by electron micrographs. (A) Early in embryogenesis the three germ cell layers 
(ectoderm, mesoderm and endoderm) lie close to each other. The ectoderm gives rise to the neural 
plate (pink), the precursor of the central nervous system. Process starts with the inhibition of BMP 
signalling in the neural plate region. (B) The neural plate then buckles at its middle to produce the 
neural grove. (C) Extrinsic signals from BMP and Shh together with the expression of intrinsic factors 
finally gives rise to the neural tube by closure of the dorsal neural folds. (D) The neural tube finally 
lies over the notochord and is flanked by somites, a group of mesodermal cells that give rise to muscle 
and cartilage. Figure adapted from E. R. Kandel, 2013, Principles of Neuroscience, 5th ed., McGraw-
Hill. 
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Secondary Neurulation 
 
The posterior region of the neural tube develops after the posterior region and in a 
different manner. In the posterior neural tube, cells condense to form a epithelial cord 
of cells known as the medullary cord (Shoenwold and Delongo 1980; Shoenwolf 
1984). The outer cells of the medullary cord then undergo a process of 
pseudostratification similar to that of the neural plate during primary neurulation. 
The pseudostratified cells then become polarized and form and fuse to form small 
lumina around a central core of mesenchymal cells. These inner cells are removed 
during cavitation. Finally cavitation results in the formation of a single secondary 
lumen which will join the primary lumen of the rostral neural tube.  
 
Once the neural tube is completely formed and closes, the future CNS consist of a 
single layer of neuroepithelial cells that line the lumen of the neural tube. The 
neuroepithelial cells then undergo symmetric proliferation to produce daughter stem 
cells which will then divide asymmetrically and give rise to more specialised 
postmitottic neuron/glia type of cells that migrate out of the neural tube and will 
contribute to the formation of the CNS (Chenn and McConell, 1995). These cells 
build up 6 new distinct cell layers: the ventricular (VZ), subventricular (SVZ), 
intermediate, subplate, cortical plate and marginal zone (Molnar et al., 2006). 
 
The lumen of the neural tube is the developing VZ of the brain. Neural development 
of the VZ proliferating cells proceeds following an “inside out” principle were 
neurons are born in the VZ, migrate to the cortical plate and then localize further out. 
 
Young neurons migrate from the VZ to other regions of the developing brain to build 
up the mature brain and spinal cord. In order for the correct type of neuron to arrive 
to the correct brain region radial glial cells, which differentiate from neuroepithelial 
cells at the beginning of neurogenesis, guide and support the newly generated 
neurons out of the VZ (Rakic, 1972). Neurons migrating along radial glial cells form 
columns, which could produce a highly ordered cortex based on the pattern of 
underlying neural tube. In addition to acting as a guidance of newly generated 
neurons, radial glial cells, are a source of neural progenitors that have a more 
restricted fate than neuroepithelial cells and will replace these later in differentiation 
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(Campbell and Gotz, 2002). As a consequence, most of the neurons in the brain are 
derived, either directly or indirectly, from radial glial cells. In addition, radial glial 
cells mainly generate neurons when isolated during early neurogenesis (Anthony et 
al., 2004) while producing both neurons and astrocytes when isolated in late 
neurogenesis (Malatesta et al., 2003).  
 
The AP patterned neural tube further develops into different domains of the 
developing and adult brains; forebrain, midbrain, hindbrain and spinal cord, 
successively. The boundaries of each domain defined by morphology and marker 
genes are being identified and further subdivide the CNS into distinct regions. 
 
1.3.3 Adult neurogenesis 
 
 
The early studies of Altman and Das in the 1960’s provided the first evidence of 
neurogenesis in the adult brain (Altman and Das, 1965). Almost 30 years after their 
study, multipotent neural stem cells (NSCs) were successfully derived from 
mammalian brain (Reynolds and Weiss, 1992; Richards et al., 1992). Later with the 
introduction of bromodeoxyuridine, a nucleotide analog that can be used to trace 
proliferating cells, the neuroscience field demonstrated that neurogenesis was likely 
in humans (del Rio and Soriano, 1989; Kuhn et al., 1996; Eriksson et al., 1998). It is 
now well established that adult neurogenesis occur in most mammals throughout 
adulthood and in two neurogenic areas of the adult mammalian CNS: the 
subventricular zone (SVZ) of the lateral ventricles (Lois and Alvarez-Buylla, 1994) 
and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus (Kuhn et 
al., 1996; Taupin and Gage, 2002), however, neurogenesis declines with ageing in 
both areas (Molofsky et al., 2006).  
 
During development, NSCs give rise to all the neurons of the mammalian CNS. They 
are the source of neurons, astrocytes and oligodendrocytes (Doetsch et al., 1999; 
Alvarez-Buylla et al., 2001). Two different types of NSCs are present in the SVZ and 
SGZ. These have been identified according to marker expression, morphology, 
proliferation and differentiation potential (Zhao et al., 2008). These are type B and 
type C cells in the SVZ and type 1 and 2 in the SGZ. Type 1 and type B cells have 
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radial processes and ramifications at their end, these express markers such as GFAP, 
Nestin, Blbp and Sox2. Type 2 and type C cells are non-radial cells that have very 
short processes. Type 2 cells maintain the expression of Sox2 and Nestin and some 
express doublecortin, a neuroblast marker, while type C cells are negative for GFAP 
but express Dlx2, Mash1 and epidermal growth factor (EGF) receptor. Cell dividing 
ablation studies have revealed that radial type NSCs (type 1 and type B) are slow 
growing infrequent dividing cells or quiescent cells that can generate more actively 
dividing NPCs (type 2 and type C) (Doetsch et al, 1999; Ahn and Joyner, 2005). 
However, studies at the single cell level instead of population level, suggest that 
GFAP positive radial cells are NSCs that can differentiate into neurons and 
astrocytes (Seri et al., 2004), while another study proposed that non-radial NPCs that 
are Sox2 positive have the potential to self-renew and give rise to neurons and 
astrocytes (Suh et al., 2007). 
 
SVZ adult neurogenesis 
 
In the adult SVZ type B dormant NSCs line the lateral ventricle and give rise to 
actively proliferating type C NPCs (Figure 1.7) (Doetsch et al., 1999).  These type C 
cells are able to self-renew and differentiate into neuroblasts (type A cells) which 
then migrate through a dense glial tube along the rostral migratory stream (RMS) for 
several days until they reach the olfactory bulb (Lois and Alvarez-Buylla, 1994, Lois 
et al., 1996). Once there the neuroblasts differentiate into olfactory GABAergic, 
dopaminergic or glutamatergic interneurons and integrate into the neuronal circuit 
(Carleton et al., 2003; Brill et al., 2009). However, it has recently been proposed that 
type B NSCs, similarly to type C NPCs, also have the ability to asymmetrically 
divide into more specialised glial type of cells (Morrens et al., 2012). Finally, it is 
important to note that recent findings have suggested that SVZ adult neurogenesis is 
largely absent in humans and only present in early stages of infancy (Sanai et al., 
2011).  
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Figure 1.7 Adult neurogenesis in the subventricular zone (SVZ). 
Different types of NSCs can be observed in the SVZ, these can be classified depending self-renewal 
and differentiation capabilities. Type B NSCs are GFAP positive NSCs located at the SVZ of the 
lateral ventricles that can asymmetrically divide to give rise to another type B cell and Type C cell. 
Type B cells have long processes that allow them to contact the lateral ventricles and blood vessels. 
The actively dividing type C cells give rise to neuroblast type A cells that migrate to the olfactory 
bulb. Figure adapted from Suh et al., 2009. 
 
SGZ adult neurogenesis  
 
The hypocampus is a cortical structure found in both hemispheres of the mammalian 
brain where hippocampal neurons from the granular zone of the dentate gyrus, and 
cornu ammonis (CA) form a trisynaptic circuitry that plays a central role in cognitive 
functions such as learning and memory (Milner et al., 1998) (Figure 1.8).   The 
process by which type 1 NSCs give rise to specialised granular zone neurons is a 
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multi-step process that starts with either their symmetrical or asymmetrical division. 
If cells divide symmetrically they will give rise to two radial type 1 NSCs whereas if 
they divide asymmetrically, they can either self-renew and give rise to a NSC and a 
non-radial NPC or divide into two non-radial NPCs (Bonaguidi et al., 2011; Encinas 
et al., 2011). Following this step the newly generated NPCs or type 2 cells, can give 
rise to actively proliferating neuroblasts also called type 3 cells. The neutrally 
committed neuroblast then will start to mature and extend its dendrites and axon to 
reach the molecular layer and hilus, respectively. Once fully mature the new neuron 
will be able to excite CA3 pyramidal cells and join the trisynaptic circuitry (Zhao et 
al., 2006; Toni et al., 2008). 
 
  
 
 
Figure 1.8 Stages of adult neurogenesis in the subgranular zone (SGZ). 
Adult NSCs are located at the SGZ of the dentate gyrus of the hippocampus. Two different types of 
NSCs (green cells) can be distinguished: relative quiescent radial type 1 NSCs and actively dividing 
non-radial type 2 NSCs. These NSCs proliferate and give rise to granular neurons (pink cells). 
Granular neurons can be found in the granular layer and have been shown to connect the dentate 
gyrus, conrnu ammonis 3 (CA3), and interneruons in the hilus of the hippocampus. Figure adapted 
from Suh et al., 2009. 
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1.4 Neurodegenerative disorders 
 
 
Recent studies have suggested that certain symptoms associated with 
neurodegenerative diseases may arise as a result of impaired adult neurogenesis 
(Lazic et al., 2004; Winner et al., 2004; Rodriguez et al., 2008). While various 
neurodegenerative diseases are characterised by the death of neurons as a 
consequence of accumulation of toxic proteins, numerous studies in mouse models of 
neurodegenerative disease have shown abnormal levels of adult neurogenesis which 
could have contributed to the development of the condition. In Parkinson’s disease 
mouse models levels of adult neurogenesis are heavily downregulated at both the 
SVZ and SGZ (Winner et al., 2004). Similarly, Huntington’s disease models display 
impaired olfactory function as a consequence of reduced adult neurogenesis at the 
SVZ (Lazic et al., 2004). Interestingly in certain Alzheimer’s disease models, the 
number of NSCs present was significantly reduced and linked to the presence of 
amyloid-β plaques in hippocampal neurons indicating that there may be an 
association between the accumulation of toxic proteins and disruption of adult 
neurogenesis (Rodriguez et al., 2008). Therefore studying the mechanisms that 
regulate NSC and NPCs in vivo and in vitro could potentially provide novel 
therapeutics for treating neurodegenerative diseases.  
 
1.5 Neural stem cells  
 
Neural stem cells are defined by their ability to self-renew and differentiate into the 
three main CNS cell lineages: neurons, astrocytes and oligodendrocytes (Gage, 
2000). Neural stem cells in early stages of development have the capacity of 
producing early-born neurons while neural stem cells in later stages of development 
are more restricted to a gliogenic potential (i.e. producing non-neuronal astrocyte or 
oligodendorcyte populations) (Temple, 2001). A similar neurogenesis to gliogenesis 
potential transition is preserved when neuroectodermal cells are cultured or 
embryonic stem cells (ESCs) are differentiated along the neural lineage (Li et al., 
2004). Therefore it has been suggested that the mechanisms regulating neuronal and 
glial lineage development is retrained in vitro, and highlights the feasibility of using 
ESCs as a tool to study neural differentiation processes.  
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The balance between stem cell maintenance and differentiation is regulated by 
complex regulating network which acts at different cellular levels and where intrinsic 
and extrinsic regulators play a key role. Fully elucidating the roles of each regulator 
will aid in understanding the biology of NSCs and create hope in using these cells for 
regenerative medicine.  
 
1.5.1 Extrinsic regulators 
 
NSCs ability to self-renew, proliferate and differentiate is known to be regulated by 
their niche, a local microenvironment that provides nurturing factors and stem cell to 
stem cell interactions that allows the maintenance of their characteristics (Fuchs et 
al., 2004; Morrison and Spradling, 2008). Some of these nurturing factors present in 
the niche include several signalling molecules such as BMP, wnt, Notch, Sonic 
hedgehog and fibroblast and epidermal growth factors.  
 
Fibroblast and epidermal growth factors  
 
In order to generating a sufficient number of neural stem cells, it is assumed that cell 
proliferation may be predominant in the early phases, and that more cells 
differentiate during later stages. This implies that there is higher probability for 
generating two undifferentiated daughter cells at early stages (symmetric division), 
and later division favour the production of neurons and later glial cells (asymmetric 
division). Neural stem cells in the developing neocortex undergo both symmetrical 
and asymmetrical divisions (Cai et al., 1997). Several pathways that interact to 
regulate cell proliferation have been identified. Perhaps the best understood are those 
triggered by growth factors. All neural stem cells respond to multiple growth factors, 
but the exact subset of growth factors acting at a specific stage may be unique for a 
particular stage of neural stem cell differentiation. Early neural stem cells respond 
solely to FGF2 [also known as basic fibroblast growth factor (bFGF)], and loss of 
FGFs or FGF receptors leads to a significant reduction in neural stem cell 
proliferation (Raballo et al., 2000). Later appearing neural stem cells require either 
FGF2 or EGF for proliferation (Tropepe et al., 1999). In vivo and in vitro 
experiments have shown that presence of EGF increases NSCs proliferation 
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(Reynolds and Weiss, 1992; Bain et al., 1995). It is well known that cell self-renewal 
is tightly linked to this potential. Self-renewal is essential for neural stem cells 
because it is required for the cells to perpetuate themselves, so that at least one of the 
daughter cells retains the molecular characteristics of the original cells. It is 
important to note that while a process of self-renewal occurs, neural stem cells may 
undergo changes in their abilities to produce different progeny during development 
(Shen et al., 1998).   
 
Bone morphogenetic proteins  
 
BMPs of the TGF- β protein family of extracellular ligands are important for many 
steps of neural induction and differentiation, including the initial specification of the 
neural plate region as well as neural crest and tube formation (Streit and Stern, 
1999). In mouse ESCs (mESCs) BMPs synergizes with leukaemia inhibitory factor 
(LIF) to maintain self renewal (Nakashima et al., 1999; Ying et al., 2003). 
Furthermore, in mice, BMP2/4 inhibits neurogenesis of mouse neuroepithelial cells 
(Di-Gregorio et al., 2007). In contrast, addition of BMPs to hESCs has been shown 
to induce differentiation (Xu et al., 2002), while addition of BMP antagonists such as 
noggin induces neural differentiation (Pera et al., 2004; Gerrard et al., 2005).  
 
It is important to note that extrinsic factors may collaborate with intrinsic factors to 
maintain and determine the functional characteristics of neural stem cells (Faux et 
al., 2001; Nagao et al., 2007). Extrinsic factors may regulate intrinsic factors by 
various cascades with stimulatory or inhibitory effects that will lead to the 
maintenance of the NSCs characteristics or to their differentiation. These may be 
through transcription factors, signalling pathways or epigenetic modifications. 
 
1.5.2 Intrinsic factors 
 
Extensive studies have revealed that intrinsic regulators as well as extrinsic 
regulators are required for the regulation of NSC multipotency. They are important 
for the development of the embryonic CNS as well as for the maintenance of NSCs. 
Some of these include but are not limited to: members of the SRY-box containing 
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genes (Sox) and basic helix-loop-helix (bHLH) genes, paired box protein 6 (Pax6) 
and neuron restrictive silencer factor (NRSF) also known as REST. 
 
Sox2 
 
Sox genes are a group of transcription factors belonging to the family of high 
mobility group of DNA binding protein that play a role in maintaining the 
undifferentiated state of NSCs both in vivo and in vitro. Sox2 is the most extensively 
examined as it has been shown to be essential for the maintenance of NSCs. In 
vertebrate, Sox2 is expressed in NSCs from early development to adulthood (Pevny 
and Placzek, 2005). Sox2 is highly expressed in quiescent NSCs of the SGZ and is 
downregulated upon post-mitotic differentiation (Suh et al., 2007), consistent with 
the essential role of Sox2 in maintenance of NPCs identity (Graham et al., 2003). 
Ectopic expression of Sox2 in chick neural tube inhibits post-mitotic neural 
differentiation and allows the maintenance of neural progenitor characteristics 
(Bylund et al., 2003). Conditional deletion of Sox2 in Nestin expressing NSCs leads 
to a marked reduction of type 1 and type 2 cells of the adult hippocampus (Favaro et 
al., 2009). In ESCs it has been shown that ectopic expression of Sox2 promotes 
neuroectoderm fate (Kopp et al., 2008) and that low Oct4 and high Sox2 expression 
is required for ESCs to differentiate into the neuroroectoderm lineage (Thomson et 
al., 2011). In fact, ectopic expression of Sox2 has been shown to be sufficient to 
reprogram mouse and human fibroblasts into induced NSCs (Ring et al., 2012), 
further supporting Sox2 importance in NSC identity. Taken together, these results 
suggest that Sox2 may play a critical role in the maintenance and priming of 
neuronal differentiation of cultured NSCs. While the mechanism behind this dual 
role is still largely unknown a recent report has proposed that Sox2 carries these 
functions by maintaining optimal levels of Lin28 transcription (Cimadamore et al., 
2013) required for NSCs proliferation and differentiation potential (Zhao et al., 
2010). 
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Pax6 
 
Pax6 is a member of the paired box family of transcription factors which are crucial 
for the development of specific tissues. Pax6 is a highly conserved transcription 
factor involved in the development of the CNS (Hanson and Van Heyningen, 1995). 
Mutation in human Pax6 leads to aniridia, a disease characterized by mild mental 
retardation and loss of the iris in the eye, indicating the importance of this gene in 
neural development (Jordan et al., 1992). Pax6 mutant mice display impaired 
cerebral cortex development, thinner ventricular zone, slower cell proliferation and a 
reduction in new-born neurons (Fukuda et al., 2000). Given that Pax6 is highly 
expressed in neural NSCs and NPCs of the CNS (Simpson and Price, 2002), it is 
possible that an impairment of its expression results in the neurological disorders 
observed both in human and mice. In addition, Pax6 controls the expression of bHLH 
transcription factors such as Mash1 (Marquardt et al., 2001), which has been shown 
to be involved in neuronal differentiation of retinal stem cells (Philips et al., 2005; 
Xu et al., 2007). Taking all this into account, it has been proposed that Pax6 
functions in cortical development to prevent precocious neuronal differentiation and 
depletion of the progenitor pool, as well as in the maintenance of retinal stem cells 
indirectly by the regulation of Mash1.  
 
BHLH genes 
 
 
Basic helix-loop-helix genes (named for a shared basic helix-loop-helix tertiary DNA 
structure that defines their DNA binding domain) are a family of transcription factor 
encoding genes that are important to define the neural or glial fate. Two sets of 
bHLH genes are involved in neural differentiation and have opposite functions. One 
set function as repressors while the other set act as activators (Bertrand et al., 2002). 
A good example of repressors and activators of bHLH would be HES genes and 
Mash1, respectively. HES genes are expressed in NSCs to suppress neuronal 
differentiation. Overexpression of the HES gene HES1 inhibits neuronal 
differentiation in the CNS (Ishibashi et al., 1994) while, mutations in HES1 or HES5 
induce neuronal differentiation (Ohtsuka et al., 1999). In contrast, Mash1 and 
Neurogenin have been shown to be highly expressed in differentiating neurons 
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(Kageyama et al., 2005). Ectopic expression of either these two genes in NSCs 
results in neuronal fate restriction rather than glial induction while cells from 
Mash1:Neurogenin double knockout mice become glial cells (Nieto et al., 2001). All 
together, these data indicate that there is a fate switch regulated by bHLH 
activator/repressors that controls the fate of NSCs as well as their maintenance 
(Hatakeyama et al., 2004).  
 
1.6 The repressor element 1-silencing transcription factor  
 
In addition to signalling pathways and transcription factors regulating neurogenesis, 
research in the past decade has shown that regulation of tissue-specific gene 
expression is also regulated by epigenetic modulators. Hence it is not surprising that 
epigenetic regulators are one of the key molecular mechanisms involved in 
controlling the various steps of neurogenesis.   
 
REST, also known as NRSF, is a 116-kiloDalton (kDa) zinc finger containing 
protein that is composed of a DNA-binding domain and two repressor domains: one 
at the N-terminal and the other at the C-terminal of the protein (Figure 1.9) (Ballas et 
al., 2005). REST was first identified as a protein that binds to a 21-base pairs (bp) 
DNA sequence consensus known as repressor element 1 (RE-1), to repress 
expression of neural specific genes Nav1.2 and SCG10 (Chong et al., 1995; 
Schoenherr and Anderson, 1995). Later genome-wide analyses by four independent 
groups have found that the RE1 target site of REST is present in a wide variety of 
genes (Bruce et al., 2004; Jones and Pevzner, 2006; Mortazavi et al., 2006; Wu and 
Xie, 2006), which generate a complete set of genes that contain RE-1 binding motif 
and may be regulated by REST, including many genes that are involved in 
neurogenesis. Several of them have been validated to be REST target genes or have 
been shown to be indirectly regulated by REST, these include BDNF (Timmusk et 
al., 1999), Synaptosomal associated protein, Snap25 (Bruce et al., 2004), L1 cell 
adhesion molecule, L1CAM (Kallunki et al., 1997), Mash1 (Ballas et al., 2005), 
GFAP (Kohyama et al, 2010) neurogenin 2, Ng2 and Sox2 (Singh et al., 2008).  
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Figure 1.9 Schematic representation of REST domains. 
Full length REST contains a middle DNA binding domain composed of eight zinc finger proteins 
(green ovals) and an N-terminal (red-blue rectangle) and C-terminal (green rectangle) repression 
domains.    
 
Although genome-wide analysis has indicated that REST may have wider functions 
than originally thought, REST first well known main function is to suppress neuronal 
gene expression in non-neuronal cells of the brain as an aid to inhibit neuronal 
differentiation. This was based on the observations that REST expression was rarely 
observed in neurons and was more limited to non-neuronal cells, and that a large 
proportion of its target genes are involved in neural differentiation (Ballas et al., 
2005). However, REST was also found to be expressed in certain mature neurons in 
adults (Griffith et al., 2001; Shimojo and Hersh, 2004), suggesting that its repression 
is regulated by an unknown mechanism or that its expression is maintained in a 
specific type of neurons. Regarding whether REST is required to maintain 
pluripotency of ESCs or multipotency of NPCs there is much controversy in the 
literature. While some groups indicate that REST is not required for pluripotency 
others indicate that it is required (Singh et al., 2008; Buckley et al., 2009; Jorgensen 
et al., 2009; Covey et al., 2012;). Furtheremore, since most of these studies were 
carried out in mouse ESCs and NPCs; this makes it even more difficult to ascertain 
whether REST is required to maintain self-renewal in hESCs and human NPCs. 
 
Truncated isoforms of REST have been observed in both rat (Palm et al., 1998) and 
human tissue (Palm et al., 1999; Coulson et al., 2000). In humans, two variants of 
REST termed hREST-N4 and hREST-N62 were only detected in neuronal tissues. 
These transcripts are generated by alternative splicing of a neuron-specific exon 
(exon N) located between exons V and VI (Figure 1.10). Exon N is 62 bp in length 
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and contains a premature stop codon. Alternative splicing of REST into hREST-N62 
leads to the insertion of exon N, which under the presence of a premature stop codon, 
results in an insertion of 13 amino acids (VGYGYHLVIFTRV) upon translation 
(Figure 1.10), while splicing of REST into hREST-N4 results in no amino acid 
insertion only a stop codon. hREST-N4 and hREST-N62 retain the N-terminal 
repression domain and five out of the eight zing fingers of full length REST. This 
neuron specific splicing of REST has been observed in human, mouse and rat (Palm 
et al., 1998, 1999).  
 
 
 
Figure 1.10 Representation of human REST gene transcripts and rodent 
rREST4 transcript. 
Introns are shown as doted boxes and exons as continuous line boxes. Exon numbers appear in roman 
numbers I to VI under the respective exon boxes. The neuron specific exon is located between exons 
V and VI and is indicated with a N. Vertical green bars indicate zinc finger motifs. The open reading 
frames of each transcript are shown in filled yellow boxes while empty boxes denote no transcription. 
The long doted line across the figure separates human from rodent REST transcripts. Note that, 
similarly, human hREST-N62 and rodent rREST4 transcripts encode five out of the 9 zinc finger 
motifs encoded by full length REST but lack its C-terminal repression domain. 
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Although no function has been ascribed to hREST-N62, the rodent protein 
orthologous to this REST variant known as rodent REST4 (rREST4) has been shown 
to counteract the repressive role of REST in the regulation of its target genes, 
particularly during neurogenesis (Palm et al., 1999; Shimojo et al., 1999; Tabuchi et 
al., 2002; Uchida et al., 2010; Raj et al., 2011). Whilst the protein sequence encoded 
by exon N differs between hREST-N62 and rodent rREST4, both retain the REST N-
terminal domain and 5 of the 9 zinc-finger DNA binding domains, but lack the C-
terminal repression domain (Figure 1.10).  
 
1.6.1 Post-translational regulation of REST expression in NPSCs 
 
Expression of REST is high in ES cells, decreases during neural induction, and 
decreases further upon formation of neurons (Ballas and Mendel, 2005).  Therefore it 
is assumed that in order to achieve neural differentiation of ES cells, REST 
repression needs to be alleviated. In fact it has been shown that activation of REST 
target genes in NSCs is sufficient to cause neuronal differentiation (Su et al., 2006), 
further supporting this hypothesis. However, how REST is regulated to allow neural 
differentiation is still unclear. Two studies in mouse NSCs have shown that REST is 
regulated post-translationally by the E3 ubiquitin ligase β-TrCP (Guardavaccaro et 
al., 2008; Westbrook et al., 2008). β-TrCP binds and polyubiquitinates REST so that 
ubiquitinated REST can be recognised by the proteasome for degradation. Therefore, 
the presence of β-TrCP in NSCs reduces REST protein levels and allows neuronal 
differentiation. Furthermore, another study has found that the neural specific Ser/Arg 
repeat-related protein of 100 KDa nSR100 promotes the alternative splicing of REST 
into rREST4, thus contributing to REST inactivation during mouse NPC 
differentiation (Raj et al., 2011). However, in this study they showed that as a 
consequence of the induced splicing of REST into rREST4, REST protein levels 
were greatly downregulated therefore it remains unclear if the promotion of neuronal 
differentiation is due to the reduction of REST protein or the previously reported 
antagonistic effect of rREST4 over REST repression activity. Interestingly, this study 
claims that the nSR100 dependent switch from REST to rREST4 is an independently 
acting mechanism to that of β-TrCP and suggests that the downregulation of REST is 
a consequence of the alternative splicing which acts as an additional mechanism. 
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Recently, in human NPCs it has been found that deubiquitylase HAUSP can 
antagonise the ubiquitination of β-TrCP on REST and hence stabilises the expression 
of REST to maintain NPC identity (Huang et al., 2011). These results suggest that 
regulation of REST may depend on the species or type of cell, which is line with the 
findings observed in in vivo neural development.  
 
1.6.2 Mechanism of REST repression on its target genes 
  
REST mediated repression is coordinated by the recruitments of two separate co-
repressor complexes, mSin3 and CoREST, to their N-terminal and C-terminal 
repressor domains, respectively (Figure 1.11) (Andres et al., 1999; Roopra et al., 
2000). At the N-terminal domain, mSin3a binds to REST (Grimes et al., 2000) and 
recruits chromatin remodelling enzymes, histone deacetylases (HDACs) 1, 2, 4 and 5 
(Huang et al., 1999; Nakagawa et al., 2006). At the C-terminal domain, REST 
recruits Co-REST which in turn recruits HDACs 1 and 2 (You et al., 2001), H3K4 
demethylase LSD1 (Shi et al., 2004) and BRG1, a member of the SWI/SNF 
chromatin remodelling family (Battaglioli et al., 2002; Ooi et al., 2006). BRG1 has 
been shown to stabilise REST binding to the RE1 sites in vivo (Ooi et al., 2006), 
which is thought to occur by BRG1 changing the chromatin environment around the 
RE1 site to allow REST gain better access (Watanabe et al., 2006). In addition to 
chromatin remodelling, REST has been shown to regulate gene expression more 
directly by affecting the basal transcription machinery. REST has been shown to 
inhibit transcription initiation by interacting with TATA binding protein and RNA 
polymerase II-bound small C-terminal domain phosphatases (Murai et al., 2004; Yeo 
et al., 2005). 
 
These findings indicate that in order for REST to repress its target genes, other 
repressors and chromatin remodelling factors are required to be recruited co-
ordinately to its N-terminal and C-terminal domains. Interestingly it has been 
reported that overexpression of REST mutants lacking either of its repression 
domains results in partial repression of REST  (Andres et al., 1999; Huang et al., 
1999; Grimes et al., 2000), which suggests that at least some of the REST-regulated 
genes require both REST repressor domains to be repressed. This may indicate that 
repression by REST can occur at different levels of intensity. It is also worth 
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indicating  that overexpression of REST mutants lacking either of the repressor 
domains of full length REST has a similar effect on REST than the presence of 
REST4 in cells, which lacks the C-terminal repression domain (Tabuchi et al., 2002; 
Shimojo and Hersh, 2004).  
. 
 
 
Figure 1.11 REST mechanism of repression. 
REST binds the RE1 element of target genes using its DNA binding domain. REST interacts with 
Sin3A/B at its N-terminal and CoREST at its C-terminal region to recruit histone deacetylase (HDAC) 
and associated proteins to the promoter region. While REST interaction with Sin3A/B results in 
epigenetic changes that limit accessibility of DNA transcription factors, REST interaction with 
CoREST inhibits transcription start by blocking RNA pol II binding (RNA Pol II).  
 
1.7 Embryonic stem cells 
 
ESCs were first isolated from the inner cell mass (ICM) of pre-implantation mouse 
embryo in 1981 (Evans and Kaufman, 1981; Martin 1981). Building on this research 
and in the later derivation of non-human primate ESCs, the first hESCs line was 
derived also from the ICM of pre-implantation embryos (Thomson et al., 1998). 
Following the isolation of hESCs, several lines have been derived in multiple 
laboratories throughout the world (Thomson et al., 1998; Reubinoff et al 2000; Amit 
et al., 2002; Richards et al., 2002). HESCs, similarly to mouse ESCs (mESCs), grow 
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in colonies and have a have a high nucleus to cytoplasmic ratio. They are able to 
differentiate into the three embryonic germ layers by embryoid body formation 
(Itskovitz-Eldor et al., 2000) and can form teratomas when injected into nude mice 
(Tzukerman et al., 2003; Lensch et al., 2007), reflecting their potential to 
differentiate in vivo.  
 
1.7.1 Regulation of self-renewal and pluripotency in undifferentiated embryonic 
stem cells 
 
ESCs self-renewal and pluripotency is governed by key intrinsic and extrinsic 
factors. The best studied intrinsic factors are Oct4, Nanog and Sox2, which play 
essential roles in both mESCs and hESCs.  Oct4, Nanog and Sox2 are highly 
expressed in ESCs and downregulated upon differentiation (Rogers et al., 1991; 
Reubinoff et al., 2000; Chambers et al., 2003; Fong et al., 2008). They form a 
regulatory circus to maintain expression of pluripotent genes and to repress 
expression of lineage-specific genes (Boyer et al., 2005; Chew et al., 2005; Rodda et 
al., 2005). The significant roles of these factors have been further confirmed by their 
ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) 
(Takahashi et al., 2007; Yu et al., 2007; Nakagawa et al., 2008; Yamanaka et al., 
2008).  
 
Extrinsic factors, such as growth factor signaling pathways, are also very important 
for regulating self-renewal of ESCs. However, unlike the intrinsic factors, which 
seem to be regulated by very similar means in both mESCs and hESCs, the signalling 
pathways required to maintain the ESCs characteristics in mESCs and hESCs differ 
considerably.  Although, initially mESCs and hESCs were maintained throughout 
their co-culture with MEFs, the extrinsic factors that are contributing to retain their 
undifferentiated state may be different.  While maintenance and propagation of 
mESCs properties requires leukaemia inhibitory factor (LIF) (Smith et al., 1988; 
Williams et al., 1988), hESCs self-renewal has been shown to require the presence of 
FGF2/bFGF (Reubinoff et al., 2000). This is likely to be because of the lack of LIF 
receptors (LIFR)/gp130 complexes in hESCs (Brandenberger et al., 2004), which in 
mESCs bind LIF and mediate pluripotency through the activation of signal 
transducer and activator of transcription 3 (STAT3) (Yoshida et al., 1994). In fact, 
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BMP and LIF has been shown to be sufficient to maintain self-renewal and 
pluripotency in mESCs without the need of serum or feeder layers (Ying et al., 
2003), while hESCs are currently thought to be mainly maintained by FGF 
signalling. Fibroblast growth factor receptor (FGFR) 1, the receptor of FGF2, is 
abundantly expressed in hESCs in contrast to differentiated cells (Brandenberger et 
al., 2004; Carpenter et al., 2004). Other FGFRs, including FGFR2, FGFR3 and 
FGFR4, also appear to be enriched in the undifferentiated hESCs (Dvorak and 
Hampl, 2005). 
 
1.7.2 Potential applications of hESCs  
 
While the generation of hESC lines has raised major ethical issues, hESCs provide a 
new useful cell source for basic science and to some extent, translational medicine. 
In the context of basic science research, the property of hESCs to differentiate into 
most if not all cell types of the human body makes them very useful to study human 
embryonic development. In fact, many studies have demonstrated that differentiation 
of hESCs into specific cell types recapitulates, to a large extent, the normal 
development of those cells in vivo (Gerrard et al., 2005; Hay et al., 2008; Zhang et 
al., 2010; Lancaster et al., 2013). hESCs have particularly been an important tool in 
illuminating key mechanisms underlying neuronal development  (Chamberlain et al., 
2008; Crook and Kobayashi, 2008). These cells allow investigators to assess aspects 
of human neurogenesis that otherwise would not be possible due to technical and 
ethical obstacles in obtaining human embryonic and foetal tissues. Furthermore, it 
has been shown that the mechanisms that regulate embryonic and adult neurogenesis 
in vertebrates can be very different between species; therefore hESCs provide a 
unique tool to advance our understanding in human development. A full 
understanding of the mechanisms that regulate the development of the different cells 
types in the human body is required prior to using hESCs in translational medicine.    
 
In the translational medicine context, hESCs have been reported to partially restore 
impaired cardiac functions in several animal models of myocardial infarction (Caspi 
et al., 2007; Laflamme et al., 2007).  Furthermore, two recent food and drug 
administration (FDA)-approved hESC therapy trials for spinal cord injury and 
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macular degeneration used hESC-derived oligodendrocyte cells and retinal pigment 
epithelium (RPE) cells, respectively, for treating the conditions (Lu et al., 2009; 
Sharp et al., 2010). However, while hESCs have provided some success in 
translational medicine, a range of ethical and technical issues such as embryo 
destruction upon hESCs derivation or immune rejection of the transplanted 
cells/tissue, has massively halted their application to patients. The direct 
reprograming of somatic cells to a hESC-like cell type known as iPSCs by the groups 
of  Yamanaka and Thomson in 2007 (Takahashi et al., 2007; Yu et al., 2007) raised 
the possibility of circumventing the immune rejection and ethical problems of 
hESCs. Ectopic expression of four pluripotency intrinsic factors (Oct3/4, Sox2, c-
Myc, and Klf4 or Oct3/4, Sox2, Nanog, and Lin28) was found to be enough to 
reprogram human fibroblasts into iPSCs. iPSCs largely resemble hESCs in terms of 
pluripotency, surface markers, morphology, proliferation, feeder dependence, global 
transcriptomic profile and epigenetic status, promoter activities, telomerase activities, 
and in vivo teratoma formation (Takahashi et al., 2007; Yu et al., 2007). These 
findings indicate that patient specific iPSCs could be generated with translational 
medicine intentions; however, high incidence of cancer, low reprogramming 
efficiency and the use of retroviruses, have slow down the use of these cells.  
Recently, several studies have managed to use less factors and non-viral means to 
produce iPSCs albeit with a relatively low reprograming efficiency still (Yusa et al., 
2009; Meng et al., 2012; Churko et al., 2013), which provides hope to use these cells 
for translational medicine purposes in the near future. 
  
1.8 Neural differentiation of human embryonic stem cells 
 
Owning to their unique properties, ESCs provide a good in vitro model to study early 
development and lineage fate regulation. Several protocols have been developed to 
drive hESCs differentiation toward neural lineages, either through cell aggregation or 
via monolayer differentiation (Shulz et al., 2003, Gerrard et al., 2005, Chambers et 
al., 2009). These studies have shown that inhibition of the SMAD signalling 
pathway, a family of transcription factors, is critical for neural differentiation 
initiation.  Our laboratory has previously demonstrated that it is necessary to block 
the BMP signalling pathway during initial differentiation of hESCs to block SMADs 
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1, 5 and 8 signalling and induce neural differentiation, from which we have 
developed a monolayer culture system to efficiently generate NPCs from hESCs 
(Figure 1.12) (Gerrard et al., 2005). While recent investigations have proposed that 
additional inhibition of SMADs 2 and 3 with the inhibitor SB431542 induces a more 
rapid conversion of hESCs to NPCs (Chambers et al., 2009), our laboratory did not 
find major differences between the dual or single inhibition protocols and therefore 
uses the single inhibition as the method of choice for neural differentiation. 
Treatment of hESCs with the BMP antagonist noggin progressively and efficiently 
generates a morphologically distinct neural-like population of cells that express 
neuroectodermal markers, such as Pax6, Musashi1 and Sox2 but not mesoderm and 
endoderm lineage markers. Following neural initiation (N1) and neural progenitor 
formation, noggin can be replaced by bFGF/EGF and NPCs can be maintained in 
these conditions for an extended time (N2 and N3). However, continuous culture of 
NPCs results in the progressive shift from a bipolar morphology to triangular shape 
morphology. By passage 15, all cells exhibited triangular morphology and remained 
constant, without significant change (N3). It is also noticeable that early NPCs (N2) 
are more like neuronal progenitors and mainly generate neurons upon further 
differentiation, while late NPCs (N3) are able to differentiate to both neurons and 
glia, thus NSC-like, though their differentiation preference is gradually shifted 
toward glial differentiation as other researchers have found in NSC cultures (Tropepe 
et al., 1999; Raballo et al., 2000; Gerrard et al., 2005).  
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Figure 1.12 Schematic representation of the different stages of neural 
differentiation.  
From left to right, small clusters of hESCs were cultured with N2B27 media supplemented with the 
BMP antagonist noggin for approximately one week, until the cells formed neural tube-like structures 
(N1 neural initiation, passage 1-2).  Following N1 stage, noggin is replaced by bFGF (FGF2) and 
cultured in these conditions until bipolar early NPC morphology was observed (N2 Early NPCs, 
passages 4-14). Continuous culture of NPCs in bFGF progressively shifts cells from a bipolar 
morphology to a triangular morphology typical of late NPCs (N3 Late NPCs, passage 15 onwards). 
Once this morphology was observed cells were cultured with bFGF and EGF. Following N3 stage cell 
morphology did not vary.  
 
1.9 Aims of the project 
 
Knockout studies in mice have indicated that TRF1 and TRF2 may play an important 
role during embryonic development (see sections 1.2.4 and 1.2.5). However, due to 
embryonic lethality, it remains unclear what roles they play in development. 
Furthermore, TRF2 has been suggested to be involved in neurogenesis (Jung et al., 
2004; Zhang et al., 2008) and preliminary data in our laboratory showed that TRF2 
protein may be dramatically upregulated during neural differentiation. Thus, 
elucidating its role in normal neural development, particularly in brain function may 
aid in the improved procurement of human neural cells for potential use in 
regenerative therapies.  Therefore, in this project, I explored TRF2 function during 
neural differentiation using hESCs as an in vitro system.  
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1.9.1 Hypothesis  
 
TRF2 may play an important role in the neural differentiation of hESCs. 
 
1.9.2 Aim and Objectives  
 
The overall aim of my project is to investigate whether TRF2 plays a role in neural 
differentiation of hESCs and, if so, to explore the possible molecular mechanisms. 
The specific objectives are to:  
 
1. Characterise TRF2 and TRF1 expression patterns in hESCs, their neural 
derivatives and other cell lineages.  
 
This will help to determine if TRF2 is differentially expressed during neural 
differentiation of hESCs.  
 
2. Investigate the role of TRF2 in hESC neural differentiation.  
 
Carry out gain or loss of TRF2 function experiments in hESCs and NPCs to 
determine the effect TRF2 in telomere regulation and neural differentiation.  
 
3. Explore the molecular interactions of TRF2 during hESC neural 
differentiation.  
 
Immunoprecipitation of TRF2 in hESCs and their neural progenitor derivatives may 
shed some light on the binding partners of TRF2 during neural differentiation and aid 
in the determination of a molecular mechanism.  
 
4. Investigate the molecular pathway where TRF2 may play a role in neural 
differentiation. 
 
Carry out appropriate experiments to determine how TRF2 is affecting neural 
differentiation. 
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Chapter 2 Materials and methods 
 
2.1 Cell biology materials and methods 
 
2.1.1 Cell culture reagents 
 
Item Supplier 
Catalogue 
Number 
0.01% Poly-L-lysine (PLL) Sigma-Aldrich P4707 
0.02% ethylene-dinitrilo tetraacetic acid 
(EDTA) 
Sigma-Aldrich E8008 
100X L-Glutamine Life Technologies 25030-024 
100X Non-Essential Amino Acids (NEAA) Life Technologies 11140-035 
100X Penicillin/Streptomycin (P/S) Life Technologies 15140-122 
2% Gelatin Sigma-Aldrich G1393 
20% Bovine serum albumin (BSA) Sigma-Aldrich A9418 
2-mercaptoethanol Life Technologies 31350-010 
Accutase Sigma-Aldrich A6964 
B27 Supplement Life Technologies 17504-044 
bFGF Peprotech 100-18C 
Collagenase Life Technologies 17104-019 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2650 
DMEM:F12 (1:1) Life Technologies 21331-020 
Dulbeccos modified eagles medium (DMEM) Life Technologies 11960-044 
EGF Peprotech 100-15 
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Item 
 
 
Supplier 
 
 
Catalogue 
Number 
Foetal bovine serum (FBS) Sigma-Aldrich F7524 
Hexadimethrine bromide (Polybrene) Sigma-Aldrich H9268-5G 
   
Knockout Dulbecco’s modified eagles 
medium (KO-DMEM) Life Technologies 
10829-018 
Knockout serum replacement (KSR) Life Technologies 10828-028 
Laminin  Sigma-Aldrich L2020 
Matrigel  Life Technologies 12760021 
Neurobasal medium Life Technologies 21103-049 
Noggin R&D systems 719-NG-050 
PBS without Ca2+& Mg2+ Life Technologies 14190-169 
phosphate buffer saline (PBS) Life Technologies 14190-094 
Puromycin Sigma-Aldrich P8833 
TryLE Express Life Technologies 12604-013 
Trypsin  Sigma-Aldrich T3924 
Y-27632 ROCK inhibitor Reagents direct 53-B85 
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2.1.2 Cell culture media and stock solutions 
 
KSR medium 
 
  Component Amount (ml) Final Concentration 
KO-DMEM 400 -- 
KO-SR 100 20% 
10ng/ml bFGF 0.2 4ng/ml 
100X NEAA 5 1X 
2-mercaptoethanol 1 0.1mM 
100X L-Glutamine 5 1X 
 
N2B27 medium 
 
  Component Amount (ml) Final Concentration 
DMEM/F12  250 50% 
Neurobasal medium 250 50% 
100X N2 2.5 0.5X 
50X B27 5 0.5X 
100X L-Glutamine 1 1X 
   Mouse embryonic fibroblast (MEF) 
medium 
 
  Component Amount (ml) Final Concentration 
DMEM 440 -- 
FBS 50 10% 
100X L-Glutamine 5 1X 
   Embryoid body (EB) differentiating 
medium 
 
  Component Amount (ml) Final Concecntration 
KO-DMEM 400 -- 
FBS 100 20% 
100X NEAA 5 1X 
2-mercaptoethanol (50 mM) 1 0.1mM 
100X L-Glutamine 1 1X 
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bFGF stock solution 
 
Component Amount Final Concentration 
FGF2 250 μg 10 µg/ml 
PBS 25 ml -- 
20% BSA 250 μl 0.20% 
   Collagenase stock solution 
   
Component Amount Final Concentration 
Collagenase IV 20,000 units 200 units/ml 
KO-DMEM 100 ml -- 
 
 
2.1.3 Primary and secondary antibodies 
 
Primary 
antibodies 
 
Type Company 
Catalogue 
Number 
 
IF 
Dilution 
 
WB 
Dilution 
 
-Actin
mouse 
monoclonal 
Sigma-
Aldrich 
A5441 1:5000 1:5000 
-tubulin III 
(Tuj1)
mouse 
monoclonal 
Sigma-
Aldrich 
T8660 1:1000 - 
Caspase 3 
rabbit 
polyclonal 
Cell 
Signalling 
9662 1:1000 - 
GFAP  
rabbit 
antiserum 
DAKO Z0334 1:500 - 
HA 
mouse 
monoclonal 
Sigma-
Aldrich 
H3663 - 1:1000 
HA 
rabbit 
polyclonal 
Sigma-
Aldrich 
H6908 - 1:1000 
HNF4 (H-171) 
rabbit 
polyclonal 
Santa Cruz sc-8987 1:50 1:200 
Muscle actin   
(1E12-s) 
mouse 
monoclonal 
Hybridoma 
Bank 
1E12 1:50 - 
Myc 
mouse 
monoclonal 
Santa Cruz SC-40 - 1:1000 
Nestin 
mouse 
monoclonal 
Chemicon 
MAB 
5326 
1:200 1:500 
Oct4 
rabbit 
polyclonal 
Abcam ab19857 1:200 1:500 
Oct4 
mouse 
monoclonal 
Santa Cruz sc-5279 1:250 1:1000 
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Primary 
Antibody 
 
 
Type 
 
 
Company 
 
 
Catalogue 
Number 
 
 
IF 
Dilution 
 
 
WB 
Dilution 
      
p21  
(Cip1/WAF1) 
mouse 
monoclonal 
DAKO  M7202 - 1:250 
Pax-6 
mouse 
monoclonal 
Hybridoma 
Bank 
- 1:50 - 
Pax-6 
rabbit 
polyclonal 
Millipore AB2237 1:500 1:1000 
Phospho Histone 
H3 (Ser10) 
rabbit 
polyclonal 
Millipore 05-806 1:200 - 
RAP1 
Rabbit 
polyclonal 
Bethyl labs 
A300-
306A 
- 1:1000 
REST 
rabbit 
polyclonal 
Millipore 07-579 - 1:1000 
REST4 
Rabbit 
monoclonal 
Epitomics 2417-1 - 1:2000 
 
Sox1 
rabbit 
polyclonal 
Abcam  ab87775 1:500 1:1000 
Sox2 
rabbit 
polyclonal 
Abcam ab97959 1:500 1:1000 
Sox2 
goat 
polyclonal 
R&D 
System 
AF2018 1:400 - 
SSEA4 
mouse 
monoclonal 
Hybridoma 
Bank 
MC-813-
70 
1:5 - 
Tra-1-81 
mouse 
monoclonal 
Santa Cruz sc-21706 1:50 - 
TRF1 
mouse 
monoclonal 
Millipore 04-638 - 1:1000 
TRF2 
mouse 
monoclonal 
Millipore 05-521 1:500 1:500 
TRF2 (H-300) 
rabbit 
polyclonal 
Santa Cruz sc-9143 1:30 1:200 
γ-H2A.X (S139) 
rabbit 
polyclonal 
Upstate 07-164 - 1:500 
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Secondary antibodies Company 
Catalogue 
Number 
IF 
Dilution 
WB 
Dilution 
     
Goat Anti-Mouse IgG 
Alexa Fluor 488 
Life 
Technologies 
A11001 1:400 - 
Goat Anti-Rabbit IgG 
Alexa Fluor 488 
Life 
Technologies 
A11008 1:400 - 
Goat Anti-Rabbit IgG 
Alexa Fluor 568 
Life 
Technologies 
A11011 1:400 - 
Goat Anti-Mouse IgG 
Alexa Fluor 568 
Life 
Technologies 
A11004 1:400 - 
Goat anti-mouse Light 
chain specific 
Jackson Labs 115-035-174 - 1:25000 
Mouse anti-rabbit 
Light chain specific 
Jackson Labs 211-032-171 - 1:25000 
 
     
      
2.1.4 Preparation of mouse embryonic fibroblast conditioned medium 
 
MEFs isolated from embryonic day 13.5 (E13.5) CD-1 mouse were grown and 
expanded in MEF culture medium for up to 3 passages. Cells were trypsinised, 
collected in 50 ml falcon tubes (Corning) by centrifugation (Hettich Universal 320 
centrifuge), irradiated with 40 grays (Gy) (IBL 637 Cell irradiator), and seeded with 
MEF medium at ~80,000 cells/cm
2
 in 0.5% gelatin coated T225 cell culture flasks 
(Corning). Cells were allowed to attach and recover overnight. The following day 
MEF media was replaced with 150 ml KSR medium supplemented with 4 ng/ml 
human bFGF, and incubated for 24 hours. The next day the 150 ml KSR MEF 
conditioned media (CM) was collected into sterile 150 ml collection bottles 
(Corning) and stored at -80C until required. MEFs were fed again with KSR media 
as the day before for another collection next day. The procedure can be repeated for 
6 days maximum. On the day of use in hESCs cell culture, CM was defrosted, mixed 
with 1X L-glutamine and filtered to remove any MEF cells. Fresh bFGF was added 
into the medium (8 ng/ml) prior use for hESCs cell culture. 
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2.1.5 Preparation of matrigel coated plates  
 
Growth factor-reduced matrigel was slowly thawed on ice at 4°C overnight and 
diluted 1:2 with ice cold KO-DMEM. This 1:2 diluted matrigel-KO-DMEM solution 
was aliquoted in 1 ml volumes and stored at -20°C until required. To prepare 
matrigel coated plates, frozen stock matrigel solution was slowly defrosted at 4°C 
overnight and then diluted 1:15 in ice cold KO-DMEM (final working concentration 
1:30), which was then plated into cell culture plates and incubated overnight at 4°C. 
In emergency instances, the coating could be shortened to 3 hour at room 
temperature. Matrigel coated plates can be maintained at 4°C for up to a week before 
use.  
 
2.1.6 Human embryonic stem cell culture 
 
The hESCs used in this project were the H1 and H7 lines, two of the first hESC lines 
derived in 1998 (Thomson et al., 1998). These were obtained from WiCell Research 
Institute (Madison, VA). hESCs were grown and maintained in an undifferentiated 
state on matrigel-coated plates with MEF-CM supplemented with 8 ng/ml bFGF (Xu 
et al., 2001). They were routinely passaged in 6-well plates (Corning) at 1:3 ratio by 
incubating for 5-10 minutes with 200 U/ml collagenase IV at 37°C. The collagenase 
was then washed off from the cells and the cells mechanically scrapped with a 5 ml 
strippette (Corning) to generate small clumps of cells that were subsequently plated 
into new matrigel-coated wells.  
 
2.1.7 Neural differentiation of human embryonic stem cells 
 
Human embryonic stem cells were differentiated into neural NPCs using the 
laboratory published protocol (Gerrard et al., 2005). Confluent hESCs were treated 
with 0.02% ethylene-dinitrilo tetraacetic acid (EDTA) to reduce the adhesion, 
flushed with culture medium, and broken into small clumps which were then split at 
a 1:5 ratio and plated onto PLL/laminin coated 6-well plates (passage 1). The 
differentiating cells were cultured in N2B27 medium supplemented with 100 ng/ml 
noggin. Upon confluence, cells were split 1:3 using collagenase IV and scraping (as 
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with hESC culture). Following the formation of neural rosettes approximately at 
passages 2-3, noggin was replaced with bFGF and EGF (20 ng/ml each). NPCs were 
propagated with TrypLE and maintained in the same culture conditions (See Figure 
1.12 for a schematic representation). For further differentiation into neurons and glia, 
growth factors were withdrawn from the N2B27 medium for 1-2 weeks. 
 
2.1.8 Fibroblast differentiation of human embryonic stem cells 
 
Fibroblast differentiation of hESCs was induced by replacing hESC culture medium 
with DMEM supplemented with 10% FBS and 1% L-glutamine. The hESCs colonies 
were allowed to differentiate over three weeks into human embryonic fibroblasts 
(HEFs), passaging them with trypsin when required.  
 
2.1.9 Differentiation of hESCs by Embryoid Body formation 
 
Differentiation of hESCs via EB formation was induced by culturing hESCs in 
suspension and in EB differentiation medium.  A confluent well of a 6-well plate 
(Corning) of hESCs was treated with 1 ml collagenase IV and treated as in hESCs 
propagation, except small clumps of cells were generated in 2 ml of EB 
differentiation medium. Cell clumps were transferred to one well of a low attachment 
plate (1:1 split). 2 ml of differentiation medium were added to make up a total 
volume of 4 ml per well. After overnight culture in suspension, ES cells formed 
floating aggregates known as EBs.  To change the medium, EBs were transferred 
into a 15-ml tube and allowed to settle for 5 min. Supernatant was then replaced with 
fresh differentiation medium (4 ml/well), and the EBs transferred again into a low 
attachment 6 well plate for further culture.  Medium was changed every 2 to 3 days. 
EBs were kept in culture for 7 days and then dissociated in a 24-well plate containing 
0.5% gelatine coated glass coverslips and 1 ml differentiation medium. The 
dissociated EBs were allowed to further differentiate in these conditions for 1-2 more 
weeks, then fixed for immunofluorescence (IF) or harvested for ribonucleic acid 
(RNA) or protein extraction.  
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2.1.10 mESCs and human hepatoblasts 
 
Protein lysates of mESCs, mouse epiblast stem cells (mEpiSCs) and mouse NPCs 
(mNPCs) were a kind gift of Professor Meng Li’s laboratory (Cardiff University, 
Stem Cell Neurgenesis group). The H1 hESCs-derived hepatoblast lysates used in 
this thesis were a kind gift of Jason Yu (Imperial College London, Stem Cell 
Differentiation group) who differentiated the cells and provided me with the protein 
lysate. 
  
2.1.11 hESCs and NPCs transduction 
 
Human embryonic stem cells were split 24 hours prior to infection with accutase and 
plated into matrigel-coated plate under hESCs culture conditions and supplemented 
with 10 µM Rock inhibitor Y-27632 (Watanabe et al., 2007). Medium was replaced 
with fresh hESC media with no Rock inhibitor and 20 µl of concentrated virus in a 
total volume of 1 ml medium containing 8 µg/ml Hexadimethrine bromide 
(Polybrene). For packaging and production of lentiviruses see section 2.2.3. Cells 
were selected for their respective selection marker resistance 48-72 hours after 
infection. Surviving cells were then cultured and propagated as in routine hESC 
culture. NPCs were infected similarly to hESCs with the following modifications. 
NPCs were split with TripLE and no Rock inhibitor was added. Same dilution of 
viruses was tested and 4 µg/ml Polybrene used for the infection. Infection was 
carried out under NPC culture conditions. The lentivector pLVTHM containing 
green fluorescent protein (GFP) complementary DNA (cDNA) was used as a control 
for infection (Appendix, Figure A2), GFP expression was visualised by fluorescent 
microscopy (Nikon Eclipse TE 2000-U). 
 
 
 
 
 
 
 
69 
 
2.2 Molecular biology materials and methods 
 
2.2.1 Molecular biology reagents 
 
Item Supplier 
Catalogue 
Number 
100 bp DNA ladder NEB N0468S 
1 kb DNA ladder NEB N0467S 
2-Mercaptoethanol Sigma-Aldrich  M6250 
30% bis/acrylamide VWR 100639 
Agarose Sigma-Aldrich A9539 
Ammonium persulfate (APS) VWR 443073E 
BCA protein assay kit  Fisher 23227 
BSA Sigma-Aldrich A7906 
Calcium Phosphate Transfection Kit Sigma-Aldrich CAPHOS-1KT 
Chloroform solution Sigma-Aldrich 25666 
Chondroitin sulphate from shark cartilage Sigma-Aldrich C4384-1G 
CL-XPosure X-ray film Fisher 34090 
Colcemid Life Technologies 15212012 
DNase I Sigma-Aldrich AMPD1-1KT 
Dynabeads Protein G  Life Technologies 10003D 
Glass coverslips VWR 631-0149 
Glass slides VWR 631-1558 
Goat serum Sigma-Aldrich G9023 
Hexadimethrine bromide (Polybrene) Sigma-Aldrich H9268-5G 
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Item Supplier 
Catalogue 
Number 
Immobilon-P membrane, PVDF Millipore IPVH-000-10 
Lipofectamine LTX plus reagent  Life Technologies 15338030 
Luminata Forte Western blot substrate Millipore WBLUF0500 
MG132 Calbiochem 474791 
Normal rabbit IgG & mouse IgG Santa Cruz sc-2027/2025 
Oligo dT 12 18 Primer Life Technologies 18418012 
One Taq DNA polymerase NEB M0480L 
Page Ruler Plus protein ladder Fermentas SM1811 
PCR-graded water Life Technologies  10977-023 
Phase lock gel tubes 5 Prime 2302820 
Phenol solution Sigma-Aldrich P4557 
Phenylmethanesulfonyl fluoride solution 
(PMSF) 
Sigma-Aldrich 93482 
Positively charged nylon membrane Roche 
 
Protease Inhibitor Sigma-Aldrich P8340 
Protein A/G plus agarose beads Santa Cruz sc-2003 
QIAfilter Plasmid Maxi Kit Qiagen 12263 
QIAquick gel extraction kit Qiagen 28704 
Resolving gel buffer Bio-Rad 161-0798 
Restriction enzymes NEB Various 
RNase OUT Life Technologies 10777019 
Site-directed Quickchange mutagenesis 
kit 
Agilent 200519 
Stacking gel buffer Bio-Rad 1610799 
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Item Supplier 
Catalogue 
Number 
SuperScript II RT Life Technologies 18064014 
SYBR® Green JumpStart™ Taq 
ReadyMix™  
Sigma-Aldrich S4438 
T4 DNA ligase NEB M0202L 
TAM1 Competent Cells Active Motif 11096 
Telomere PNA FISH Kit/FITC DAKO K5325 
TeloTAGGG Telomere Length Assay kit Roche 12209136001 
Tetramethylethylenediamine (TEMED) VWR 443083G 
Thermanox coverslips Thermo Scientific 174950 
Tri reagent Sigma-Aldrich T9424 
Triton X-100 Sigma-Aldrich T8787 
Ubiquitin Aldehyde R&D Systems U-201 
Vectashield DAKO H-1200 
 
2.2.2 Construction of expression vectors  
 
All original plasmids were obtained from Addgene unless indicated and all 
restriction enzymes as well as modification enzymes were purchased from New 
England Biolabs. Lentiviral vectors for overexpressing and knocking down TRF2 
were derived from pLVTHM (Addgene 12247, Wiznerowicz and Trono, 2003). 
TRF2 cDNA was isolated from pLPC-TRF2 (Addgene 18002, Wang et al., 2004). 
Briefly, site-mutagenesis was performed to mutate stop codon of PURO cDNA in 
pPUR (Clonetech) which enable the insertion of a 2A foot and mouth disease virus 
sequence PCR fragment downstream of PURO. An Agilent site directed mutagenesis 
kit was used following the manufacturer instructions. The PURO-2A fragment was 
then assembled with TRF2 cDNA in pBluescript KS II (-) (Stratagene) to generate 
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PURO-2A-TRF2 fusion protein fragment, which subsequently substituted GFP in 
pLVTHM to generate a TRF2-expressing lentiviral vector. The knockdown plasmid 
was generated by replacing scramble short hairpin ribonucleic acid (shRNA) in 
pLVTHM with a duplex oligonucleotide targeting TRF2 mRNA 5′-CGC GCA GGA 
GCA TGG TTC CTA ATA ATA CTG CAG TAT TAT TAG GAA CCA TGC TCC 
TGT TTT T -3′ and 5′-GCA AAA ACA GGA GCA TGG TTC CTA ATA ATA 
CTG CAG TAT TAT TAG GAA CCA TGC TCC TG -3′. The lentiviral vector 
pLCMV-Neo-Myc-REST was a kind gift from Dr Shideng Bao (Huang et al., 2011) 
and was used to generate both REST4 and REST4 mutant expression vectors. REST4 
expression vector was generated by subcloning REST XbaI/BamHI fragment from 
pLCVM-Neo-Myc-REST into pBluescript KS II (-), where the NdeI/BamHI 
fragment containing REST C-terminal domain was then replaced with an 
oligonucleotide duplex containing REST4 exon N coding sequence (5′-TAT GCG 
TAC TCA TTC AGT GGG GTA TGG ATA CCA TTT GGT AAT ATT TAC TAG 
AGT GTG AG-3′ and 5′-GAT CCT CAC ACT CTA GTA AAT ATT ACC AAA 
TGG TAT CCA TAC CCC ACT GAA TGA GTA CGCA-3′). The resulting REST4 
cDNA was then inserted back into pLCMV-Neo-Myc-REST with XbaI and BamHI 
replacing full length REST. The REST4 mutant vector was generated by replacing 
exon N sequence with a stop codon using the oligonucleotide duplex 5′-TAT GCG 
TAC TCA TTC AGGT-3′ and 5′-GAT CCT CAA CCT GAA TGA GTA CGC ATG 
AG-3′. pCS2-HA-TRF2 was generated by cloning TRF2 cDNA into pCS2-HA. All 
constructs were verified by sequencing (Beckman Coulter Genomics, UK).  
 
2.2.3 Packaging and production of lentivirus 
 
Lentiviral packaging of pLVTHM or its modified versions (see section 2.2.2) was 
carried out using the helper construct pCMVΔ8.91 (Addgene 12263) and the 
envelope construct pVSV-G (Addgene 8454). HEK (Human embryonic kidney) 
293T cells were used for lentivirus packaging, these were cultured and maintained in 
DMEM with 1% glutamine and containing 10% FBS. Briefly, HEK 293T cells were 
transfected in a 3:2:1 DNA ratio of lentivector (15 µg), helper construct (10 µg) and 
envelope constructs (5 µg) using CAPHOS kit (Sigma-Aldrich) following the 
manufacturer’s instruction. Lentiviral particles were harvested from the cell culture 
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medium 48 and 72 hours post transfection, centrifuged at 290 g (Hettich Zentrifugen 
Universal 320) and filtered using a 0.45 μm sterile filter. 4 µl (20 mg/ml stock) 
Polybrene and 4µl (20 mg/ml stock) chondroitin sulphate were added to the virus 
supernatant and vortexed briefly. Samples were then incubated at 37°C in a 
humidified CO2 incubator for 20 minutes. Viruses were then spun at 10000 g 
(Beckman Coulter Avanti J-20 XPI) at room temperature for 30 min. This produced 
a pellet containing the vector polybrene-chondroitin sulphate complex. Supernatant 
was discarded and the complex resuspended in 400 µl fresh DMEM by gently 
pipeting up and down until pellet was dissolved. Lentiviruses were immediately 
stored at -80ºC until use. 
 
2.2.4 Telomere fluorescent in situ hybrydization and immuno-fluorescent in situ 
hybridisation  
 
To prepare metaphase spreads, cells were treated with 0.5 µg/ml colcemid at 37°C 
for 4 hours, harvested, resuspended in 0.8% sodium citrate and incubated at 37°C for 
15 minutes. Cells were then fixed in methanol-acetic acid (3:1 ratio) and dropped 
onto a clean glass slide. Fluorescent in situ hybridisation (FISH) was carried out 
using a telomere peptide nucleic acid (PNA) FISH kit from DAKO following the 
manufacturer’s instructions. For immuno-FISH experiments, cells grown on 
coverslips were first subjected to the IF protocol as indicated in section 2.2.6 of 
materials and methods. Cells were then incubated in 3.7% formaldehyde, dehydrated 
in cold ethanol series and incubated with denatured PNA probe at 85°C for 5 
minutes. Hybridisation were performed by incubating the cells overnight at 37°C, 
followed by washing in 70% formamide and 2X saline sodium citrate (SSC) for 5 
minutes each. Finally, the cells were dried and mounted with VECTASHIELD 
solution containing 4,5-diamidino-2-phelylindole (DAPI). 
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2.2.5 Telomere length assay  
 
Telomere lengths were measured by telomere restriction fragment (TRF) southern 
blotting analysis using Roche’s TeloTAGGG telomere length assay kit, according to 
the manufacturer protocol. Genomic DNA was isolated from cell pellets using 
phenol-chloroform extraction and phase lock gel tubes. 2 μg of genomic DNA were 
digested with 0.75 μl of RsaI and HinfI each, in a total volume of 25 μl at 37ºC 
overnight. Fragmented DNA was separated on a 0.8% agarose gel at 100V for 20 
minutes and then 30V for ~16 hours. Following separation the gel was depurinated in 
0.25 M HCl, denatured in 1.5 M NaCl/0.5 M NaOH, neutralised in 0.5 M Tris/1.5 M 
NaCl and blot onto a positively charged nylon membrane overnight by capillary 
transfer. The membrane was cross-linked to the DNA by ultraviolet (UV) irradiation, 
pre-hybridized at 42ºC for 1 hour with digoxigenin (DIG) easy hybridisation solution 
and hybridised to a DIG-labelled (AATCCC)n telomere-specific probe overnight. 
After stringent washes, non-specific antibody binding was blocked by incubation 
with blocking reagent for 30 minutes and then the membrane was incubated with a 
sheep anti-digoxigenin antibody (diluted 1:10,000) conjugated to alkaline 
phosphatase. Finally the membrane was washed, treated with a chemiluminescent 
alkaline phosphatase substrate and exposed to X-ray film for different times.  
 
2.2.6 Immunoblotting and IF 
 
For immunoblotting, cells were lysed in cold radio immuno precipitation assay 
(RIPA) buffer [150 mM NaCl, 50 mM Tris HCl pH 8.0, 12 mM sodium 
deoxycholate, 0.1 % sodium dodecyl sulphate (SDS), 1 % NP-40] supplemented with 
protease inhibitor cocktail and 0.2 mM PMSF. Protein lysates were assayed for their 
protein concentration with a bicinchoninic acid (BCA) protein assay kit (Pierce). 20 
μg of total protein from each extract were separated in 7% SDS-polyacrylamide gel 
and electrobloted onto polycinylidene fluoride (PVDF) membranes. Quantification of 
the immunoblots was carried out using Quantity One software (Bio-Rad). For IF, 
hESCs were grown on matrigel coated Thermanox coverslips while NPCs and their 
derivatives were grown on PLL/laminin coated glass coverslips. They were fixed in 
4% paraformaldehyde (PFA) for 10 min and blocked and permeabilised with PBS 
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containing 0.3% triton X-100, 10% goat serum and 2.5% bovine serum albumin 30 
min. They were then incubated with primary antibodies for 1 h, followed by 
fluorescent conjugated secondary antibodies for 30 min with washing in between. 
After mounting the coverslips with VECTASHIELD solution containing DAPI, cells 
were visualized and captured with a Leica SP5 confocal microscope. Primary and 
secondary antibodies are listed in section 2.1.3. 
 
2.2.7 Fluorescence activated cell sorting  
 
The analysis of the cell surface antigen Tra-1-81 was performed as follows: cells 
were harvested by trypsinisation and 1.5x10
6
 cells were washed twice in 
fluorescence-activated cell sorting (FACS) buffer (PBS, 2% FBS), resuspended in 
primary antibody (normal mouse IgG or mouse anti-Tra-1-81 antibody) diluted in 
FACS buffer and incubated 30 min at 4ºC. Cells were then washed twice in FACS 
buffer and incubated with specific anti-mouse IgG Alexa Fluor 568. Finally, cells 
were washed twice and then resuspended in 100 μl of FACS buffer for analysis. For 
Pax6 intracellular staining, cells were harvested by trypsinisation, washed in FACS 
buffer and 1.5x10
6
 cells fixed (10 min, 37°C) with 0.1% PFA in PBS. Cells were 
then washed and permeabilised (30 min, 4°C) with cold 90% methanol. After 
washing once, cells were incubated for 30 min at room temperature with primary 
antibody diluted in FACS buffer with 0.1% Triton X-100. Cells were again washed 
twice before incubating for 30 min with secondary antibody diluted in FACS buffer 
with 0.5% Triton X-100. The cells were finally washed twice and resuspended in 600 
μl of FACS buffer before analysis on a FACScalibur flow cytometer (BD 
Biosciences) with CellQuest software. The profile of stained cells was compared to 
unstained cells and cells stained with the secondary antibody only. A list of 
antibodies and reagents used can be found in sections 2.1.3 and 2.2.1.  
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2.2.8 Immunoprecipitation 
 
Cell extracts were prepared in ice cold lysis buffer [20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) Ph 7.4, 10 mM KCl, 100 mM NaCl2, 1mM 
EDTA, 0.1mM ethylene glycol tetraacetic acid (EGTA), 0.1 % triton x100, 0.5 % 
NP-40] supplemented with protease inhibitor cocktail and 0.2 mM PMSF and pre-
cleared by centrifugation at 15,000 g for 30 minutes at 4°C. 1 mg extracts from 
NPCs or 1 mg extracts from HEK293T transfectants were incubated with 2-3 µg 
appropriate antibodies at 4°C for 1-3 h with rotation. Immunocomplexes were 
captured at 4°C with either 20 µl Protein A/G Plus agarose beads for 1 h or 50 µl 
protein G Dynabeads for 3 hours. Immunoprecipitates were eluted with 2 X Laemmli 
buffer (150 mM Tris-Cl (pH 6.8), 4% SDS, 20% glycerol, 0.02% bromophenol blue) 
for 10 min, then analysed by immunoblotting.   
 
2.2.9 REST4 ubiquitination assay 
 
HEK293T cells stably carrying either pLVTHM-PURO (Control) or pLVTHM-
PURO-2A-TRF2 (TRF2-Ov) constructs were co-transfected with pLCMV-Neo-
Myc-REST4 and HA-Ubiquitin. Following treatment with 20 µM MG132 for 5 h, 
cells were lysed in cold lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 5 
mM EDTA, 1% NP40) supplemented with protease inhibitor cocktail, 0.2 mM 
PMSF and 1 µM ubiquitin aldehyde and centrifuged at 15,000 g for 15 min at 4°C. 1 
mg lysate was subjected to immunoprecipitation followed by immunoblotting as 
described in sections 2.2.8 and 2.2.6 respectively. 
 
2.2.10 Quantitative real time-polymerase chain reaction (qRT-PCR) 
 
Total RNA was isolated from one confluent well of a 6-well plate using Tri Reagent 
following the manufacturer's instructions. Briefly, cells grown on a 6-well plate 
(Corning) monolayer were washed twice with PBS and disrupted by adding 1 ml TRI 
reagent. Samples were allowed to stand for 5 minutes at room temperature prior to 
the addition of 0.2 ml chloroform. Samples were mixed by shacking and centrifuged 
at 15110 g (Hettich Mikro 200K) for 15 minutes at 4ºC. The aqueous phase was 
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transferred to a new tube and 0.5 ml isopropanol added for 10 minutes to precipitate 
RNA. Samples were centrifuged at 12000 g for 10 minutes, the supernatant discarded 
and the pellet washed with 75% ethanol. After air-drying, the pellet was resuspended 
in PCR graded water. Concentration of RNA was measured by a Nanodrop 
spectrophotometer. 2 µg of RNA were treated with deoxyribonuclease I (DNase I) to 
remove any traces of genomic DNA in a final volume of 10 µl. First-strand cDNA 
was synthesised from total RNA using oligo(dT) (oligonucleotide deoxy-thymine) 
primers and Superscript II reverse transcriptase following the manufacturer's 
indications. Final cDNA was obtained in a volume of 20 µl, diluted 1/10 and stored 
at -20°C until use.  PCR was carried out in an Opticon 2 thermal cycler (Bio-Rad) 
with the following thermal cycling conditions: initial denaturing at 94°C for 2 
minutes followed of 39 cycles of 95°C for 15 seconds, annealing at 60°C for 30 
seconds, extending at 72°C for 30 seconds and melting curve of 60°C to 95°C with 
readings every 0.5°C.  Gene expression was normalized using the housekeeping 
genes GAPDH and HPRT as endogenous controls. Fold differences were calculated 
using the ΔΔCt method (Livak and Schmittgen 2001; Bustin and Mueller 2005). For 
a list of primers used see appendix Table A1.  
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Chapter 3  TRF2 expression during neural differentiation 
of hESCs 
3.1 Introduction 
 
TRF2 is a well-known key component of the shelterin complex which protects 
chromosome ends, regulates telomere length and, ultimately, maintains genome 
stability (Smogorzewska et al., 2000; Bradshaw et al., 2005; Palm and de Lange, 
2008). However, in addition to these functions TRF2 has been shown to interact with 
a wide range of non-telomeric proteins, acting as a protein hub and thus raising the 
possibility that it may serve functions independent of telomere maintenance. Despite 
its importance in many physiological and pathological functions, there is little 
information about how TRF2 is expressed during development and whether it plays 
an extratelomeric role in this process.  One of the reasons for this lack of information 
is the unavailability of early developmental materials. Moreover, TRF2 knockout in 
mice causes early embryonic death which restricts further interrogation of TRF2 
functions during development (Celli and de Lange, 2005). hESCs provide a good 
solution to overcome this problem since they are capable of prolonged growth in 
culture whilst retaining their capacity to differentiate into most, if not all, tissues in 
the adult body. Additionally, many studies have demonstrated that differentiation of 
hESCs into specific cell types recapitulates, to a large extent, the normal 
development of those cells in vivo (Gerrard et al., 2005; Hay et al., 2008; Zhang et 
al., 2010; Lancaster et al., 2013). Given that hESCs have the ability to mimic 
development in vivo and that TRF2 protein is very abundant in the human brain 
(Jung et al., 2004), this study was particularly focused on the differentiation of 
hESCs to neural progenitor cells, neurons and glia.   
 
The aim of this chapter is to characterise the expression of TRF2 during the neural 
differentiation of hESCs to ascertain its abundance and specificity to this lineage. 
TRF1 expression was also characterised given its close structural and functional 
resemblance to TRF2.   
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3.2 Results 
 
3.2.1 TRF2 protein levels are upregulated upon differentiation of hESCs to NPCs. 
 
In order to explore the role of TRF1 and TRF2 during hESC neural differentiation, 
hESCs from both H1 and H7 lines were differentiated into their neural derivatives 
using our laboratory established protocol (Gerrard et al., 2005). Neural 
differentiation was prompted by culturing the hESCs with N2B27 medium 
supplemented with BMP antagonist noggin. Following formation of NPCs (~passage 
4) noggin was replaced with bFGF and NPCs were able to grow in this condition for 
over several months (Wu et al., 2010). RNA and protein were extracted at various 
passages and analysed for the expression of TRF2.  
 
First, the mRNA expression of TRF1 and TRF2 was analysed in hESCs and their 
NPC derivatives.  TRF1 mRNA was found being highly expressed in hESCs but was 
radically reduced following neural differentiation and maintained at low levels 
throughout the NPC culture, whereas the expression of TRF2 transcripts did not 
exhibit an obvious pattern of change during neural differentiation (Figure 3.1 A).  
These results were consistent with our lab previous genome-wide RNA sequencing 
results (Wu et al., 2010) and published data (Miura et al., 2004; Skottman et al., 
2005), indicating that TRF1 and TRF2 transcription is controlled by different 
mechanisms.  
 
In contrast to the mRNA levels, TRF1 protein did not show a considerable reduction 
upon neural differentiation. More surprisingly, in both H1 and H7 hESC lines, TRF2 
protein levels were low in hESCs, but dramatically increased following neural 
differentiation and were maintained at these elevated levels through the culture of 
NPCs (Figure 3.1 B). TRF2, upon prolonged SDS-polyacrylamide gel 
electrophoresis (PAGE) separation, was detected as two bands of 65 and 69 kDa as 
previously reported (Bilaud et al., 1997; Broccoli et al., 1997). The discrepancy 
between mRNA and protein levels of TRF1 and TRF2 indicates that the expression 
of both proteins may be regulated at post-transcriptional levels, which is in line with 
previous findings (Chang et al., 2003; Fujita et al., 2010). 
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Figure 3.1 Expression of TRF1 and TRF2 in hESCs and their neural derivatives 
at both mRNA and protein levels.  
(A) Expression of TRF1 and TRF2 mRNAs by qRT-PCR during the neural differentiation of H1 (top 
panel) and H7 hESCs (bottom panel) and subsequent culture of their progenitors. Passage numbers 
post-differentiation are indicated. Data are presented as mean ± SD of 6-9 PCRs from three 
independent experiments.  (B) Immunoblotting showing TRF1 and TRF2 protein levels during the 
neural differentiation of H1 hESCs (top panel) and H7 hESCs (bottom panel). Left panels are 
representative images; right panels are from the densitometry analysis of the protein levels as mean ± 
SD of three experiments. Representative bottom panel immunoblot image was generated and provided 
by Miss Sarah Testori (Imperial College London). Statistical significance was tested by paired 
Student’s t-test, ** indicates P <0.005.   
 
 
Given the importance of TRF2 in genomic stability, its abundance was further 
analysed using immunocytochemistry with specific antibodies in H1/H7 hESCs and 
their neural derivatives. TRF2 protein levels in undifferentiated Oct4 positive hESCs 
was much lower than that observed in Sox1 positive NPCs (Figure 3.2). These results 
further supported the previous finding (Figure 3.1 B). In addition, they indicated that 
the hESCs and NPCs analysed by immunobloting were a relatively homogenous 
population of undifferentiated cells as shown by the abundance of Oct4 and Sox1 
positive cells, respectively (Figure 3.2). Quantification of Sox1 or Oct4 possitive 
cells was not carried out in this ocassion as our laboratory routinely mantains and 
differentiates hESCs to NPCs with an efficiency greater than 95% as previously 
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reported (Gerrard et al., 2005). Following the analysis of H1 and H7 hESCs and their 
NPC derivatives via western blotting and quantitative real-time PCR (Figure 3.1) all 
subsequent experiments were carried out in H1 hESCs and their derivatives unless 
otherwise stated in the text.  
 
 
 
 
Figure 3.2 TRF2 is differentially expressed in NPCs and hESCs. 
Representative IF images of H1 hESCs and H1 hESCs-derived NPCs using antibodies against TRF2, 
Oct4 and Sox1.  Data shows considerably higher TRF2 expression in Sox1 positive NPCs (lower 
panels) compared to Oct4 positive hESCs (upper panels). Nuclei are shown by DAPI staining (blue). 
Scale bar = 50 µm. Data shown is representative of two experiments.  
 
 
Although TRF2 proteins were predominantly located in cell nuclei of the NPCs as 
they are in hESCs (Figure 3.3 A), they appeared not to be restricted solely to the 
telomeres (Figure 3.3 B). Since TRF2 is well known to bind to telomeres, its 
expected immunocytochemistry pattern of localization is punctuated (Takai et al., 
2010). While hESCs showed the expected pattern of TRF2 localization, NPCs 
exhibited localization throughout the nuclei. This suggested that in NPCs TRF2 
proteins were potentially binding to non-telomeric regions of DNA or interacting 
with non-telomeric proteins, raising the possibility of extra-telomeric roles.   
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Figure 3.3 Localization of the telomere binding protein TRF2 in hESCs and 
NPCs. 
(A) TRF2 IF of H1 hESCs and H1 hESC-derived NPCs.  Scale bar = 5 µm. Data shown is 
representative of the independent experiments. (B) Immuno-FISH double staining of TRF2 and 
telomeres in H1 NPCs. TRF2 protein was stained by TRF2 antibody (left) and telomeres by telo-FISH 
in NPCs (right). Only a proportion of TRF2 signals show co-localization with telomeres (arrowheads). 
Scale bar = 5 µm. Data is representative of two independent experiments. Nuclei are shown by DAPI 
staining (blue). 
 
Overall these results indicate that whilst TRF1 protein levels are relatively similar 
between hESC and NPCs at various stages of the neural differentiation process, there 
is in contrast, a considerable upregulation of TRF2 protein. Additionally TRF2 
appears to be abundantly distributed throughout the nuclei of the NPCs rather than 
being confined to the telomeres only, which suggests a potential extra-telomeric role. 
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3.2.2 Differential TRF2 protein levels are specific to the neural lineage 
 
Since TRF2 exhibited a more distinctive change during the neural differentiation of 
hESCs, subsequent studies were focused on TRF2. We asked whether TRF2 
upregulation is a general phenomenon in hESC differentiation or is more restricted to 
neural lineages. To address this question, hESCs were differentiated via EB 
formation to the three germ layers. Differentiation of hESCs by EB formation 
generates cells of all three germ layers (Itskovitz-Eldor et al., 2000) while losing the 
hESC characteristics, such as downregulation of Oct4 expression, a pluripotent 
marker.  
 
Following 14 days in EB differentiation medium, no Oct4 possitve cells were 
detected, indicating that these cells had been differentiated (Figure 3.4, top panel). 
High levels of TRF2 protein were mainly detected in Sox2 positive cells (Figure 3.4, 
middle panels) but not in HNF4α (endoderm marker) positive cells (Figure 3.4, lower 
panel), showing its specificity in neural progenitors.  
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Figure 3.4 TRF2 differential expression is restricted to the neural lineage.  
H1 hESCs were differentiated through embryoid body (EB) formation for 14 days and immunostained 
with TRF2 and indicated antibodies. Nuclei are shown by DAPI staining (blue). Scale bar represents 
50 µm. Images are representative of a single experiment carried out in duplicate. 
 
 
To further corroborate these findings, hESCs were specifically differentiated to 
neural, hepatic or fibroblast lineages where the majority of the cells displayed their 
lineage-specific morphology and gene expression (Figure 3.5 A-B). The 
differentiated fibroblasts (FC) did not express any hESC pluripotent markers such as 
Nanog, neither markers of the ectoderm or endoderm lineage such as Sox1 and Sox17 
respectively. On the other hand, undifferentiated H1 hESCs expressed high levels of 
Nanog, while their NPC and hepatoblast cell (HPC) derivatives expressed high levels 
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of Sox1 and Sox17 respectively. At the protein level, only NPCs expressed high 
levels of TRF2 protein (Figure 3.5 C). 
 
 
 
Figure 3.5 Comparison of TRF2 expression in hESCs derived NPCs, fibroblast 
and hepatoblasts. 
(A) Phase-contrast images of H1 hESCs and their derived progenies: NPCs, FC, fibroblast cells; HPC, 
hepatocyte progenitor cells. Scale bars represent 50 μm.  (B) Expression of lineage-specific marker 
genes in the cells of (A) by qRT-PCR. Data is presented as mean ± SD of 6 RT-PCRs from three 
independent experiments. (C) TRF2 protein levels in the cells of (A) by immunoblotting. Images are 
representative of a single experiment produced in duplicate. 
 
 
In order to explore whether TRF2 upregulation also happens during neural 
differentiation of mouse ESCs (mESCs), TRF2 protein levels in mESCs and mouse 
NPCs (mNPCs) were analysed. Interestingly, TRF2 protein was found at lower levels 
in mESCs than in hESCs and did not exhibit any upregulation upon neural 
differentiation (Figure 3.6 A). Therefore, TRF2 levels are much lower in mouse 
NPCs than in human NPCs, highlighting yet another difference between human and 
mouse biology.  
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Figure 3.6  TRF2 protein levels in mouse stem cells and other cell types. 
(A) Comparison of TRF2 protein abundance between mESCs, mouse epiblast stem cells (mEpiSC), 
H1 hESCs and their respective NPC derivatives as indicated by immunobloting, showing that TRF2 
protein levels are not upregulated upon neural differentiation of mESCs. TRF2 (S) and TRF2 (L) 
indicate short and long exposure times to the x-ray film. Images are representative of two independent 
experiments. (B) High levels of TRF2 protein as observed in human NPCs, were not detected in other 
cell lines. Western blotting of HeLa cancer cells, Hs27 foreskin fibroblasts and BJ5ta immortalised 
fibroblasts revealed no dramatic increases of TRF2. Images are representative of two independent 
experiments. 
 
 
In addition, the abundance of TRF2 protein in other cell types including a cancer cell 
line (HeLa), human foreskin fibroblasts (Hs27) and an immortalised human skin 
fibroblasts cell line (BJ5ta) was also analysed. Abundance of TRF2 protein levels 
was still restricted to human NPCs as the levels of TRF2 protein in HeLa, Hs27 and 
BJ5ta cells was almost undetectable by western blotting (Figure 3.6 B). 
 
To address whether the abundance of TRF2 protein was specific to human NPCs or 
if it was also present in their derived post-mitotic neurons or glia, early and late 
NPCs were further differentiated into neurons and glia by withdrawal of growth 
factors. 14 days following differentiation, the high levels of TRF2 protein present in 
early and late NPCs were downregulated to levels similar to that of hESCs. Co-IF of 
TRF2 and the neural maker Tuj1 in NPCs, with and without growth factors, revealed 
that the high levels of TRF2 protein were only present in NPCs where protein levels 
of Tuj1 were low (Figure 3.7 A, upper panel). This was further supported by 
immunoblotting (Figure 3.7 A, lower panel). Similarly, co-staining of late NPCs with 
TRF2 and the glia marker GFAP showed a dramatic decrease of TRF2 protein 
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following differentiation into glia (Figure 3.7 B, upper panel). TRF2 downregulation 
in late NPCs was also supported by TRF2 immunobloting (Figure 3.7 B, lower 
panel). 
 
Taken together, these results demonstrate that TRF2 protein expression is 
dynamically regulated during neural differentiation and neuron/glia formation with 
higher levels restricted to human NPCs. 
 
 
 
Figure 3.7  TRF2 protein levels are downregulated following differentiation of 
human NPCs into post-mitotic neurons and glia. 
H1 hESC-derived NPCs from early (A) and late (B) neural differentiation were further differentiated 
for 14 days by the withdrawal of bFGF/EGF growth factors (GF). Figure shows IF of the resulting 
cells with the indicated antibodies (upper panel) and immunoblotting of TRF2 (lower panel). Nuclei 
are shown by DAPI staining (blue). Scale bar = 50 µm in all microscopic images. IF images of (A) 
and B are representative of a single experiment carried out in triplicate while immunoblotting images 
are representative of a single experiment.  
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3.2.3 TRF2 protein levels are not dependent on telomere length  
 
A previous study in our group demonstrated that hTERT was dynamically expressed 
during H1 and H7 hESC neural differentiation and during the culture and 
differentiation of their NPC derivatives (Sheldon et al., 2013 under revision). hTERT 
was highly expressed in undifferentiated hESCs but dramatically downregulated 
upon neural differentiation of both H1 and H7 hESC lines. However, during 
extended culture of NPCs, hTERT expression was upregulated again, accompanied 
by the activation of functional telomerase. The reactivation of telomerase was neither 
associated with a transformed phenotype nor affected the characteristics of NPCs 
(Sheldon et al., 2013 under revision). 
 
Since TRF2 has been reported to regulate telomere length in tumour cell lines and 
was suggested to act as a measuring unit of telomere length (Smogorzewska et al., 
2000; Palm and de Lange, 2008), we speculated whether the differential expression 
of TRF2 detected in both H1 and H7 hESCs derived NPCs was related to the changes 
in telomere length previously observed in our lab. To answer this question, the 
telomere length of H1 hESCs and their NPC derivatives was analysed by southern 
blotting. Repeated telomere length assays indicated that hESCs have long stable 
telomeres of approximately 10 to 12 Kb in length (Figure 3.8 B).  Upon neural 
differentiation, the high expression of telomerase observed in hESCs is dramatically 
downregulated and consequently telomeres shortened with cell proliferation (Figure 
3.8 A-B). Quantitative RT-PCR analyses showed that hTERT was indeed expressed 
at high levels in undifferentiated hESCs and was downregulated after neural 
differentiation (Figure 3.8 A).  However, with extended culture, hTERT expression 
became upregulated again to levels similar to that of hESCs (Figure 3.8 A) as 
previously observed in our group (Sheldon et al., 2013 under revision). Concurrently, 
hTERT expression reactivation was also followed by gradual telomere elongation 
(Figure 3.8 B) to a relatively stabilised length which was in line with the expression 
of hTERT.  These dynamic changes of telomere length were notably different from 
the levels of TRF2 protein (Figure 3.1 B vs Figure 3.8 B).  
 
 
89 
 
 
 
Figure 3.8 No correlation between TRF2 protein levels and telomere length or 
telomerase expression in NPCs. 
(A) Expression of telomerase catalytic subunit hTERT mRNA in H1 hESCs and their neural 
progenitors by qRT-PCR. Data is presented as mean ± SD of three experiments. (B) Dynamic changes 
of telomere length in H1 hESCs and their NPC derivatives by southern blotting. Image is 
representative of two independent experiments. (C) Comparison of telomere length (upper panel, by 
telomere FITC-FISH) and TRF2 protein accumulation at the telomeres (lower panel, by IF) in hESCs 
and their neural progenitor derivatives (p55). Inserts are the same images but with a higher 
magnification. Images are representative from the analysis of 15 chromosomal spreads of two 
independent experiments. Scale bars= 10 µM. 
 
 
Comparative analysis of telomere length and protein levels of TRF2 in hESCs and 
their NPCs derivatives (Figure 3.1 B vs Figure 3.8 B) revealed no correlation. TRF2 
protein expression was low in hESCs, which have long telomeres. However, in early 
differentiated NPCs at passage 4 (p4), which have similar telomere length as hESCs, 
TRF2 was dramatically upregulated. Furthermore, while telomeres were significantly 
shorter in p27 NPCs, and re-lengthened to longer length at p50, TRF2 protein levels 
remained at relative stable higher levels. Similarly, TRF1 protein expression did not 
seem to correlate with telomere length either as TRF1 protein levels did not change 
dramaticaly upon shortening or re-lengthening of the telomeres (Figure 3.1 B vs 
Figure 3.8 B). Taken together, these results suggest that TRF2 protein levels may not 
be dependent on telomere length as previously suggested (Smogorzewska et al., 
2000). 
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Although the telomere length assays and western blotting data suggested that TRF2 
protein expression did not correlate with telomeres length in these cells, it was not 
clear whether the TRF2 protein accumulated in NPCs with shorter telomeres was 
telomere bound or not (Figure 3.3 B). In order to address this TRF2 IF and telomere 
FISH were carried out, in parallel, in hESCs and p55 NPCs chromosomal spreads 
(Figure 3.8 C). Telomere length was assessed by examining the intensity of the 
fluorescein isothiocyanate (FITC) telomere probe signal, where longer telomeres 
bind more probe and therefore emit a higher intensity signal. While hESCs and late 
NPCs (p55) revealed similar telomere lengths (Figure 3.8 C top panels), it appeared 
that NPCs had more TRF2 bound to their telomeres than hESCs (Figure 3.8C lower 
panels). These results reflect those obtained by TRF assay, where longer telomeres 
do not necessarily accumulate more TRF2 protein. Over 15 chromosomal spreads 
from different preparations were examined and similar staining patterns were 
observed. 
 
These results have demonstrated that TRF1 and TRF2 protein levels may be 
independent of telomere length and telomerase levels. In addition, they also indicate 
that the sustained growth and proliferation of hESC-derived NPCs may be attributed 
to the reactivation of telomerase. 
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3.3 Discussion 
 
In this chapter, the expression of TRF2 was characterised in H1/H7 hESCs, their 
neural derivatives and other cell types. In the course of this characterisation, it was 
found that TRF2 is differentially expressed during neural differentiation and that this 
differential expression may be specific to the neural lineage. Furthermore, we found 
that the mRNA expression of TRF1 and TRF2 did not correlate with their protein 
levels, suggesting that they may be regulated post-transcriptionally.  
 
The expression of TRF1 and TRF2 protein observed during neural diferentiation did 
not correspond with that of mRNA levels, suggesting that TRF1 and TRF2 may be 
regulated at the post-transcriptional level. Indeed, TRF1 stability and localisation to 
telomeres is regulated by several post-translational modifications. In human cells, 
TRF1 is poly ADP-ribosylated by tankirase-1, a poly(ADP-ribose) polymerase, 
resulting in TRF1 depletion from telomeres. Following depletion, unbound TRF1 is 
ubiquitinated for proteosomal degradation by Fbx4, an F-box protein that functions 
as substrate for ubiquitin E3 ligases (Lee et al., 2006). However, when bound to the 
telomere, TIN2 stabilises TRF1 by protecting it from poly (ADP-ribosyl)ation by 
tankirase 1 and by sequestering its degradation motif from Fbx4 (Zeng et al., 2006). 
In addition, Pin1 has been identified as another factor being able to deplete TRF1 
from telomeres and to promote its degradation (Lee et al., 2009). As for TRF2, a 
recent study in fibroblasts (Fujita et al., 2010), has reported that TRF2 can be 
ubiquitinated for degradation by Siah1 (a p53-inducible E3 ubiquitin ligase) which is 
induced by activated p53 upon critical shortening of the telomeres. Upregulation of 
Siah1 results in a degradation of TRF2 protein while TRF2 mRNA expression 
remains unchanged, explaining the differences in TRF2 mRNA and protein 
expression. However, these reported post-translational regulations of TRF1 and 
TRF2 are telomere length dependent and in our experiments the protein levels of 
TRF1 and TRF2 did not seem to correlate with telomere length. H1 hESCs which 
have long and stable telomeres had low levels of TRF2 protein while their derivative 
NPCs had high levels of TRF2 protein regardless whether their telomeres were short 
or long. Furtheremore, TRF1 protein levels did not seem to change dramatically 
upon telomere shortening or re-lengthening. These results prompt two questions: are 
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the TRF2 protein levels observed in hESCs enough to ensure t-loop formation? And 
why shorter telomeres accumulate equal or more protein levels of TRF1 or TRF2? 
Regarding the low levels of TRF2 protein in hESCs, a recent publication has 
indicated that you only require few molecules of TRF2 at the telomere to protect it 
from DDR activation (Cesare et al., 2013), explaining why our hESCs show such 
low levels of TRF2 protein. As for the high levels of TRF1 or TRF2 protein in NPCs 
with short telomeres, we propose that since TRF2 is mainly responsible for the 
formation of telomere t-loop structure and TRF1 aids in this function, it is possible 
that some cell types have high levels of TRF1 and TRF2 protein to ensure proper t-
loop formation upon telomere shortening. In fact, a study by (Karlseder et al., 2004) 
reported that upon overexpression of TRF2 in cells with short telomeres, increased 
protection of the telomeres was observed. Since TRF1 and, TRF2, specially, are 
crucial for the formation of the t-loop, it is possible that during hESC differentiation 
to NPCs maintenance of their protein levels upon telomere shortening occurs as a as 
an effort to maintain t-loop structure, avoiding DNA damage response and, 
ultimately, cell apoptosis. This could suggest that TRF1 and TRF2 are regulated 
posttranscriptionally by a telomere length independent pathway. 
 
It is important to note that while western blotting and southern blotting may be good 
assays to measure protein and telomere length, they may not be specific and sensitive 
enough to detect changes at the telomere level and therefore to address if TRF1 and 
TRF2 proteins are telomere length dependent in our cell types we would need to use 
more sensitive techniques such as quantitiative FISH or telomere qRT-PCR.  
  
Differentiation of H1 and H7 hESCs to their NPC derivatives resulted in a dramatic 
increase of TRF2 protein expression while TRF1 expression remained to similar 
levels. Remarkably, the IF of TRF2 in NPCs showed large quantities of TRF2 
protein that were not restricted to the telomeres (Figure 3.3 B). This was surprising 
as immunostainning of shelterin members is well known for revealing a punctuate 
pattern of localisation that corresponds to the telomeres (Li and de Lange, 2003; Ye 
et al., 2004b; Hockemeyer et al., 2007). The pattern of protein localization shown in 
NPCs indicated that TRF2 could potentially be located elsewhere in the nuclei of 
these cells, perhaps carrying out functions independent of telomere protection and 
regulation as it has been suggested in several reports (Bradshaw et al., 2005: Yang et 
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al., 2011; Chen et al., 2008; Zhang et al., 2008; Kim et al., 2009; Giannone et al., 
2010; Simonet et al., 2011).  
 
Differentiation of hESCs via embryo body formation and direct differentiation 
revealed no increase of TRF2 protein levels in other lineages. Furthermore, 
differentiation of NPCs to neurons and glia resulted in a downregulation of TRF2 
protein.. These results suggest that the differential expression of TRF2 may be 
specific to the neural lineage and moreover to NPCs. However, a previous report has 
shown that TRF2 was also expressed in the cytoplasm of terminally differentiated 
neural cells (Jung et al., 2004). While this data may seem contradictory to ours, a 
later report has shown that some mature neurons can express a truncated ~35 KDa 
version of TRF2, termed TRF2 short (TRF2-s), in their cytoplasm (Zhang et al., 
2011). Since we only detect a single 66 KDa TRF2 band by immunoblot (see 
appendix Figure A1) and we have shown by immnufluorescence that TRF2 is present 
only in the nuclei of hESCs and NPCs (Figure 3.3), it is very likely that the TRF2 
cytoplasm staining detected in neurons by Jung and collegues is in fact TRF2-s and 
not full length TRF2. While these findings could benefit from further 
characterisation, specially the embryoid IF data which requires more lineage specific 
markers, these findings are consistent with previous reports in the sense that they 
suggest that TRF2 may have an extratelomeric role in neural differentiation (Jung et 
al., 2004; Zhang et al., 2008; Simonet et al., 2011). Thus, the observed nontelomeric 
localization and specific differential expression of TRF2 in NPCs raised the 
possibility that TRF2 could have a role in neural differentiation.   
 
Given the specific and differential TRF2 protein expression observed upon the 
differentiation of H1 and H7 hESCs to NPCs, this protein was investigated with 
more attention. Interestingly, a recent study has found that TRF2 transcription is 
activated by the Wnt/β-catenin signalling pathway (Diala et al., 2013). This study 
revealed that TRF2 contains six putative binding sites of the TCF-LEF family of 
transcription factors. Furthermore they demonstrated that activation of the canonical 
Wnt signalling pathway triggers the translocation of β-catenin to the nucleus where it 
subsequently binds to members of the TCF-LEF family of transcription factors which 
unltimately activate gene expression of TRF2. Given that it has been shown that Wnt 
signalling is sufficient to extinguish BMP4 mRNA expression (Baker et al., 1999), it 
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is possible that during neural differentiation of hESCs the Wnt signalling pathway is 
activated to help inhibit BMP signalling and induce neural differentiation, resulting 
in increased expression of TRF2 which could then be post-translationally regulated 
by the telomere dependent Siah1-p53 pathway or an alternative unknown telomere 
independent pathway. 
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Chapter 4 TRF2 induces differentiation of hESCs to the 
neural lineage and regulates their ability to produce 
functional NPCs 
4.1 Introduction 
 
In chapter 3, the expression of telomere binding proteins TRF1 and TRF2 during the 
differentiation of hESCs to the neural lineage was analysed. It was found that in 
contrast to TRF1, TRF2 protein expression was dramatically upregulated upon 
differentiation to NPCs. Surprisingly this differential expression was specific to 
NPCs, not restricted to telomeres and independent of telomere length. Since only 
TRF2 showed significantly dynamic changes in this process, the subsequent 
investigations were focused on TRF2. Given its abundance in the human brain (Jung 
et al., 2004) and its dramatic protein increase upon differentiation of hESCs to NPCs, 
TRF2 may indeed play a role in the neural differentiation process. In this context, it 
has been previously reported that overexpression of TRF2 in COS cells induces 
neurite-like processes (Jung et al., 2004). However, another study has shown that 
inhibition of TRF2 promotes neural differentiation in NTera2 human embryonic 
carcinoma cells (Zhang et al., 2008).  It is unclear whether the discrepancies are 
attributable to the differences in the two cell types used in these studies. COS cells 
are a fibroblast-like immortalised cell line derived from monkey kidney tissue and as 
such they are not derived from human tissues nor have the same potential to 
differentiate to the neural lineage as a human pluripotent stem cell line would. 
NTera2 cells are a human carcinoma stem cell line derived from a malignant 
testicular cancer and as such may not reflect the normal neural development situation 
in vivo. Nonetheless, these two cell types are unlikely to reflect normal human 
embryonic development. Given the contradictory results of the two studies, it is 
necessary to investigate this issue in a cell model system that is closer to normal 
embryonic development; hESCs provide a good cell source for such studies. 
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The aim of this chapter is to use gain or loss of TRF2 function approaches to 
investigate whether modification of TRF2 expression affects the self-renewal of 
hESCs and their ability to differentiate to the neural lineage. I hypothesised that 
overexpression of TRF2 in the low TRF2 expressing hESCs would induce their 
differentiation towards NPCs and that inhibition of TRF2 in hESCs may hinder their 
neural differentiation to NPCs. 
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4.2 Results 
 
4.2.1 TRF2 overexpression in hESCs compromises their self-renewal and induces 
expression of neural markers 
 
Since TRF2 is significantly upregulated during neural differentiation of hESCs, we 
speculated that TRF2 may play a role in this process. Gain- and loss- of function 
approaches were applied to address this question, whereby TRF2 was ectopically 
expressed in H1 hESCs by lentiviral transduction in the first instance (Figure 4.1 A). 
The lentivector that gave rise to the lentiviral particles was generated from pLVTHM 
backbone, in which PuroR (puromycin resistant gene) and TRF2 cDNAs were linked 
with a 2A foot and mouth disease virus sequence. This allows the expression of 
PuroR and TRF2 to be controlled by the same promoter and translated as one fusion 
protein first, then cleaved at the 2A peptide to produce two functional proteins. This 
approach ensures that cells resistant to puromycin treatment definitely express TRF2. 
In addition, the elongation factor-1 alpha (EF1) promoter was replaced in the 
original vector with a cytomegalovirus (CAG) enhanced promoter to maximise the 
transgenic expression levels. Same lentivector containing PuroR cDNA only was 
used as the control. Efficiency of transduction of hESCs was assessed using original 
pLVTHM containing GFP cDNA (appendix, Figure A2). After optimisation of the 
transduction efficiency, hESCs transduced with control or TRF2 overexpressing 
(TRF2-Ov) lentivirus were selected with puromycin in hESC CM culture conditions. 
Following 2 weeks in selection, several colonies in the TRF2-Ov plates revealed 
neural rosette-like structures (Figure 4.1 B, top right panel), which became more 
evident upon continuous culture with the appearance of bipolar neural progenitors 
(Figure 4.1 B, bottom right panel). By contrast, no such colony was found in the 
controls (Figure 4.1 B, top and bottom left panels). These phenotypic changes were 
reproducible in repeated experiments.  
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Figure 4.1 TRF2-overexpression in hESCs induces neural differentiation. 
(A) Schematic map of TRF2-expressing lentiviral vector. CAG, CAG promoter; PuroR, puromycin 
resistant gene; 2A, 2A foot and mouth disease virus sequence; TRF2, TRF2 cDNA. (B) 
Representative phase-contrast images of control and TRF2-overexpressing hESCs 2 passages post-
infection. Arrows point to neural rosette-like structures. Scale bar = 100 µm. Images are representative 
of two independent experiments. (C) TRF2 overexpression in hESCs mainly increased the expression 
of neural marker genes but reduced the expression of pluripotent genes as detected by qRT-PCR in 
cells 5 passages after infection. Data are presented as mean ± SD of 6 repeats of 2 independent 
experiments. Statistical significance was tested by paired Student’s t-test, ** p≤0.01, *** p≤0.001, 
**** p≤ 0.0001, NS p> 0.05 (non-significant). (D) Immunoblot showing indicated protein expression 
in control and TRF2-overexpressing hESCs 5 passages after infection. Images are representative of 
two independent experiments. 
                                                                                                                                                                       
Successful TRF2 overexpression via lentiviral infection resulted in a dramatic 
increase of TRF2 expression compared to control, as determined by qRT-PCR and 
western blotting (Figure 4.1 C and D). Analysis of gene expression in TRF2-Ov 
hESCs revealed a downregulation of pluripotent markers, Oct4 and Nanog, and an 
upregulation of neural markers Sox1, Mash1 and Snap25 (Figure 4. 1 C). No 
significant change of expression was observed for the endoderm marker Gata6 
(Figure 4.1C).  Expression of the neural transcription factors Sox1 and Mash1 
increased three and five fold, respectively while expression of the neural membrane 
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protein Snap25 increased three fold (Figure 4.1 C). At the protein level, TRF2 
overexpression was readily detected in TRF2-Ov hESCs (Figure 4.1 D). 
Overexpression of TRF2 had a dramatic effect in the expression of Oct4 protein 
which was heavily downregulated (Figure 4.1 D). These results indicate that these 
cells were differentiating toward neural lineages as a consequence of TRF2 
overexpression. In addition, increase of H2AX protein levels was not deteceted in 
these cells (Figure 4.1 D and Figure A3).  
 
4.2.2 TRF2-Ov hESCs differentiate predominantly to the neural lineage 
 
Since TRF2-Ov hESCs exhibited a concession of self-renewal and a tendency to 
differentiate to neural lineage, we questioned whether this overexpression was 
inducing neural lineage differentiation specifically or all three lineages. To answer 
this question these transgenic cell lines were characterised further. Flow cytometry of 
pluripotent surface marker Tra-1-81 staining clearly revealed that control hESCs 
displayed one predominant peak of 80% of cells positive for Tra-1-81 while TRF2-
Ov cells produced two clear populations with only 57% of them expressing Tra-1-81 
and the rest being negative (Figure 4.2 A, top panels). As such, over 40% TRF2-Ov 
cells compared to only 20% of control did not express the hESC cell surface marker 
and therefore were considered as differentiated cells. When analysing with anti-Pax6 
antibody, I found that 17.5% of TRF2-Ov hESCs expressed the NPC marker 
compared to only 4.5% of control (Figure 4.2 A, lower panels). This indicated that 
the overexpression of TRF2 in hESCs increased the proportion of NPCs by almost 
four fold. Only 2.5% of TRF2-Ov hESCs expressed the endoderm lineage marker 
Gata6 compared to 1.4% of control indicating less than a fold increase (Figure 4.2 A, 
bottom panels). 
 
 
 
100 
 
 
 
Figure 4.2 TRF2 overexpressing hESCs differentiate into neurons in hESC 
culture conditions.  
(A) Flow cytometry analysis of Tra-1-81, Pax6 and Gata6 protein expression in control and TRF2-
overexpressing hESCs (passage 11) shows decreased Tra-1-81 and greately increased Pax6 positive 
population in TRF2 overexpressing cells. Gata6 positive cell number increased slightly in TRF2-Ov 
hESCs. (B) IF with indicated antibodies depicting areas of neural differentiation in TRF2-
overexpressing hESCs (passage 5). This is shown by positive staining of Pax6, Nestin and Tuj1. 
Nuclei are shown by DAPI staining (blue). Scale bar = 50 µm. Images are representative of two 
independent experiments. 
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To support the flow cytometry data IF of NPCs with markers Pax6 and Nestin was 
carried out (Figure 4.2 B). Similarly to the immunoblot and flow cytometry results, 
TRF2 overexpression affected the self-renewal of hESCs and induced neural 
differentiation, as shown by the decreased proportion of Oct4 positive hESCs and the 
increase of Nestin and Pax6 positive cells (Figure 4.2 B, top and middle panel sets). 
In fact, under hESCs self-renewing culture conditions, the TRF2-Ov hESCs were 
able to differentiate into Tuj1 positive neurons (Figure 4.2 B, bottom panel sets). It is 
also worth mentioning that the protein expression of Pax6 and Nestin found in the 
TRF2-Ov cells was detected in cells which exhibited a neural rosette like structure 
similar to that previously observed under phase contrast conditions (Figure 4.1 B, top 
right panel vs Figure 4.2 B, middle panel set). 
 
When subjecting hESCs into neural differentiation conditions shortly after 
transduction (Passage 1), and prior observing a neural differentiation phenotype, the 
TRF2-Ov hESCs differentiated faster than controls. Protein expression of Oct4 in the 
TRF2-Ov hESCs was much further downregulated than control 12 days following 
neural induction (Figure 4.3 A). This was further supported by IF of the same cells 
using Oct4 and Pax6 antibodies. IF revealed that after 12 days in neural 
differentiation conditions, control cells still remained majorly pluripotent, as shown 
by the Oct4 positive staining, while most cells in the TRF2-Ov cells became NPCs as 
indicated by positive Pax6 and negative Oct4 protein expression (Figure 4.3 B). 
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Figure 4.3 Ectopic expression of TRF2 in hESCs accelerates their differentiation 
into NPCs under neural differentiation conditions. 
Control and TRF2-ov hESCs were subjected to neural differentiation for 12 days, one passage after 
their transduction and selection. Cell extracts were analysed by immunoblotting (A) and showed 
accelerated downregulation of Oct4 protein in TRF2-Ov hESCs only. Image is representative of a 
single experiment. (B) IF with Pax6 and Oct4 antibodies in cells of (A) showing clear downregulation 
of Oct4 and upregulation of Pax6 in TRF2Ov hESCs following 12 days in neural differentiation 
conditions. Nuclei are shown by DAPI staining (blue). Scale bars = 50 µm. Images are representative 
of a single experiment done in triplicate. 
 
4.2.3 Differentiation to the neural lineage is unlikely to be a consequence of 
telomere shortening  
 
A recent publication has reported that ES cells with short telomeres have unstable 
differentiation (Pucci et al., 2013). Given that TRF2 regulates telomere length and 
that when overexpressed in cancer cell lines it shortens telomeres, we questioned 
whether the differentiation observed was a consequence of telomere shortening. To 
answer this question genomic DNA was extracted from control and TRF2-Ov hESCs 
and telomere length assays carried out on both DNAs.It was found that TRF2-Ov did 
not result in telomere shortening during the first 5 passages (Figure 4.4 left panel). 
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However, over continuous culture in hESCs self-renewing conditions, telomeres 
showed a slight shortening of the telomeres at passage 14 (Figure 4.4, right panel). 
 
 
Figure 4.4  Neural differentiation of hESC is not a result of telomere shortening.  
Comparison of telomere length in control and TRF2-overexpressing hESCs at two indicated passages 
by southern blotting shows that telomere length shortening occurs in TRF2-overexpressing hESCs 
only after 5 passages. Images are representative of three independent experiments. 
 
 
Since the neural differentiation appeared as early as passages 2-5 while telomere 
attrition was not detected in TRF2-Ov hESCs before passage 5, it is unlikely that the 
differentiation is a consequence of telomere shortening. However, it is important to 
note that alternative highly sensitive techniques to measure telomere length may 
show shortening of the telomeres over TRF2-Ov during the first 2-5 passages. These 
results suggest that TRF2 plays a positive role in promoting neural differentiation of 
hESCs, which is likely to be independent from its roles in regulating telomere length 
and telomere protection.  
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4.2.4 TRF2 knockdown in hESCs does not affect their self-renewal  
 
To further address the role of TRF2 in hESCs, TRF2-deficent hESCs were generated 
by shRNA-knockdown. TRF2 knockdown lentivector (TRF2-Sh) was generated by 
inserting a shRNA sequence specifically targeting TRF2 into pLVTHM-CAG-PURO 
and the lentivector and the lentivector without the shRNA was used as the control. 
hESCs were infected with both control and TRF2-Sh viruses and selected with 
puromycin 48 hours post infection. No striking differences were observed between 
control and TRF2-Sh cells 2 weeks after selection (Figure 4.5 A). Gene expression 
revealed a successful ~50% knockdown of TRF2 transcripts, which had no 
significant effect in the expression of pluripotent markers Oct4, Nanog and Sox2 
(Figure 4.5 B). These gene expression results were further supported by 
immunoblotting with Oct4 and TRF2 antibodies (Figure 4.5 C). These results 
demonstrated that under self-renewing CM culture conditions, TRF2 knockdown, 
unlike TRF2 overexpression, did not seem to have an effect on hESC self-renewal 
and pluripotency. 
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Figure 4.5 TRF2 knockdown in hESCs does not affect their self-renewal. 
(A) Phase-contrast images of H1 hESCs overexpressing puromycin only (Control) and puromycin 
with TRF2 shRNA (TRF2-Sh). Scale bar = 100 µm. (B) Quantitative real-time PCR expression 
analysis of the indicated genes, showing no-significant differences in gene expression. Data are 
presented as mean ± SD of 6 repeats of 2 independent experiments. Statistical significance was tested 
by paired Student’s t-test, *** p≤0.001, NS p> 0.05 (non-significant).  (C) Immunoblot analysis with 
the indicated antibodies of NPCs 6 and 10 passages following selection. Oct4 protein levels were not 
significantly affected by TRF2 knockdown. Images are representative of a single experiment carried 
out in duplicate. 
 
4.2.5 TRF2 knockdown in hESCs affect their ability to differentiate to the neural 
lineage 
 
To support the above data further, control and TRF2-Sh hESCs were differentiated 
by embryoid body formation to the three germ layers. Cells were grown in 
suspension for 7 days, plated on coverslips, cultured a further 7 days, and stained 
with the appropriate antibodies. Interestingly despite both cells exhibited similar 
staining for HNF4α (endoderm) and muscle actin (mesoderm), they revealed striking 
differences in Sox2 and Tuj1 (ectoderm) staining, a NPCs and neural marker 
respectively (Figure 4.6 A). Expression of Sox2 and Tuj1 was hardly detectable in 
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the EB differentiated TRF2-Sh cells. In order to verify that the Sox2 positive cells in 
the control samples were not undifferentiated hESCs, control and TRF2-Sh cells 
were co-stained with Sox2 and TRF2. Since we previously found that only hESC-
derived NPCs express high levels of TRF2 (Figure 3.4), it was expected that if these 
cells were hESCs they would be TRF2 negative and if they were NPCs they would 
be TRF2 positive. The control cells co-expressed high levels of TRF2 and Sox2 
while TRF2-Sh cells were hardly positive for TRF2 or Sox2 staining. These results 
reveal that the differentiation process does not affect TRF2 knockdown levels and 
that upon TRF2 knockdown, no Sox2 positive NPCs are formed (Figure 4.6 B).   
 
 
 
 
Figure 4.6  TRF2 knockdown in hESCs affected their ability to differentiate to 
the neural lineage.  
IF of control vs TRF2-Sh EBs with endoderm (HNF4α), mesoderm (Muscle Actin) and ectoderm 
(Sox2 and Tuj1) lineage markers (A) and TRF2/Sox2 co-staining (B). Nuclei are shown by DAPI 
staining (blue). Scale bar = 40 µm in all microscopic images. Images are representative of a single 
experiment carried out in duplicate. 
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To further test if TRF2 knockdown affects the ability of hESCs to specifically 
differentiate into the neural lineage, control and TRF2-Sh hESCs were differentiated 
to NPCs using the same protocol used to differentiate wild type hESCs. A clear 
difference was observed in their morphology within 5 passages of differentiation 
(Figure 4.7 A). The control cells displayed a homogenous population of NPC 
morphology, whereas TRF2-Sh cells were heterogeneous in cell morphology with a 
proportion of them revealing a flatter and rounder phenotype that differed from the 
typical triangular or bipolar NPC morphology (Figure 4.7 top and bottom right 
panels). Gene expression analysis showed that the expression of NPC markers, Sox1, 
Sox2 and Mash1, was heavily downregulated in the TRF2-Sh cells after neural 
differentiation while expression of the neural markers Tuj1 and Snap25 did not 
significantly change (Figure 4.7 B). This differentiation did not affect the levels of 
TRF2 knockdown (Figure 4.7 B).  
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Figure 4.7 TRF2 knockdown in hESCs affects the ability of their derived NPCs 
to terminally differentiate into neurons or glia.  
(A) Phase contrast images of control and TRF2-Sh hESC-derived NPCs. Left panel images scale bar 
is 100 µM right panel images 50 µM. (B) qRT-PCR gene expression analysis of TRF2, NPC marker 
genes (Sox1, Sox2 and Mash1) and neural maker genes (Tuj1 and Snap25). Data are presented as mean 
± SD of 6 repeats of 3 independent experiments. Statistical significance was tested by paired Student’s 
t-test, ** p≤0.01, *** p≤0.001, **** p≤ 0.0001, NS p> 0.05 (non-significant).  (C) IF of terminally 
differentiated control and TRF2-Sh hESC-derived NPCs with Tuj1 and GFAP makers. Nuclei are 
shown by DAPI staining (blue). Scale bar= 40 µM in all images. Images are representative of two 
independent experiments. 
 
 
When these NPCs were allowed to further differentiate into post-mitotic neurons and 
glia by the withdrawal of growth factors, only few of the TRF2-Sh NPCs managed to 
terminally differentiate as indicated by little protein expression of Tuj1 and GFAP 
markers, as well as little neuron or glia typical cell processes (Figure 4.7 C). In 
contrast, control NPCs showed clear expression of these markers and cell prcesses. 
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4.2.6 TRF2 knockdown effect on neural differentiation is unlikely to be due 
telomere attrition 
 
Given that TRF2 is well known to be important for telomere length regulation and 
DNA damage protection, we questioned whether the knockdown had affected these 
cells in either of these ways. Telomere length assay showed no clear differences on 
telomere length. While TRF2-sh hESCs seem to show a higher molecular weight 
than control hESCs, control heSCs do show faint bands at approximately the same 
molecular weight. Therefore the difference in genomic DNA loading could be giving 
the impression TRF2-sh hESCs have longer telomeres. In order to be able to address 
this question further telomere length assays need to be performed (Figure 4.8 A). 
Furthermore, chromosomal spreads of at least 10 spreads from two independent 
experiments revealed no differences between control and TRF2-Sh hESCs. 
Chromosomes were of the correct number with no apparent NHEJ of the telomere 
ends (Figure 4.8 B). However, these results would benefit greately by carrying out 
FISH on the chromosomal spreads of both cell lines, as in this way a more accurate 
distinction of NHEJ of telomere ends could have been achieved and quantified. 
However, due to time constraints this was not possible.  
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Figure 4.8 TRF2 knockdown in hESCs does not affect telomere length or induce 
non-homologous telomere end joining. 
(A) Southern blotting assessing telomere length of control vs TRF2-Sh cells. Both control and TRF2-
Sh cells showed similar telomere lengths despite differences in genomic DNA loading. Image is 
representative of a single experiment. (B) Chromosomal spreads of control and TRF2-Sh hESCs 
counterstained with DAPI which show no obvious non-homologous end joining of telomere ends. 
Images are representative of two independent experiments. Scale bar= 10 µM. 
 
Altogether, knockdown of TRF2 in hESCs does not affect their self-renewal or 
ability to differentiate into cells of the mesoderm and endoderm germ layers. 
However, it appears to hinder hESCs to differentiate into functional NPCs. 
Furthermore, NPCs derived from these cells exhibit a dramatic reduction in their 
ability to generate post-mitotic neurons and glia.  
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4.3 Discussion 
 
The previous chapter described how TRF2 protein is specifically abundant in NPCs 
and that its localization is both telomeric and extratelomeric, suggesting an 
extratelomeric function within the neural lineage. These results were consistent with 
previous findings showing that TRF2 levels were specifically abundant in human 
brain tissue (Jung et al., 2004), and with previous suggestions that TRF2 may play a 
role in neurogenesis (Zhang et al., 2008; Simonet et al., 2011). To explore this 
possibility further, gain and loss of function approaches were used to determine the 
importance of TRF2 in hESCs. Ectopic expression of TRF2 in hESCs promoted 
neural differentiation. TRF2 overexpression in hESCs resulted in the increase of 
neuronal maker expression at both the mRNA and protein level without clear 
changes in Gata6 expression (Figure 4.1 C and Figure 4.2). Since TRF2 
overexpression has been shown to diminish the repair of single strand breaks in 
human fibroblasts (Richter et al., 2007), which can result in DNA damage 
accumulation (Ward and Chen, 2001), and since DNA damage has been recently 
reported to induce differentiation of neural progenitors (Schneider et al., 2013), the 
protein levels of H2AX were analysed via western blotting and IF to ensure the 
neural differentiation phenotype observed following TRF2 overexpression was not a 
consequence of DNA damage accumulation. No dramatic changes of γH2AX were 
observed upon TRF2-Ov in hESCs (Figure 4.1 D and Figure A3). Thus, while these 
results could benefit of additional analysis, our available data suggests that the 
induction of neuronal differentiation was likely to not be a result of DNA damage. 
Furthermore, it is also worth mentioning that in order to terminally differentiate 
NPCs, bFGF and EGF, which promote NPC growth in vitro, need to be removed 
from the medium to allow terminal differentiation.  However, our TRF2-Ov hESCs 
managed to differentiate into neurons under these self-renewing conditions (Figure 
4.2 C). This suggested that the increase of TRF2 protein levels has a potent effect in 
inducing neural differentiation.  In fact when control and TRF2-Ov hESCs were 
introduced in neural differentiation conditions, one passage following transduction 
and prior TRF2 overexpression inducing neural differentiation, TRF2-Ov hESCs 
differentiated to NPCs at a much faster rate. 
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Given that TRF2 is important in the maintenance of telomere length and recent 
reports have indicated that ESCs with short telomeres have unstable differentiation 
(Pucci et al., 2013), telomere length in control and TRF2-Ov hESCs was analysed at 
different passages. The results indicated that the neural differentiation observed in 
the TRF2-Ov hESCs was unlikely to be a consequence of telomere shortening, as 
neural differentiation was observed as early as passages 2-5 and at this stage no 
shortening of the telomeres was observed. Shortening of telomeres was only 
observed after passage 5 following neural differentiation, indicating that telomere 
shortening was much more likely to be the consequence of neuronal differentiation 
and not the other way around. However, it is important to note that the uneven 
loading of the sample’s genomic DNA makes the data difficult to interprate. The 
experiment would need to be repeated or an alternative more sensitive telomere 
length analysis technique such as q-FISH or telomere qRT-PCR should be used to 
fully address this question.   
 
Since TRF2 overexpression induces neural differentiation, we questioned whether 
TRF2 knockdown would conversely inhibit neural differentiation. TRF2 knockdown 
in hESCs did not affect their self-renewal neither had an obvious detrimental effect 
(Figure 4.5). It is possible that this may be due to the fact that ESCs are derived from 
pre-implantation embryos and TRF2 knockout mice only resulted in embryonic 
lethality at a later embryonic stage (Celli and de Lange, 2005). TRF2 knockdown 
was confirmed by qRT-PCR and western blotting of two different passages. TRF2 
knockdown did not affect the expression of pluripotent markers Oct4, Nanog and 
Sox2 significantly and cells appeared no different from control under the microscope. 
Oct4 was not affected at the protein level either. However, when these cells were 
differentiated to the three germ cell lineages by EB formation, significant events 
unfolded. While TRF2-Sh hESCs were able to differentiate to the endoderm and 
mesoderm similarly to control hESCs, differentiation to the ectoderm lineage was 
impaired. Expression of Sox2, a NPCs marker, was greatly reduced and in addition 
so was the expression of the neuronal marker Tuj1. To confirm these Sox2 positive 
cells were NPCs and not undifferentiated hESCs, which do not express high levels of 
TRF2, co-staining with Sox2 and TRF2 antibodies was carried out, resulting in a 
strong positive staining of both markers in control cells only.  It is likely that the 
reduction on the neural maker Tuj1, observed in TRF2-Sh EB-derived cells, is a 
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consequence of the reduced number of Sox2 positive NPCs as Sox2 has been 
extensively reported to be critical in maintaining NPCs self-renewal and 
multipotency (Graham et al., 2003; Suh et al., 2007).  It is possible that the 
knockdown had an effect on the differentiation of viable NPCs and consequently 
resulted in a reduction of postmitotic neurons. To see if this was the case, control and 
TRF2-Sh hESCs were differentiated to NPCs by the same protocol used to 
differentiate wild type hESCs to NPCs. Differentiation of TRF2-Sh hESCs to NPCs 
appeared hindered as a large proportion of the cells did not display the triangular/bi-
polar morphology typical of NPCs, instead cells were flatter and of a rounder shape. 
Gene expression analysis confirmed that the expression of NPCs markers Sox1, Sox2 
and Mash1 was heavily downregulated but neural markers Tuj1 and Snap25 were not 
significantly affected. The non-significant change in neuronal marker expression 
observed could be due to the presence of growth factors during the hESCs to NPCs 
differentiation, which inhibit neuronal differentiation and therefore the expression of 
these markers. To investigate if TRF2 knockdown could also affect the ability of the 
derived NPCs to differentiate to neurons or glia these cells were allowed to further 
differentiate into neurons or glia by withdrawal of growth factors. Interestingly, only 
control cells displayed strong Tuj1 and GFAP staining with typical neuron or glia 
processes. This indicated that TRF2 knockdown in hESCs affects their ability to 
differentiate to healthy NPCs that have the capability to further differentiate into 
neurons and glia.  
   
TRF2 knockdown has been well reported in cancer cells to induce NHEJ of the 
chromosome ends leading to cell senescence and apoptosis (Karlseder et al., 1999; 
Denchi and de Lange, 2007). It could be that the detrimental effects observed on 
differentiation upon TRF2 knockdown are a consequence of DNA damage and 
NHEJ; however this would not explain why the detrimental effects occur specifically 
in the neural lineage. Nevertheless, the telomere lengths and chromosomal spreads of 
both control and TRF2-Sh hESCs were analysed. It was unclear whether telomere 
length was affected upon TRF2 knockdown, at an initial glance there appears to be 
no dramatic changes on telomere lentheven 10 passages after TRF2 knockdown. 
However, to confirm this we would need to use more sensitive techniques to measure 
telomere length which could not be achieved due time constraints.  TRF2 knockdown 
did not appear to result in NHEJ of telomere ends; chromosomes were of the correct 
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number and appeared without NHEJ. This could be due to the level of TRF2 
knockdown achieved. A recent publication has shown that only high levels of TRF2 
knockdown result in NHEJ of chromosome ends (Cesare et al., 2013). Therefore 
while TRF2 knockdown may not have been sufficiently efficient to lead to NHEJ of 
chromosome ends, it was efficient enough to suggest that TRF2 has a role in neural 
differentiation.  
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Chapter 5 TRF2 is required to maintain NPCs 
differentiation potential 
5.1 Introduction 
 
The previous results chapters demonstrated that TRF2 is specifically upregulated in 
NPCs. Ectopic expression of TRF2 in hESCs induced their differentiation to the 
neural lineage under hESC self-renewing conditions, while TRF2 knockdown 
affected their ability to differentiate into NPCs that give rise to neurons and glia. 
Given that high TRF2 protein expression is abundant in NPCs and that modulation of 
its expressions in hESCs affects neural differentiation, we attempted to further 
elucidate its role in NPCs. In the developing CNS, NPCs exist at different 
developmental stages. The developmental stage of a NPC alters its differentiation 
potential. NPCs in their early stages of CNS development have more potential to 
differentiate into neurons while NPCs in late stages are more prone to give rise to 
glia (Temple, 2001). In addition to their more limited differentiation potential, NPCs 
have shorter telomeres than hESCs and express lower levels of telomerase. 
Interestingly, it has recently been reported that mouse ES cells with short telomeres 
display unstable differentiation (Pucci et al., 2013). This phenotype was shown to be 
only rescued upon re-lengthening of the telomeres by introduction of telomerase 
catalytic subunit TERT. The aim of this chapter is to carry out a similar approach of 
gain or loss of TRF2 function in late stage NPCs, taking particular interest in 
telomere length and differentiation potential. 
 
 
 
 
 
 
 
 
 
116 
 
5.2 Results 
 
5.2.1 TRF2 knockdown in NPCs hinders their ability to terminally differentiate 
into neurons and glia 
 
In the previous chapter, TRF2 knockdown in hESCs affected their ability to 
differentiate into proper NPCs, rendering the resulting TRF2-Sh hESC-derived NPCs 
unable to generate neurons and glia (see section 4.2.5 for details). To further validate 
the function of TRF2 in NPCs, TRF2 knockdown was carried out directly in hESC 
derived NPCs using the same TRF2 shRNA-expressing lentivirus particles. 
Following infection and selection in puromycin, the surviving TRF2-Sh NPCs 
exhibited evident TRF2 deficiency as measured by qRT-PCR, WB and IF (Figure 5.1 
B-D), displaying almost 75% reduction at the mRNA level. Although these cells did 
not show distinct changes in morphology (Figure 5.1 A), they revealed significant 
downregulation of two important NPCs markers, Sox2 and Mash1, by qRT-PCR. In 
addition, Snap25, a cell membrane protein often related to neural synaptic vesicle, 
was also heavily downregulated upon TRF2 knockdown. In agreement with these 
mRNA data, western blotting and IF also showed obvious decrease in Sox2 and 
Nestin protein levels (Figure 5.1 C and E). TRF2 knockdown also triggered 
activation of DNA damage response as shown by the increase of γH2AX (Figure 5.1 
C). These results indicate that TRF2 deficiency indeed modified the gene expression 
profile of NPCs, particularly those that are important in neurogenesis, which could 
consequently affect the differentiation potential of these cells. 
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Figure 5.1 TRF2 knockdown in NPCs affects their marker expression.  
(A) Phase contrast images of control and TRF2-Sh NPCs following selection. Scale bar= 100 μm. (B) 
Gene expression analysis of NPCs markers (Sox1, Sox2, Mash1) neural marker Snap25 and TRF2 by 
qRT-PCR. Error bars represent standard derivation from 6 repeats of two independent experiments. 
Statistical significance was tested by paired Student’s t-test, * p≤ 0.05, ** p≤0.01, *** p≤0.001, NS 
p> 0.05 (non-significant). (C) Immunobloting of control and TRF-Sh NPCs with the selected 
antibodies. Image is representative of two independent experiments. (D) IF with TRF2 antibody 
showing the evident reduction of TRF2 in cell nuclei after TRF2-shRNA knockdown. Nuclei are 
shown by DAPI staining (blue). White squares magnify the area they surround as shown in the bottom 
panels. Scale bar = 50 μm. Images are representative of two independent experiments. (E) 
Sox2/Nestin co-IF in control and TRF2-Sh NPCs showing a significant downregulation of both 
markers upon TRF2 knockdown. Nuclei are shown by DAPI staining (blue). Scale bar= 40 μm. 
Images are representative of three independent experiments. 
***           NS            **            *              ** 
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To validate the functional effect of TRF2 knockdown, these cells were further 
differentiated into neurons and glia by withdrawal of growth factors, subsequently 
revealing different differentiation potentials. Control cells developed long and 
multiple processes of interconnecting outgrowths, whereas the TRF2-sh cells 
appeared flatter, with fewer outgrowths (Figure 5.2 A). These phenotypic differences 
were reflected by the lack of Tuj1 and GFAP staining in the TRF2-sh cells (Figure 
5.2 B, lower panels). These results indicate that TRF2 deficiency significantly 
diminishes the capability of NPCs to further differentiate into neurons and glia, and 
as such, TRF2 knockdown may therefore compromise the neuropotency of neural 
progenitors, leaving them unable to further differentiate. These results are in line 
with the previously generated gene expression data where several neural progenitor 
and neuronal markers, particularly the neural transcription factors, Sox2 and Mash1, 
were expressed at considerably lower levels (Figure 5.1 B). As these transcription 
factors are essential for the maintenance of neural progenitors, this deficiency in 
expression may therefore account for their hindered ability to differentiate into 
neurons and glia.  
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Figure 5.2 TRF2 knockdown in NPCs affects their ability to terminally 
differentiate into neurons and glia. 
(A) Phase-contrast images of control and TRF2-Sh NPCs terminally differentiated for 10 days in NPC 
culture medium without growth factors (-GF). Scale bar= 100 µm. (B) IF of terminally differentiated 
control and TRF2-Sh NPCs with neuronal marker Tuj1 and glial marker GFAP. Nuclei are shown by 
DAPI staining (blue). Scale bar= 50 µm. Images are representative of three independent experiments. 
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5.2.2 TRF2 knockdown in NPCs results in slight telomere lengthening but no 
obvious telomere NHEJ  
 
Telomere length in these TRF2-sh NPCs was found to be partially elongated (Figure 
5.3 A), which is similar to that observed in telomerase positive cells (Takai et al., 
2010). It has been demonstrated in some cells that TRF2 plays an important role in 
telomere structure and protection and that lack of TRF2 leads to unprotected 
telomere, resulting in chromosomal end joining (Karlseder et al., 2004; Denchi and 
de Lange, 2007; Karlseder et al., 2009). However, no obvious end-to-end 
chromosome fusions were detected in at least 10 spreads from two independent 
experiments of control and TRF2 deficient NPCs (Figure 5.3 B), even though TRF2 
knockdown was shown to trigger activation of DNA damage response indicated by 
the increase of γH2AX (Figure 5.1 C). Similarly to the chromosomal spreads 
analysed in the previous chapter (Figure 4.3), these experiment would benefit 
greately from FISH analysis as this technique would more clearly indicate if control 
or TRF2-sh NPCs contain any NHEJ of their telomere ends and help to properly 
address this question. However, due to time constraints this was not possible. 
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Figure 5.3 TRF2 knockdown does not induce NHEJ in NPCs but results in 
telomere re-lengthening.  
(A) Telomere repeat fragment (TRF) southern blotting assay of control and TRF2-Sh NPCs. TRF2 
knockdown in NPCs increases telomere length. Images are representative of two independent 
experiments. (B) Chromosomal spread analysis of control and TRF2-Sh NPCs revealing no obvious 
NHEJ of telomeres upon TRF2 knockdown. Images are representative of two independent 
excperiments each carried out in triplicate. Scale bar= 10 µM. 
 
Since TRF2 is well known for its telomere protection function we questioned 
whether TRF2 knockdown had increased their apoptosis or affected their 
proliferation. Control and TRF2-Sh NPCs were seeded at a density of 5x10
5
 per 6 
well plates and passaged every three days. Cells were counted at each split and 
population doubling (PD) calculated. While control cells proliferated at a rate of 5.2 
PD per 6 days of cell culture, TRF2-Sh NPCs only proliferated at a rate of 4.1 PD 
(Figure 5.4 A). Furthermore, IF of control and TRF2-Sh NPCs with the active 
mitosis marker phospho-H3, revealed 0.9% and 0.6% positive staining of the 
respective cells (Figure 5.4 B). Staining with the apoptosis marker Caspase 3 did not 
show marked differences between control and TRF2-Sh NPCs. All this together 
indicates that the slower proliferation observed in TRF2-Sh NPCs may be a 
consequence of a reduced active mitosis rather than cell death. 
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Figure 5.4 Proliferation and apoptosis analysis in TRF2-knockdown NPCs. 
(A) Growth curve of control and TRF2-Sh NPCs. Image is representative of four independent 
experiments carried out in triplicate each. Error bars indicate standard deviation of three repeats. (B) 
Representative images of phospho-H3 antibody staining in both control and TRF2-Sh NPCs, 
quantitative data is shown below. Scale bars= 30µm.  Experiment was carried out once in triplicate. 
(C) IF with Caspase 3 antibody in the two cell types. Scale bars= 50µm. Nuclei are shown by DAPI 
staining (blue) in all IF images. Experiment was carried out once in triplicate. 
 
5.2.3 Ectopic expression of TRF2 in NPCs does not hinder their ability to 
terminally differentiate into neurons and glia 
 
Chapter 3 revealed that the upregulation of non-telomere bound TRF2 was 
exclusively detected in NPCs and that this upregulation was dramatically 
downregulated to levels similar to that of hESCs upon further differentiation of these 
cells into neurons or glia. We hypothesised that downregulation of TRF2 protein 
levels may be required for NPCs to properly differentiate into neurons and glia. To 
address this question TRF2 was overexpressed in NPCs using lentiviral particles. 
Once NPCs were transduced and selected, the resulting cells were analysed for 
changes in their differentiation potential. TRF2 protein expression was greatly 
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increased in TRF2-Ov NPCs when compared to control NPCs (Figure 5.5 C). While 
these cells appeared morphologically normal under phase-contrast microscopy 
(Figure 5.5 A), in-depth gene expression analysis revealed that the expression of 
neuronal and glial markers was significantly affected. For example, expression of 
neuro-markers NeuroD2 and Tuj1 increased 6-fold and 2-fold respectively and 
expression of the glial marker GFAP also increased by 2-fold.  
 
 
 
Figure 5.5 TRF2 overexpression in NPCs increases expression of neuronal and 
glial markers 
(A) Phase-contrast images of control vs TRF2-Ov NPCs. Scale bar 100 µm. (B) Gene expression 
analysis of NPCs (Pax6), neuronal (NeuroD2, Tuj1) and glial (GFAP) markers by qRT-PCR. Error 
bars represent standard derivation from 6 repeats of three independent experiments. Statistical 
significance was tested by paired Student’s t-test, *** p≤0.001, **** p≤ 0.0001, NS p> 0.05 (non-
significant).   (C) Immunobloting of TRF2 in control and TRF2-Ov NPC protein lysates. Image is 
representative of three independent experiments. 
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Given that NPCs were being cultured in NPC culture conditions, it is possible that 
the effect of TRF2-Ov may have been masked greatly by the presence of growth 
factors in the media. Therefore, the growth factors from the media were withdrawn 
and the cells allowed to terminally differentiate for 7 days prior analysis.   
Interestingly, no morphological differences were observed under light microscopy. 
Both control and TRF2-Ov cells showed terminal differentiation into the typical 
morphology of neurons and glia (Figure 5.6 A). Gene expression analysis of Tuj1 
and GFAP did not show significant differences between control and TRF2-Ov 
terminally differentiated cells (Figure 5.6 B). Co-staining of TRF2 and Tuj1 or TRF2 
and GFAP in NPCs under self-renewing conditions did not reveal significant 
differences in neuronal or glial staining (Figure 5.6 C-D, upper panels). Furthermore, 
both control and TRF2-Ov NPCs were able to terminally differentiate into post-
mitotic neurons or glia, indicating that a reduction of TRF2 protein expression is not 
required for their differentiation (Figure 5.6 C-D, lower panels). 
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Figure 5.6 TRF2 overexpressing NPCs can terminally differentiate into neurons 
and glia with no significant changes in their marker expression.  
(A) Light microscopy images of control and TRF2-Ov terminally differentiated NPCs. Scale bar= 100 
µm. (B) qRT-PCR of genes Pax6, Tuj1 and GFAP. Error bars represent standard derivation from 6 
repeats of two independent experiments. Statistical significance was tested by paired Student’s t-test, 
NS p> 0.05 (non-significant).  (C) IF of control and TRF2-Ov NPCs with and without growth factors 
(+/-GF), with TRF2 and neuronal marker Tuj1. Images representative of a single experiment carried 
out in duplicate. (D) IF of genetically modified NPCs with and without growth factors with TRF2 and 
glial marker GFAP. Nuclei are shown by DAPI staining (blue) in all IF images. Scale bar= 30 µm in 
all IF images. Images representative of a single experiment carried out in duplicate. 
 
5.2.4 Exogenous expression of TRF2 in NPCs accelerates telomere shortening but 
does not results in an obvious NHEJ of telomere ends phenotype 
 
Next, telomere length and chromosomal spreads of both control and TRF2-Ov NPCs 
were analysed. As previously reported and observed in TRF2-Ov hESCs, TRF2 
overexpression in NPCs also resulted in increased shortening of telomeres compared 
to control (Figure 5.7 A). However, this did not seem to hinder their ability to 
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terminally differentiate into neurons or glia (Figure 5.6 C-D) and did not result in 
NHEJ of telomere ends (Figure 5.7 B).  
 
 
Figure 5.7 Ectopic expression of TRF2 in NPCs induces telomere shortening but 
no NHEJ. 
(A) Telomere length analysis by southern blotting of control and TRF2-Ov NPCs genomic DNA. 
Image is representative of two independent experiments. (B) Chromosomal spread preparation of both 
cell types indicating no formation of NHEJ of chromosomal ends. Scale bar= 10 µM. Images are 
representative of two independent experiments carried out in duplicate. 
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5.3 Discussion 
 
In this chapter the effects of gain and loss of TRF2 function in NPCs were addressed 
to support the data obtained in hESCs and to further explore the possible role of 
TRF2 in neural differentiation. TRF2 knockdown in NPCs affected the expression of 
key neural progenitor markers at both the mRNA and protein levels and hindered 
their ability to terminally differentiate into neurons and glia in a similar fashion to 
that observed in TRF2-Sh hESC-derived NPCs. Interestingly, a recent publication 
using the embryonic carcinoma stem cell line NTera2 showed that knockdown of 
TRF2, via dominant inactive TRF2 overexpression, resulted in induction of neuron 
formation instead of hindering neural differentiation (Zhang et al., 2008). While the 
discrepancy in neural induction phenotypes may be attributed to different cell types 
used, it is worth mentioning that accumulation of DNA damage can induce 
differentiation to the neural linage in some cell types (Schneider et al., 2013). 
Therefore, since TRF2 depletion is known to result in uncapping of the telomeres 
leading to accumulation of DNA damage and cell senescence (van Steensel et al., 
1998; Karlseder et al., 1999; Karlseder et al., 2004), it is possible that depletion of 
endogenous TRF2 in NTera2 cells induced neural differentiation as a consequence of 
DNA damage accumulation. While DNA damage accumulation as a neural induction 
mechanism could explain the phenotype observed in NTera2 cells, it could not 
explain the phenotype observed in our TRF2-Sh NPCs as these cells revealed 
hindered ability to differentiate. However, it is possible that instead of inducing 
neural differentiation accumulation, DNA damage accumulation in our cells 
triggered cell senescence, explaining why these cells could not differentiate. To 
address this possibility we analysed TRF2-sh NPCs with DNA damage (γH2AX), 
cell proliferation (H3 phosphorylation) and cell senescence markers (Caspase 3). 
TRF2-sh NPCs revealed increased expression of γH2AX, slower proliferation rate 
and a decrease in H3 phosphorylation. These results suggested that the increase of 
γH2AX DNA damage signals could have resulted in p53 activation which in turn 
stalled cell cycle progression in an attempt to repair the damaged DNA, explaining 
the decrease in H3 phosphorylation and cell proliferation. However, while these 
results may explain why TRF2-sh NPCs proliferate slightly slower, they did not 
explain TRF2-sh NPCs inhability to differentiate as these cells revealed no increases 
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in Caspase 3 expression or NHEJ of telomeres, indicating these cells were not 
genomically unstable or senescing. While the proliferation, cell senescence and 
chromosomal spread experiments presented here could benefit from further 
characterisation, such as caspase 3 quantification or FISH, a recent study has 
reported that accumulation of DNA damage and NHEJ at telomeres, as a 
consequence of TRF2 knockdown, is directly dependent on the levels of TRF2 
depletion (Cesare et al., 2013), indicating that perhaps the TRF2 knockdown 
approach used in our cells did not induce enough DNA damage to result in cell 
senescence. This report indicated that very small levels of TRF2 protein are 
sufficient to inhibit NHEJ of telomeres and DDR activation, which is in line with the 
levels of TRF2 protein expression observed in hESCs (Figure 3.3 A). Therefore, this 
could explain why TRF2-Sh NPCs do not go into NHEJ or senescence and indicate 
that the hindered neural differentiation observed is unlikely to be due DNA damage 
accumulation. Altogether, the different cell types and approaches to knockdown 
TRF2 used in our study and Zhang et al could explain the discrepancies observed. It 
is likely that given their testicular carcinoma origin, NTera2 cells use a different 
mechanism to regulate neural differentiation to that of normal human NPCs.  
 
TRF2 overexpression in NPCs was carried out using the same lentiviral particles 
used to overexpress TRF2 in hESCs. While TRF2 overexpression in NPCs resulted 
in an increase of expression of neuronal markers that reminisce to the effects of 
TRF2 overexpression in hESCs, morphological changes were not observed. Since the 
presence of growth factors bFGF and EGF could have greatly masked the potential 
neural differentiation effect of TRF2 overexpression these were withdrawn from the 
media. Following growth factor withdrawal, both control and TRF2-Ov NPCs 
differentiated into neurons and glia normally, without revealing any distinct 
differences in morphology, or marker expression. This indicated that TRF2 
downregulation, which is observed in wild type NPCs upon differentiation to 
neurons or glia (Figure 3.7), is not required for the terminal differentiation of NPCs. 
 
Telomere elongation or shortening as a result of TRF2 knockdown or TRF2 
overexpression in NPCs, respectively, did not seem to be the cause of the neural 
differentiation phenotypes observed. It has been recently published that ES cells with 
short telomeres have unstable differentiation (Pucci et al., 2013). The NPCs used in 
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this study were of short telomere length and upon TRF2 overexpression this length 
became even shorter. However, these cells still had the ability to terminally 
differentiate normally into neurons and glia unlike the TRF2-Sh NPCs which had 
increased telomere length upon TRF2 knockdown. This indicated that telomere 
length in NPCs is unlikely to be a factor contributing to the detrimental effect 
observed in neural differentiation upon TRF2 knockdown.  
 
Altogether these results suggest that TRF2 is regulating neural gene expression in 
NPCs through an unknown mechanism and that this mechanism, according to our 
available data and the literature, is likely to be independent of telomere length and 
telomere DNA damage accumulation.  
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Chapter 6 TRF2-mediated stabilization of human REST4 is 
vital for neural differentiation and maintenance of neural 
progenitors 
 
6.1 Introduction 
 
TRF2 has been previously reported to inhibit neuronal differentiation of human 
embryonic carcinoma NTera2 cells by interacting with REST and stabilising its 
protein levels (Zhang et al., 2008). REST is a master transcriptional repressor that 
regulates the expression of hundreds of genes, many of which are critical for neural 
differentiation and the development of the central nervous system such as Mash1, 
Snap25, NeuroD2, Tuj1, GFAP and Sox2 (Lietz et al., 2003; Bruce et al., 2004; 
Ballas and Mendel, 2005; Singh et al., 2008; Kohyama et al., 2010). Several splice 
variants of REST have been discovered in rodent and human (Palm et al., 1998, 
1999), In human one of these isoforms has been previously reported to be generated 
by the alternative splicing of a neural-specific exon (exon N) located between exon 
IV and V to produce a 62 nucleotide insertion in the REST mRNA, containing an in-
frame stop codon that causes premature translation termination and synthesis of a 
truncated REST protein known as hREST-N62 (Palm et al., 1999). In rodent, a 
similar isoform of REST termed rREST4 has very similar protein structure to 
hREST-N62 and has been shown to antagonize the repressive function of REST on 
its target genes, in neural tissues (Palm et al., 1999; Shimojo et al., 1999; Tabuchi et 
al., 2002; Uchida et al., 2010; Raj et al., 2011). Rodent rREST4 like hREST-N62, 
both retain the REST N-terminal domain and 5 of the 9 zinc-finger DNA binding 
domains, but lack the C-terminal repression domain. As such, here hREST-N62 
variant has been termed human REST4 (REST4) given the similarity in protein 
structure to rodent rREST4 (Figure 6.1 C), posit its involvement in regulating neural 
differentiation through a similar mechanism.  
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The previous chapters demonstrated that TRF2 plays a critical role in the neural 
differentiation of hESCs and maintenance of NPCs multipotency. Given the critical 
importance of REST and rREST4 in neural differentiation, we questioned wheter 
TRF2 could be regulating neural differentiation of hESCs through either of these 
factors. To address this question the protein levels of REST and REST4 were 
analysed during neural differentiation of hESC.  TRF2-Ov hESCs and TRF2-Sh 
NPCs were also analysed to address the relationship between TRF2 and 
REST/REST4. The aim of this chapter is to decipher the mechanism underlying the 
role of TRF2 in regulating neural differentiation of hESCs.  
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6.2 Results 
 
6.2.1 TRF2 protein affects REST4 but not REST expression in hESCs and NPCs. 
 
Given the critical importance of REST in neural differentiation and that TRF2 has 
been previously suggested to stabilise REST (Zhang et al., 2008), REST and TRF2 
protein expression was first analysed in hESCs and their neural derivatives to 
ascertain if their expression correlates. Surprisingly, even though TRF2 was clearly 
upregulated upon differentiation of hESCs to NPCs, no significant difference in 
REST protein levels was observed (Figure 6.1 A). Overexpression or knockdown of 
TRF2 in hESCs and NPCs, respectively, did not result in REST mRNA or protein 
level changes either (Figure 6.2 A-C). To further validate this lack of TRF2-REST 
correlation TRF2 was also overexpressed in HEK293T cells, revealing no changes in 
REST protein expression (Figure 6.2 D).  
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Figure 6.1 Neural differentiation of H1 and H7 hESCs does not result in a 
dwnregulation of REST but upregulation of its splice variant human REST4. 
(A) Cell extracts isolated from H1 and H7 hESCs and their early and late NPCs were analysed by 
immunobloting with indicated antibodies. Quantitative analysis is presented as a histogram (right 
panels). Arrows in immunoblot point to REST and REST4 human proteins. Immunoblot image is 
representative of two independent experiments. (B) Immunobloting of HEK293T cell extracts 
overexpression human REST and REST4. Arrows point to REST and REST4 human proteins which 
are of the same molecular weigth as the endogenous REST and REST4 proteins detected in (A). (C) 
Schematic map of human REST gene comparing the structural similarithy between human REST, 
human REST4 (also known as hREST-N62) and rodent rREST4.  Open and colored boxes represent 
exons and copding regions, respectively. Specific amino acid sequence derived from exon N 
expression is shown in red. Long doted line across schematic map separates human from rodent REST 
transcripts. 
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It is noteworthy, that the relative stable REST protein expression observed during 
neural differentiation of hESCs is different from that reported during mESC neural 
differentiation, which shows a downregulation of REST. This reduction is thought to 
alleviate REST repression on neural genes, hence promoting neural differentiation 
(Ballas et al., 2005). These results raised the question as to how REST-mediated 
repression on neural genes is reduced during hESC neural differentiation. It was 
noticed that the REST antibody, raised against the N-terminus of human REST 
(Epitomics antibody, see section 2.1.3 for details), consistently detected a ~40-kDa band 
in NPCs, which is lower in molecular weight than that of REST (Figures 6.1 A and 6.7 
A). Although the antibody also detected a couple of other bands, these did not appear 
when using other batches of the antibody, and were therefore considered to be non-
specific (Figures 6.1 A, 6.6 C, 6.7 A). Interestingly, this ~40kDa protein exhibited a 
pattern of upregulation similar to that of TRF2 during neural differentiation (Figure 6.1 
A histograms) and is of a similar molecular weight to the predicated size of hREST-N62, 
a human REST isoform that is orthologous to the rodent neural-specific REST isoform 
rREST4 (Palm et al., 1998; Palm et al., 1999; Shimojo et al., 1999). Correspondingly, 
immunoblotting with the REST antibody on HEK293T cell extracts overexpressing 
human REST and hREST-N62 revealed the presence of only two bands of ~170-200 
KDa and ~40 kDa, respectively (Figure 6.1 B). hREST-N62 is generated by the 
alternative splicing of a neural-specific exon (exon N) located between exon IV and V to 
produce a 62 nucleotide insertion in the REST mRNA, containing an in-frame stop 
codon that causes premature translation termination and synthesis of truncated REST 
protein (Figure 6.1 C) (Palm et al., 1999). Although no function has been ascribed to 
hREST-N62, the rodent protein orthologous rREST4 has been shown to counteract the 
repressive role of REST in the regulation of its target genes, particularly during 
neurogenesis (Shimojo et al., 1999; Palm et al., 1999; Tabuchi et al., 2002; Uchida et 
al., 2010). Whilst the protein sequence encoded by exon N differs between REST-N62 
and rodent rREST4, both retain the REST N-terminal domain and 5 of the 9 zinc-finger 
DNA binding domains, but lack the C-terminal repression domain (Figure 6.1 C). Hence, 
we have appropriately termed this hREST-N62 variant as human REST4 (REST4) 
(Figure 6.1 C) and given the similarity in protein structure to the rodent rREST4, posit 
its involvement in regulating neural differentiation through a similar mechanism.  
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Figure 6.2 Modulation of TRF2 protein levels affect the expression of REST4 
but not REST.  
(A) mRNA expression analysis of REST, REST4 and nSR100 in TRF2 overexpressing hESCs and 
control by qRT-PCR with sequence specific primers. Data are presented as mean ± SD of three 
independent experiments. Comparison of protein expression in TRF2 overexpressing H1 hESCs (B) 
and TRF2 knockdown H1 NPCs (C) by immunobloting with the indicated antibodies. (D) REST and 
REST4 protein expression analysis in two different HEK293T TRF2 infected cell lines by 
immunobloting. No difference in REST expression was detected and REST4 was not detected as it is 
expressed only in neural lineage tissues. Immunoblot images are representative of at least two 
independent experiments.                                                                                                   
 
In line with the neural differentiation data, REST4 was also found to be clearly 
upregulated in TRF2-Ov hESCs (Figure 6.2 A-B), which was also accompanied with 
the upregulation of the REST splicing regulator nSR100 transcripts (Figure 6.2 A). 
In contrast, TRF2 knockdown in NPCs reduced REST4 protein level (Figure 6.2 C). 
These results demonstrate that there is a positive correlation between TRF2 and 
REST4 protein expression in hESCs and NPCs. However, REST4 protein expression 
was not detected in TRF2-Ov HEK293T cells, indicating that TRF2 probably is not 
directly involved in regulation of REST4 transcription and REST alternative splicing.  
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Taken together, these data suggests that TRF2 may act to enhance the expression of 
REST4 protein, subsequently affecting the neural differentiation of hESCs and the 
preservation of NPC neuropotency. Full immunoblots for figure 6.2 C and D can be 
found in the appendix (Figures A4 and A5). 
 
6.2.2 TRF2 specifically interacts with REST4 
 
It has been widely demonstrated that REST4 functions to counteract the repressive 
role of REST in the regulation of gene expression, particularly during neurogenesis 
(Palm et al., 1999; Shimojo et al., 1999; Raj et al., 2011). Hence, we hypothesised 
that TRF2 may promote neural differentiation of hESCs by regulating the expression 
of REST4. Although a positive correlation between TRF2 and REST4 protein 
expression was observed, it remained unclear how TRF2 may affect REST4 
expression. Since overexpression of TRF2 did not increase REST in hESCs as well 
as HEK293T cells, and did not induce REST4 expression in HEK293T cells, it seems 
unlikely that TRF2 enhances REST4 expression through direct regulation of REST 
transcription or alternative splicing. Given that TRF2 acts as a protein hub and thus 
interacts with many proteins (Kim et al., 2009; Okamoto et al., 2013), it is 
conceivable that TRF2 may affect REST4 through protein-protein interaction. For 
these reasons, the potential ability of TRF2 to interact with REST4 was first 
addressed endogenously in NPCs using co-immunoprecipitation (co-IP) approaches 
(Figure 6.3 A). The telomere binding protein Rap1, a well-known TRF2 interacting 
partner (Li et al., 2000), was used as positive control of the co-IP. 
Immunoprecipitation of TRF2 in NPCs clearly showed a co-IP of RAP1 protein 
indicating that the reaction conditions were optimal to detect protein-protein 
interactions. Indeed, TRF2 immunoprecipitation in NPCs showed that endogenous 
REST4 but not REST could be detected in TRF2 immunoprecipitates (Figure 6.3 A).  
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Figure 6.3 Interaction between TRF2 and REST4 by co-immunoprecipitation 
(A) TRF2 immunoprecipitates or whole cell lysate from NPCs were analysed with indicated 
antibodies. Rap1 is used as positive control for the interaction. (B-C) TRF2 interacts with REST4 but 
not REST proteins. HEK293T cells were transfected with HA-tagged TRF2 (HA-TRF2), Myc-tagged 
REST (Myc-REST) and Myc-tagged REST4 (Myc-REST4) expression vectors individually or 
combined as indicated for 48 hours. HA immunoprecipitates and whole cell lysates (B) or Myc 
immunoprecipitates and whole cell lysates (C) were analysed by immunoblotting with HA or Myc 
antibodies. All three immunoblots are representative images of at least two independent experiments 
each. 
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Next, to validate this interaction I transiently overexpressed TRF2, REST and 
REST4 epitope-tagged proteins in HEK293T. Myc-tagged REST (Myc-REST) or 
REST4 (Myc-REST4) together with HA-tagged TRF2 (HA-TRF2) were transiently 
expressed in HEK293T cells and their cell extracts were subjected to co-IP analysis. 
In these experiments, I showed that HA-TRF2 could only be detected in the myc-
REST4 immunoprecipitates and in the immunoprecipitates of myc-REST (Figure 6.3 
B); similarly, only myc-tagged REST4 could be detected in the HA-TRF2 
immunoprecipitates (Figure 6.3 C). Full immunoblots of figures 6.3 A-C can be 
found in the appendix (Figures A6-A8). 
 
REST4 is largely considered as a truncated REST with almost complete homology 
except for the 13 amino acids (AAs) at the C-terminus of REST4, which are encoded 
by exon N. Hence, the 13 AAs are unique to the REST4 and interestingly, they 
contain the core consensus of TRF2 binding motif [Y/F]XL (Figure 6.4 A) (Chen et 
al., 2008; Kim et al., 2009). Therefore, it is plausible that the fact that TRF2 can only 
interact with REST4 and not REST may be attributed to the 13-AA peptide. To 
address whether this 13-AA peptide is critical for the interaction between REST4 and 
TRF2, a mutant REST4 (REST4m) expression vector was generated by introducing 
an early stop codon upstream of these 13 AAs (Figure 6.4 A).  When HA-TRF2 with 
either wild-type myc-REST4 or mutant myc-REST4m were ectopically expressed in 
HEK293T cells, only myc-REST4 was detected in HA-TRF2 immunoprecipitates 
(Figure 6.4 B), indicating that the 13 AAs at the C-terminus of REST4 are essential 
for the interaction between TRF2 and REST4. These data demonstrate that TRF2 
interacts with REST4 but not REST.  
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Figure 6.4 TRF2 interacts with REST4 through its exon N protein sequence. 
(A) Schematic representation of REST4 and REST4 mutant (REST4m) mRNA. In red is the amino 
acid sequence corresponding to exon N. An early stop codon was introduced to eliminate the sequence 
from REST4m. (B) Co-immunoprecipitation of REST4 and REST4m proteins in HEK293T cells co-
transfected with HA-TRF2 and Myc-REST4 or HA-TRF2 and Myc-REST4m expression vectors for 
48 hours. HA immunoprecipitates or whole lysates were analysed by immunoblotting with Myc and 
HA antibodies. Immunoblot image is representative of two independent experiments. 
 
6.2.3 TRF2 protects REST4 from ubiquitination and proteasomal degradation 
 
Although it was ascertained that TRF2 interacts with REST4 but not REST, it 
remained unclear how TRF2 can enhance REST4 protein level. Given that TRF2 
interacts with REST4 at the protein level and that TRF2 is unlikely to be involved in 
its transcription regulation, it was hypothesised that TRF2 regulates REST4 protein 
levels at the posttranslational level; e.g. TRF2 could protect REST4 from 
proteasomal degradation. It is unknown whether REST4 protein is affected by 
proteasome degradation system, however REST has been reported to be regulated by 
ubiquitin-mediated proteasomal degradation (Westbrook et al., 2008; Zhang et al., 
2008; Huang et al., 2011). Thus, tests were run to observe if REST4 was proteasome 
degradation dependent. NPCs were treated with either proteasome inhibitor MG132 or 
protein translation inhibitor cyclohexamide (CHX) for 6 hours. The cell extracts were then 
analysed by immunoblotting for REST4 protein levels. Blocking protein degradation with 
MG132 resulted in an accumulation of REST4 protein while blocking protein 
translation resulted in degradation of REST4 (Figure 6.5 A). These results suggested 
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that REST4 protein is indeed degraded by the proteasome. Since proteasome-
mediated protein degradation requires ubiquitination of the protein, (Baumeister et 
al., 1998), the possibility that TRF2 may affect ubiquitination of REST4 was 
investigated. HEK293T cells stably overexpressing TRF2 were generated and used to 
ascertain if TRF2 is able to protect REST4 from ubiquitination and consequently 
proteasomal degradation. Myc-REST4 and HA-tagged ubiquitin (HA-Ub) were 
ectopically expressed in control and TRF2-Ov HEK293T cells for 48 hours and then 
the whole cell lysates were subjected to IgG and Myc immunoprecipitation (Figure 
6.5 B).  
 
 
 
Figure 6.5 TRF2 protects REST4 from proteasome dependent degradation. 
(A) REST4 protein can be degraded by a proteasome-dependent mechanism. hESC-derived NPCs 
were treated with either proteasome inhibitor MG132 or protein translation inhibitor CHX for 6 hours. 
The cell extracts were then analysed by immunoblotting for REST4 protein levels. Image 
representative of two independent experiments. (B) Control and TRF2 stably overexpressing 
HEK293T cells were co-transfected with Myc-REST4 and HA-tagged ubiquitin (HA-Ub) expression 
vectors. Myc immunoprecipitates (IP) or whole cell lystaes (input) were immunobloted with the 
indicated antibodies. Immunoblot is representative of two independent experiments. 
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Upon pull-down of Myc-REST4 protein and ubiquitin immunoblotting of the 
immunoprecipitates, it was found that high levels of TRF2 reduced the ubiquitination 
of REST4 and therefore could potentially prevent its proteasome-mediated 
degradation (Figure 6.5 B). Therefore, while the identity of the E3 ubiquitin ligase 
targeting REST4 remains to be elusive, these results demonstrate that high levels of 
TRF2 enhance REST4 protein expression by protecting it from ubiquitination-
proteasomal degradation, which consequently functions in promoting neural 
differentiation of hESCs and maintenance of NPCs.   
 
 
6.2.4 REST4 overexpression in hESCs induces neural differentiation 
 
Given the structural similarity between rodent rREST4 and human REST4 as well as 
their specific expression in neural tissues, we proposed that REST4 could have a 
similar function to that of its rodent ortholog in regulating neural differentiation. 
Since we found that TRF2 stabilizes REST4 we hypothesised that perhaps the 
accumulation of REST4 protein is the causative of the observed neural 
differentiation. To validate this hypothesis, REST4 was ectopically expressed (REST4-
ov) in hESCs. Following overexpression it was found that these cells exhibited 
compromised self-renewal and increased cell differentiation, particularly towards the 
neural lineage even under hESC culture conditions. Exogenous expression of REST4 
resulted in a downregulation of ESC markers Oct4 and Sox2 while increasing the 
expression of NPC markers Pax6 and Nestin (Figure 6.6 A-D). In addition, when 
subjected to neural differentiation, REST4-ov hESCs, like TRF2-ov hESCs, showed a 
quicker and more efficient neural differentiation (Figure 6.6 A and E). These results 
indicate that the presence of REST4 in hESCs counteracts the pluripotency of hESCs, 
possibly through affecting the repression of neural genes by REST.  
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Figure 6.6 REST4 overexpression in hESCs hinders their sel-renewal and 
promotes neural differentiation.  
(A) Phase-contrast images of control and REST4-ov hESCs in hESCs culture conditions (upper 
panels) as well as in neural differentiation conditions (lower panels). (B) Gene expression analysis by 
qRT-PCR of the indicated genes. Data are presented as mean ± SD of 8 repeats of 2 independent 
experiments. (C) Immunobloting showing REST4 overexpression results in a downregulation of Oct4 
and an increase of Pax6 protein. (D-E) Immunofluorescence of control and REST4-ov hESCs under 
hESC culture conditions (D) and 13 days under neural differentiation conditions (E) with the 
indicated antibodies. Scale bars represent 100 µM in A and 50 µM in D and E. 
 
 
6.2.5 REST4 overexpression in TRF2-sh NPCs rescues their neural differentiation 
deficiency 
 
While the overexpression of human REST4 in hESCs revealed that this protein has a 
similar function in promoting neural differentiation as its rodent counterpart, the 
current data could not directly attribute the neural differentiation deficiency effects 
observed in TRF2-sh hESCs and TRF2-sh NPCs to a downregulation of REST4. To 
address this directly, REST4 was overexpressed in TRF2-sh NPCs to attempt to 
rescue the neural differentiation deficiency phenotype. Overexpression of REST4 in 
TRF2-sh NPCs resulted in an increase of REST4 protein similar to that of control 
without affecting TRF2 or REST protein levels (Figure 6.7 A). REST4 
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overexpression was able to rescue some of the NPC marker gene expression and 
neuron and astrocyte formation lost upon TRF2 knockdown (Figure 6.7 B and C).   
 
 
Figure 6.7 REST4 overexpression rescues neural differentiation deficiency of 
TRF2-sh NPCs.  
(A) Immunobloting of exogenous expression of REST4 in TRF2-sh NPCs shows an increase of 
REST4 protein without affecting TRF2 or REST protein levels. (B) Gene expression analysis by qRT-
PCR of the indicated genes in control, TRF2-sh and REST4 rescue (REST4 res) NPCs. Data are 
presented as mean ± SD of 9 repeats of 3 independent experiments. (C) Immunofluorescence staining 
showing an increase in Tuj1 and GFAP positive cells upon REST4 overexpression in TRF2-sh NPCs 
(REST4-res). Quantitative analysis of the immunostaining is presented as percentage in histograms 
(right panels). Data is representative of 10 randomly chosen fields of three independent experiments. 
Statistical significance was tested by paired Student’s t-test, * p≤ 0.05 
 
* 
 * 
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REST4 overexpression in TRF2-sh NPCs (REST4-res) resulted in a significant 
increase in the numbers of Tuj1 and GFAP positive cells compared to TRF2-sh 
NPCs (figure 6.7 C). Cells recovered similar expression levels to control cells as well 
as the formation of long interconnecting processes tyical neuron and glia processes. 
 
Overall, these data suggest that TRF2 may act upstream of human REST4 to enhance 
its expression, subsequently affecting the neural differentiation of hESCs and the 
preservation of NPC neuropotency. 
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6.3 Discussion 
 
The previous chapters demonstrated that TRF2 is upregulated after neural 
differentiation and maintained at high levels in NPCs. Furthermore, they revealed 
that the high levels of TRF2 promote neural differentiation of hESCs and play an 
important role in maintaining the neuropotency of NPCs.  However, the molecular 
mechanisms underlying these phenotypes remained unknown. In this chapter, steps 
were taken to attempt to decipher the molecular mechanisms thorough which TRF2 
may regulate neural differentiation of hESCs and maintenance of NPCs. Experiments 
were focused on the relationship between TRF2 and REST because a recent report 
has shown that TRF2 stabilises REST in NTera2 cells (Zhang et al., 2008) and 
because several of the genes affected by modulation of TRF2 expression are target 
genes of REST (Lietz, 2003; Bruce et al, 2004; Ballas et al, 2005; Singh et al, 2008; 
Kohyama et al, 2010). Interestingly, when H1 and H7 hESCs were differentiated to 
NPCs, the levels of REST protein were not downregulated while TRF2 protein levels 
were dramatically increased (Figure 6.1). This was interesting because it has been 
proposed that mESCs require a downregulation of REST in order to become NPCs 
(Ballas et al., 2005) and because an increase of TRF2 protein levels did not result in 
an increase of REST protein abundance as it would have occurred if TRF2 stabilises 
REST in these cells. Furthermore, REST protein levels did not change when the 
expression of TRF2 in hESCs, NPCs and HEK293T cells was modulated (Figure 6.2 
B-D). 
 
REST was not downregulated following differentiation of H1 and H7 hESCs to 
NPCs. This raised the question as to how REST-mediated repression on neural genes 
is mitigated during hESC neural differentiation. It was observed that the protein 
levels of REST splice variant hREST-N62, here termed human REST4 for its 
similarity to rodent rREST4, increased following differentiation of H1 and H7 
hESCs to NPCs and that its expression was noticeably affected upon modulation of 
TRF2 expression in hESCs and NPCs. REST4 protein expression seemed to correlate 
with the expression of TRF2 protein in these cells.  Given that rodent rREST4 has 
been extensively reported to antagonise the repression activity of REST (Shimojo et 
al., 1999; Palm et al., 1999; Tabuchi et al., 2002; Uchida et al., 2010), it was 
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plausible to think that TRF2 could regulate neural differentiation in hESCs and NPCs 
through REST4. Co-IP experiments of endogenous TRF2 in NPCs and ectopically 
expressed epitope-tagged TRF2 in HEK293T cells confirmed that unlike NTera2 
cells (Zhang et al., 2008) TRF2 interacts with REST4 but not REST. Furthermore, 
TRF2 was shown to protect REST4 from proteasome dependent degradation 
explaining the correlation in protein expression of these two proteins in hESCs and 
NPCs. Since REST4 has extensively been shown to counteract REST activity and we 
have shown that REST4 is regulated by TRF2, it is possible that the increase of 
TRF2 expression results in the accumulation of REST4 protein, which in turn 
antagonizes the repression of REST, explaining the change in expression of REST 
target genes upon TRF2 protein level changes.   However, to address this possibility 
we first needed to stablish that REST4 can indeed induce neural differentiation in a 
similar fashion to that of rodent rREST4 and that the neural differentiation deficiency 
observed in TRF2-sh hESCs and NPCs is a consequence of REST4 downregulation. 
To answer these questions REST4 was overexpressed in hESCs and TRF2-sh NPCs. 
The results revealed that the exogenous presence of REST4 in hESCs induced these 
cells to differentiate to the neural lineage in a similar fashion to that of TRF2-ov 
hESCs. Furthermore, REST4 overexpression in TRF2-sh NPCs resulted in a partial 
rescue of the neural differentiation defiency observed suggesting that REST4 is the 
downstream partner of TRF2 and that the TRF2-mediated stabilization of REST4 is 
critical for the neural differentiation of hESCs as well as the maintenance of NPC 
multipotency. 
 
As a whole, these results suggest that repression of REST on its target genes is 
reduced in the neural differentiation of hESCs, mouse ES cells and NTera2 cells, but 
is regulated through different mechanisms. The coordinated balance of REST4 and 
REST is important for human neural differentiation and NPC maintenance for which 
high levels of TRF2 protein are crucial. 
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Chapter 7  General Discussion 
 
Increasing evidence indicates that TRF2 is not only an important factor for functional 
telomere maintenance but also may have extra-telomeric functions. Despite the 
importance of TRF2, its expression and involvement during embryonic development 
and adult tissue homeostasis remains largely unknown. In human, TRF2 has been 
reported to be highly abundant in brain tissues (Jung et al., 2004), suggesting an 
involvement in neurogenesis. Furthermore, preliminary data in our laboratory 
showed that TRF2 protein levels are dramatically upregulated during neural 
differentiation of hESCs. Thus, elucidating its role in neural development, 
particularly in brain function may aid in the improved procurement of human neural 
cells for potential use in regenerative therapies.  This study, has demonstrated a novel 
extra-telomeric function of TRF2 in the neural differentiation of hESCs and 
maintenance of NPCs which is independent of its role in regulating telomere length 
and protecting telomeres. 
 
7.1 TRF2 is a vital factor for hESC neural differentiation and 
maintenance of NPCs properties 
 
TRF2 protein is dramatically upregulated upon neural differentiation of hESCs and is 
maintained at high levels in cultured NPCs. The upregulation appears to be specific 
to hESC neural differentiation as neither the differentiation of hESCs to other 
lineages nor differentiation of mESCs to neural progenitors revealed similar 
increases. These results are consistent with the in vivo data which shows that TRF2 is 
much more abundant human brain than in other tissues (Jung et al., 2004), indicating 
that TRF2 may have an important function within neural tissues. While this previous 
study showed accumulation of TRF2 mainly in the cytoplasm of neurons, in contrast 
with this study which shows clear nuclei staining, it is likely that this is the result of 
the in-house made anti-TRF2 polyclonal antibody used detecting an isoform of TRF2 
known as TRF2 short (TRF2-s) which is known to accumulate in the cytoplasm of 
mature neurons (Zhang et al., 2011). The anti-TRF2 monoclonal antibody used in 
this study only detects the 66 KDa form of TRF2 which is nuclei specific (see 
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appendix Figure A1). Unfortunately, Jung and collegues did not describe whether the 
human brain tissue used in their immunoblotting was a NPC rich region of the brain 
such as the SVZ of the lateral ventricles or the SGZ of the dentate gyrus in the 
hippocampus. Therefore in their study it is not possible to ascertain if the abundance 
of TRF2 in brain tissue is due to the cumulative expression in neurons, high 
expression in NPCs, or both. Nevertheless, the fact that TRF2 is abundant in human 
brain compared to other tissues that its overexpression in COS cells induced neurite 
like processes and that our data suggested high specific expression in human NPCs 
prompted us to question wheter it has a role in neural differentiation.In answering 
this question it was found that similarly to previous published data (Jung et al., 
2004), ectopic expression of TRF2 resulted induction of neural processes. 
Overexpression of TRF2 in hESCs promoted neural differentiation, whilst 
knockdown of TRF2 impeded neural progenitor generation and maintenance, 
ultimately hindering the production of neurons and glia.  
    
7.2 TRF2-mediated REST4 stability is critical for differentiation and 
maintenance of neural progenitors 
 
In deciphering the molecular mechanisms underlying the role of TRF2 in neural 
differentiation, it was discovered that the differential expression of TRF2 during 
neural differentiation correlates with the expression of hREST4 protein, a truncated 
REST generated by the alternative splicing of exon N from the REST gene.. Although 
two transcripts, hREST-N4 and hREST-N62, can be generated by alternative splicing 
of exon N at different sites and both lead to premature termination of the REST 
protein, only hREST-N62 produces a truncated REST protein with the additional 13 
AAs at the C-terminus necessary for interaction with TRF2 (Palm et al., 1999). Since 
hREST-N62 transcript was similar in structure, molecular weigth and neural 
tissues/cells expression specificity as rodent rREST4 (Palm et al., 1998, 1999), this 
protein was termed here as human REST4 (REST4). Rodent rREST4 has been 
widely reported to counteract the repression of REST on target genes, promoting 
neural gene expression and neurogenesis (Shimojo et al., 1999; Tabuchi et al., 2002; 
Uchida et al., 2010; Raj et al., 2011) as it lacks the C-terminal repression domain of 
REST and is unable to interact with CoREST (Andres et al., 1999; Ooi et al., 2007). 
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Here it was demonstrated that REST4 is also able to promote the neural 
differentiation of hESCs, possibly through affecting the repression on neural genes 
by REST. Although overexpression of ‘hREST4’ in murine neuroblastoma cells was 
found not to reduce the repression of REST on human synapsin promoter-driven 
luciferase expression (Magin et al., 2002) , this was performed using only a single 
promoter in a tumour cell line, which may not be the case across all cell lines. 
Moreover, here it was demonstrated that TRF2 interacts with REST4 to protect it 
from ubiquitin-mediated degradation by the proteasome, hence positively regulating 
neural progenitor formation and maintenance.  
 
In a previous study, Zhang et al reported that TRF2 inhibits neuronal differentiation 
in embryonic carcinoma NTera2 cells by stabilising REST. In their system, 
overexpression of a dominant negative TRF2 promoted REST ubiquitination and 
degradation, enhancing neuron formation (Zhang et al., 2008). This project has taken 
this study into a more physiological context and demonstrated that TRF2 is also 
involved in regulating the neural differentiation process of hESCs. However, we 
show that TRF2 enhances REST4 expression during this process, which counteracts 
the repression of REST on neural genes to promote neural progenitor formation. The 
discrepancy of the two studies could be attributed to the two different cell types used 
where TRF2, REST and REST4 are differentially expressed. We have shown that 
TRF2 and REST are expressed at considerably higher levels in NTera2 cells than in 
hESCs, which may not reflect their physiological levels in normal pluripotent cells. 
This could affect their interaction and function due to the intricacies of protein 
complex formation. Nonetheless, the fact that high-TRF2 expressing NTera2 cells 
are more readily differentiated into neural lineages than hESCs further supports the 
idea of TRF2 promoting neural differentiation.  
 
Reducing REST repression on its target genes plays an important role in controlling 
neural gene expression and neural differentiation. During neural differentiation of 
mESCs, repression of REST is alleviated by a considerable reduction of REST 
protein in which REST undergoes proteasomal degradation through β-TrCP-
mediated ubiquitination (Ballas and Mendel, 2005). However, in both H1 and H7 
hESCs, no such reduction of REST during their differentiation into NPCs was 
observed, probably due to the abundance of HAUSP deubiquitylase and low level of 
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β-TrCP in human NPCs (Huang et al., 2011). Instead, hESCs exhibit a clear 
upregulation of REST4 following neural differentiation. This upregulation is due, at 
least in part, by the increase of TRF2 protein levels. Therefore, we propose a 
different mechanism regulating neural differentiation of hESCs: high levels of TRF2 
stabilise REST4, enhancing its accumulation. This counteracts the repression of 
REST on neural target genes, leading to the induction of neural differentiation 
(Figure 7.1). The findings in this project are further supported by the notion that 
alternative splice variants play a major role in the regulation of gene expression, 
which is particularly prominent in the central nervous system (Castle et al., 2008; 
Licatalosi et al., 2006).  
 
Overall, these results suggest that repression of REST on its target genes is reduced 
in the neural differentiation of both human and mouse ESCs but is regulated through 
different mechanisms. The balance of REST4 and REST is important for human 
neural differentiation and NPC maintenance for which high levels of TRF2 are 
crucial. 
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Figure 7.1 Schematic model for the role of TRF2, REST and REST4 in 
regulating neural differentiation of hESCs and maintenance of NPCs.  
Oval cartoons indicate the abundance of the indicated proteins. Dotted ovals indicate low protein 
levels while continuous line ovals indicate high protein levels. Transcription is indicated with an 
arrow. Red cross indicates transcription is highly repressed while pink dotted cross indicates 
activation of some transcription. In this model, upregulation of TRF2 protein results in stabilisation of 
REST4, enhancing its accumulation. This subsequently counteracts the repression of REST on neural 
target genes, leading to the induction of neural differentiation.  
 
7.3 TRF2-REST4 mechanism of neural induction 
 
While TRF2 stabilisation of REST4 may indeed result in derepression of REST 
target genes, the mechanism behind this remains to be elucidated. Given that REST4 
lacks the C-terminal repression domain of full length REST, different mechanisms 
can be proposed. One mechanism may result from a competition between REST and 
REST4 for the RE1 site of the target gene. Binding of REST4 would result in some 
derepression, as lacking the C-terminal domain would render REST4 unable to 
inhibit RNA pol II binding. An alternative mechanism is that REST4 could 
outcompete REST for Sin3A/B binding as REST4 retains the N-terminal repression 
domain. In this alternative mechanism REST4 would not bind to the RE1 site but 
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instead would inhibit recruitment of Sin3A/B to the RE1 site by REST, leading to a 
reduced repression. Both of these mechanisms are equally possible as it has been 
reported that overexpression of truncated forms of REST (i.e. lacking either the N-
terminal or C-terminal repression domain) results in partial derepression of REST 
target genes (Andres et al., 1999; Huang et al., 1999; Grimes et al., 2000).  
 
7.4 Concluding remarks and future work 
 
The work in this thesis has demonstrated that TRF2 plays a critical role in the 
differentiation and maintenance of human NPCs. It also has unravelled possible 
underlying mechanisms that the coordinated balance of REST4 and REST is 
important for human neural differentiation and NPC maintenance for which high 
levels of TRF2 are crucial. This work has contributed to understanding the roles of 
TRF2, particularly its role in neural differentiation and development, which may 
impact on future investigations: 
 
1- This study has shown that TRF2 is critical for the neural differentiation of hESCs 
and maintenance of NPC multipotency. It has also shown that TRF2 regulates these 
functions by stabilizing REST4 and that REST4 has the ability to induce neural 
differentiation. While previous reports have indicated that the REST4 rodent 
ortholog, rREST4, induces neural gene expression by antagonizing the repression of 
REST on its target genes, this has not been fully addressed for human REST4. The 
TRF2-REST4 model of neural differentiation regulation presented in this study 
makes the assumption that REST4 induces neural differentiation by antagonizing 
REST in a similar manner to what has been reported for rodent rREST4. Therefore 
this model would benefit from additional experiments that address whether REST4 
antagonizes REST. As discussed in section 7.3, REST4 could potentially antagonize 
REST by binding directly to the RE1 site of its target genes or by sequestering 
Sin3A/B from the RE1 sites. ChIP analysis of REST binding to the RE1 of its target 
genes in control and REST4-ov hESCs as well as in control and TRF2-sh NPCs 
would address if changes in REST4 protein levels affect REST binding and therefore 
would answer whether the first potential mechanism is correct. To address the second 
potential mechanism a Sin3A/B immunoblot analysis of REST4 immunoprecipitates 
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would answer whether REST4 could potentially be sequestering Sin3A/B from the 
RE1 sites.  
 
2- Assuming the experiments to address the molecular mechanism of REST4 
antagonism over REST were successful and since NPCs are essential for the proper 
development and function of the central nervous system, this study would attempt to 
address whether there is a link between neurodegenerative diseases and the 
expression of TRF2, REST and REST, as it has been shown that impaired 
neurogenesis can contribute to some types of neurodegenerative diseases. 
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Appendix 
 
Table A1. Primers for the amplification of human transcripts by qRT-PCR. 
 
Gene name  Forward primer 5'-3' Reverse primer 5'-3' 
AFP TGGGACCCGAACTTTCCA GGCCACATCCAGGACTAGTTTC 
GAPDH TCTGCTCCTCCTGTTCGACA AAAAGCAGCCCTGGTGACC 
Oct4 TCGAGAACCGAGTGAGAGGC CACACTCGGACCACATCCTTC 
GAPDH TCTGCTCCTCCTGTTCGACA AAAAGCAGCCCTGGTGACC 
Gata6 ACTTGAGCTCGCTGTTCTCG CAGCAAAAATACTTCCCCCA 
GFAP CACCACGATGTTCCTCTTGA GTGCAGACCTTCTCCAACCT 
HPRT TCCTTGGTCAGGCAGTATAATCC GTCAAGGGCATATCCTACAACAAA 
hTERT TCAACCGCGGCTTCAAG TCCAGAAACAGGCTGTGACACT 
Nanog TGATTTGTGGGCCTGAAGAAAA GAGGCATCTCAGCAGAAGACA 
Nestin GAGGGAAGTCTTGGAGCCAC AAGATGTCCCTCAGCCTGG 
NeuroD2 GGGGAACAATGAAATAAGCG  GCACGTCCGAGAGAAGG 
Pax6 TCCGTTGGAACTGATGGAGT GTTGGTATCCGGGGACTTC 
REST TGTCCTTACTCAAGTTCTCAGAAGA  GAGGCCACATAACTGCACTG 
Sox1 AACACTTGAAGCCCAGATGGA GCAGGCTGAATTCGGTTCTC  
191 
 
Gene name  Forward primer 5'-3' Reverse primer 5'-3' 
Sox2 CACACTGCCCCTCTCACACAT CATTTCCCTCGTTTTTCTTTGAA 
TRF1 AATTTGTTGAACCCTGCCAC ACAGGGTTGAGGTCAGCCTA 
TRF2 CCGTTCTCAACCAACCCCTC GCTGCCTGAACTTGAAACAGT 
Sox17 GGCGCAGCAGAATCCAGA  CCACGACTTGCCCAGCAT 
Snap25 CTGTCTTTCCTTCCCTCCCT GGGTCAGTGACGGGTTTG 
Mash1 GGAGCTTCTCGACTTCACCA CTAAAGATGCAGGTTGTGCG 
REST4 CATACACAACAGTGAGCGAG CCAAATGGTATCCATACCCC 
nSR100 GAACTGGGTGCCACCAGAGG CCCCTGGAGGAAGGTGGTGG 
Tuj1 AGTGTGAAAACTGCGACTGC ACGACGCTGAAGGTGTTCAT 
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Figure A1. Full TRF2 immunoblot corresponding to Figure 3.1 B. 
Uncropped TRF2 immunoblot of H1 hESCs and their neural derivatives revealing a 
single TRF2 band of 66 KDa. 
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Figure A2. H1 hESCs infected with pLVTHM virus 48 hours post transduction 
H1 hESCs were analysed for GFP expression 48 hours after transduction with pLVTHM-GFP virus 
particles. Left panels show the typical morphology of a hESCs colony and right panel reveals the 
expression of GFP under fluorescence of the same transduced colony. Scale bar= 100 µm in both 
images.  
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Figure A3. Overexpresssion in hESCs does not result in an increase of γH2AX 
foci. 
Immunostaining with indicated antibodies showing TRF2-ov hESCs do not have an increase of 
γH2AX foci compared to control. TRF2-sh NPCs were used as a γH2AX staining positive control. 
Scale bar = 10 µM. 
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Figure A4. Full TRF2 immunoblot corresponding to Figure 6.2 C. 
(A) Full TRF2 immunoblot. (B) Full β-Actin immunoblot. (C) Full REST immunoblot. Black 
rectangles indicate area selected for figure 6.2 C.  
 
 
 
 
Figure A5. Full immunoblots corresponding to Figure 6.2 D. 
(A) Full REST immunoblot. (B) Full TRF2 immunoblot. (C) Full β-Actin immunoblot. Black 
rectangles indicate area selected for figure 6.2 D.  
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Figure A6. Full immunoblots corresponding to Figure 6.3 A. 
(A) Full TRF2 immunoblot. (B) Full Rap1 immunoblot. (C) Full REST immunoblot. (D) Full REST 
immunoblot upon long exposure. Black rectangles indicate area selected for figure 6.3 A.  
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Figure A7. Full immunoblots corresponding to Figure 6.3 B. 
(A) Full Myc immunoblot. (B) Full Myc immunoblot upon long exposure. (C) Full HA immunoblot. 
(D) Full HA immunoblot upon long exposure. (E) Full β-Actin  immunoblot. Black rectangles 
indicate area selected for figure 6.3 B. HC = IgG heavy chain.  
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Figure A8. Full immunoblots corresponding to Figure 6.3 C. 
(A) Full HA immunoblot. (B) Full HA immunoblot upon long exposure. (C) Full Myc immunoblot. 
(D) Full Myc immunoblot upon long exposure. (E) Full β-Actin  immunoblot. Black rectangles 
indicate area selected for figure 6.3 C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
